WO2001062728A1 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
WO2001062728A1
WO2001062728A1 PCT/SE2001/000403 SE0100403W WO0162728A1 WO 2001062728 A1 WO2001062728 A1 WO 2001062728A1 SE 0100403 W SE0100403 W SE 0100403W WO 0162728 A1 WO0162728 A1 WO 0162728A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
phenoxy
hydroxy
acetamide
propoxy
Prior art date
Application number
PCT/SE2001/000403
Other languages
French (fr)
Inventor
Michael Bodkin
Tomas Eriksson
Peter Hansen
Martin Hemmerling
Krister Henriksson
Tomas Klingstedt
Lars Pettersson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0000620A external-priority patent/SE0000620D0/en
Priority claimed from SE0002234A external-priority patent/SE0002234D0/en
Priority claimed from SE0003979A external-priority patent/SE0003979D0/en
Priority to SK1213-2002A priority Critical patent/SK12132002A3/en
Priority to MXPA02008241A priority patent/MXPA02008241A/en
Priority to AT01908557T priority patent/ATE295833T1/en
Priority to CA002400293A priority patent/CA2400293A1/en
Priority to US10/204,790 priority patent/US6943188B2/en
Priority to PL01358281A priority patent/PL358281A1/en
Priority to AU36299/01A priority patent/AU783496B2/en
Priority to EP01908557A priority patent/EP1263724B1/en
Priority to IL15120801A priority patent/IL151208A0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SI200130366T priority patent/SI1263724T1/en
Priority to NZ520718A priority patent/NZ520718A/en
Priority to EEP200200470A priority patent/EE05001B1/en
Priority to JP2001561736A priority patent/JP2003523998A/en
Priority to DE60110900T priority patent/DE60110900T2/en
Priority to HU0300922A priority patent/HUP0300922A2/en
Priority to BR0108679-0A priority patent/BR0108679A/en
Publication of WO2001062728A1 publication Critical patent/WO2001062728A1/en
Priority to NO20023934A priority patent/NO323584B1/en
Priority to IS6520A priority patent/IS6520A/en
Priority to HK03101130A priority patent/HK1048990A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
  • US 5789402 describes certain indole deriatives which are said to be useful for the treatment of diseases which are caused or affected by disorders of the serotonin-affected neurological systems, particularly those relating to the serotonin 1 A receptor and those relating to the uptake of serotonin.
  • Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
  • the C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP -2).
  • IL-8 interleukin-8
  • NAP -2 neutrophil-activating peptide 2
  • the C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins l and l ⁇ (MlP-l ⁇ and MlP-l ⁇ ).
  • chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4.
  • G protein-coupled receptors among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4.
  • R represents either a group
  • n 0, 1, 2 or 3; each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
  • Y represents a CH group
  • Z represents a bond or a group (CH 2 ) q where q is 1 or 2;
  • Z 2 represents a bond or a group CH 2 , with the proviso that Z 1 and Z2 do not both simultaneously represent a bond;
  • n 0, 1 or 2;
  • each R independently represents a C r C 6 alkyl, C ⁇ -C 6 alkoxycarbonyl, -CH 2 OH or carboxyl group;
  • R , R , R and R each independently represent a hydrogen atom or a C ⁇ -Cg alkyl group, or R , R , R and R together represent a C ⁇ -C 4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R , together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;
  • R represents a hydrogen atom, a Ci-Cg alkyl group or is linked to R as defined above;
  • R and R each independently represent a hydrogen atom or a C ⁇ -C 6 alkyl group, or
  • R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle
  • R and R each independently represent a hydrogen atom or a Ci-Cg alkyl group optionally substituted by C C alkoxycarbonyl;
  • R represents a hydrogen atom or a C Cg alkyl group
  • R represents a hydrogen atom, or a C Cg alkyl group optionally substituted by carboxyl, C Cg alkoxy or Ci-Cg alkoxycarbonyl;
  • R represents carboxyl, C ⁇ -C 6 alkylcarbonyl, Ci-Cg alkoxycarbonyl, C r C 6 alkoxycarbonylC r Cg alkyl or a group -NR 17 R 18 , -NHSO 2 CH 3 , -NHC(O)CH 3 , -C(O)NR 17 R 18 , -NHC(O)NR 17 R 18 , -OC(O)NR 17 R 18 , -OCH 2 C(O)NR 17 R 18 , -NHC(O)OR 17 ' or -OR 17 "; t is 0, 1, 2 or 3; each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
  • R and R each independently represent (i) a hydrogen atom, (ii) a 5- to 6- membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or (iii) a C r Cg alkyl group optionally substituted by at least one substituent selected from halogen, trifluoromethyl, carboxyl, Ci-Cg alkoxycarbonyl and a 5- to 6-membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or
  • R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle
  • R represents a hydrogen atom, or a C j -Cg alkyl group optionally substituted by carboxyl or C r Cg alkoxycarbonyl;
  • R is defined as for R above except that R does not represent a hydrogen atom
  • R 19 and R 20 each independently represent a hydrogen atom or a C j -Cg alkyl group, or
  • R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle
  • R 21 and R 22 each independently represent a hydrogen atom or a C C alkyl group optionally substituted by C j -Cg alkoxycarbonyl; v is 0 or 1; R 23 represents a hydrogen atom or a Ci-Cg alkyl group; and R represents a hydrogen atom, or a C j -Cg alkyl group optionally substituted by carboxyl, CpCg alkoxy or C C alkoxycarbonyl;
  • R represents a group CH 2 and Q is an oxygen atom, then R is other than an unsubstituted indolyl group; or a pharmaceutically acceptable salt or solvate thereof.
  • an alkyl substituent group or an alkyl moiety in a substituent group may be linear or branched.
  • R represents a group m is 0, 1, 2 or 3; each R , 1 i .ndependently represents halogen, cyano, nitro, carboxyl, hydroxyl, C 3 -C 6 cycloalkyl, C j -C alkoxy, Ci-Cg alkoxycarbonyl, Ci-Cg haloalkyl,
  • X represents an oxygen or sulphur atom or a CH 2 , CH(CH 3 ), OCH 2 , CH 2 O, CH 2 NH,
  • Y represents a nitrogen atom or a CH or C(OH) group, provided that when X represents an oxygen or sulphur atom or a CH 2 O, CH 2 NH or NH group, then
  • Y represents a CH group
  • Z represents a bond or a group (CH ) q where q is 1 or 2;
  • Z 2 represents a bond or a group CH 2 , with the proviso that Z 1 and Z2 do not both simultaneously represent a bond;
  • Q represents an oxygen or sulphur atom or a group CH 2 or NH;
  • R represents a group n is 0, 1 or 2; each R independently represents a C r Cg alkyl, C ⁇ -C 6 alkoxycarbonyl, -CH 2 OH or carboxyl group;
  • R , R , R and R each independently represent a hydrogen atom or a Ci -Cg alkyl group, or R , R , R and R together represent a C 2 -C 4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R , R and R each represent a hydrogen atom and R and R together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;
  • R 8 represents a hydrogen atom, a Ci -C 6 alkyl group or is linked to R 4 as defined above;
  • R and R each independently represent a hydrogen atom or a Ci-Cg alkyl group, or
  • R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
  • R 11 and R 12 each independently represent a hydrogen atom or a Ci-Cg alkyl group optionally substituted by C r Cg alkoxycarbonyl;
  • R represents a hydrogen atom or a C r Cg alkyl group
  • R represents a hydrogen atom, or a Ci -C 6 alkyl group optionally substituted by carboxyl, C Cg alkoxy or Ci-Cg alkoxycarbonyl; R represents carboxyl, Ci-Cg alkylcarbonyl, C ⁇ C alkoxycarbonyl,
  • CC rr CC 66 aallkkyyllssuullpphhoonnyyll,, --CC((OO))NNRR 2211 RR 2222 ,, --NNRR 2233 CC((OO))((NNHH)) vv RR 24 , phenyl, or C r C 6 alkyl optionally substituted by carboxyl or C C alkoxycarbonyl
  • R and R each independently represent (i) a hydrogen atom, (ii) a 5- to 6- membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or (iii) a C ⁇ -C 6 alkyl group optionally substituted by at least one substituent selected from halogen, trifluoromethyl, carboxyl, Ci-Cg alkoxycarbonyl and a 5- to 6-membered saturated or uns
  • R 17 18 R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
  • R 17' represents a hydrogen atom,, or a C j -Cg alkyl group optionally substituted by carboxyl or C r Cg alkoxycarbonyl;
  • R 17" is defined as for R 17 above except that R 17" does not represent a hydrogen atom;
  • R 19 and R 20 each independently represent a hydrogen atom or a C C alkyl group, or
  • R and R together with the nitrogen atom to which they are attached form- a 4- to 7- membered saturated heterocycle
  • R 21 and R 22 each independently represent a hydrogen atom or a C Cg alkyl group optionally substituted by C j -Cg alkoxycarbonyl; v is 0 or 1 ;
  • R represents a hydrogen atom or a Ci-Cg alkyl group
  • R represents a hydrogen atom, or a C ⁇ Cg alkyl group optionally substituted by carboxyl, C j -Cg alkoxy or C2-C alkoxycarbonyl; or a pharmaceutically acceptable salt or solvate thereof.
  • R represents a group
  • n 0, 1, 2 or 3;
  • each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
  • X represents an oxygen or sulphur atom or a CH 2 , CH(CH 3 ), OCH 2 , CH 2 O, CH 2 NH,
  • Y represents a nitrogen atom or a CH or C(OH) group, provided that when X represents an oxygen or sulphur atom or a CH 2 O, CH 2 NH or NH group, then Y represents a CH group;
  • Z represents a bond or a group (CH 2 ) q where q is 1 or 2;
  • Z represents a bond or a group CH 2 , with the proviso that Z and Z do not both simultaneously represent a bond;
  • n 0, 1 or 2;
  • each R independently represents a Ci-Cg alkyl, Ci -Cg alkoxycarbonyl, -CH 2 OH or carboxyl group;
  • R , R , R and R each independently represent a hydrogen atom or a C Cg alkyl group, or R , R , R and R together represent a C 1 -C4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R , R and R each represent a hydrogen atom and R and R together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;
  • R represents a hydrogen atom, a Ci-Cg alkyl group or is linked to R as defined above;
  • R and R each independently represent a hydrogen atom or a C ⁇ -Cg alkyl group, or
  • R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle
  • R 11 and R 12 each independently represent a hydrogen atom or a Ci-Cg alkyl group optionally substituted by C r Cg alkoxycarbonyl;
  • R represents a hydrogen atom or a C r C 6 alkyl group
  • R represents a hydrogen atom, or a C j -Cg alkyl group optionally substituted by carboxyl, C Cg alkoxy or C r Cg alkoxycarbonyl;
  • R represents a group CH 2 and Q is an oxygen atom, then R is other than an unsubstituted indolyl group; or a pharmaceutically acceptable salt or solvate thereof.
  • R represents a group
  • n 0, 1, 2 or 3; each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
  • Q represents an oxygen or sulphur atom or a group CH 2 or NH
  • R represents a group
  • R , R , R and R each independently represent a hydrogen atom or a C j -C alkyl group, or R , R , R and R together represent a 0 ⁇ 4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R , R and R each represent a hydrogen atom and R and R together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;
  • R 8 represents a hydrogen atom, a Ci-Cg alkyl group or is linked to R 4 as defined above;
  • R 9 and R 10 each independently represent a hydrogen atom or a Ci-Cg alkyl group, or
  • R 9 and R 10 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle
  • R 11 and R 12 each independently represent a hydrogen atom or a C ⁇ -C 6 alkyl group optionally substituted by Cj-Cg alkoxycarbonyl;
  • R 13 represents a hydrogen atom or a Ci -Cg alkyl group;
  • R 14 represents a hydrogen atom, or a C j -Cg alkyl group optionally substituted by carboxyl, C Cg alkoxy or C r Cg alkoxycarbonyl;
  • R represents carboxyl, C r C 6 alkylcarbonyl, C r Cg alkoxycarbonyl,
  • C r Cg haloalkoxy, -NR 19 R 20 C 3 -C 6 cycloalkylamino, C C 6 alkylthio, Ci-Cg alkylcarbonyl, C r Cg alkylcarbonylamino, sulphonamido (-SO 2 NH 2 ), C r C 6 alkylsulphonyl, -C(O)NR 21 R 22 , -NR 23 C(O)(NH) v R 24 , phenyl, or C r C 6 alkyl optionally substituted by carboxyl or Ci-Cg alkoxycarbonyl;
  • R and R each independently represent (i) a hydrogen atom, (ii) a 5- to 6- membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or (iii) a C Cg alkyl group optionally substituted by at least one substituent selected from halogen, trifluoromethyl, carboxyl, C Cg alkoxycarbonyl and a 5- to 6-membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or
  • R 17 and R 18 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
  • R 17' represents a hydrogen atom, or a C Cg alkyl group optionally substituted by carboxyl or Ci -C 6 alkoxycarbonyl;
  • R 17" is defined as for R 17 above except that R 17" does not represent a hydrogen atom
  • R 19 and R 20 each independently represent a hydrogen atom or a C ⁇ Cg alkyl group, or R 19 and R 20 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
  • R 21 and R 22 each independently represent a hydrogen atom or a Ci -C 6 alkyl group optionally substituted by C ⁇ -C 6 alkoxycarbonyl; v is 0 or 1 ;
  • R represents a hydrogen atom or a Ci-Cg alkyl group
  • R represents a hydrogen atom, or a Ci -Cg alkyl group optionally substituted by carboxyl, Ci-Cg alkoxy or Ci-Cg alkoxycarbonyl; or a pharmaceutically acceptable salt or solvate thereof.
  • the integer m is preferably 0, 1 or 2.
  • Each R independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, nitro, carboxyl, hydroxyl, C 3 -Cg cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), Ci-Cg, preferably C C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C Cg, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C r C 6 , preferably C 1 -C4, haloalkyl (e.g. trifluoromethyl),
  • Ci-Cg preferably C1-C4, haloalkoxy (e.g. trifluoromethoxy), -NR R ,
  • C -C 6 cycloalkylamino e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino
  • C ⁇ C preferably C 1 -C4, alkylthio (e.g. methylthio or ethylthio), C Cg, preferably C1-C4, alkylcarbonyl (e.g.
  • Ci-Cg preferably C1-C4, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), sulphonamido,
  • Ci -Cg preferably C 1 -C 4 , alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), -C(O)NR U R 12 , -NR 13 C(O)-(NH) p R 14 , phenyl, or Ci-Cg, preferably C1-C4, alkyl (e.g.
  • each R independently represents halogen (particularly chlorine or fluorine), cyano, nitro, C ⁇ -C 6 alkoxy (especially methoxy), C ⁇ -C 6 alkylcarbonyl (especially methylcarbonyl) or C r Cg alkylcarbonylamino (particularly methylcarbonylamino).
  • X represents an oxygen atom or a CH 2 , OCH 2 , CH 2 O, NH or carbonyl group.
  • Y represents a nitrogen atom or CH group.
  • Preferred combinations of X - Y include O - CH, OCH 2 - CH, NH - CH, CH 2 O - CH, CH 2 - N, C(O) - N and CH 2 - CH.
  • Preferred combinations of Y, Z and Z include:
  • Q preferably represents an oxygen atom.
  • Each R independently represents a Ci -Cg, preferably -C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C ⁇ Cg, preferably CJ-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), -CH 2 OH or carboxyl
  • IItt i iss pprreeffeerrrreedd tthhaatt RR represents a methyl, methoxycarbonyl, ethoxycarbonyl,
  • R , R , R and R each independently represent a hydrogen atom or a C ⁇ -C 6 , preferably C ⁇ -C 4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or R , R , R and R together represent a Ci-C4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle (e.g. cyclohexyl or preferably cyclopentyl), or R , R and R each represent a hydrogen 4 8 atom and R and R together with the carbon atoms to which they are attached form a 5- to
  • 6-membered saturated carbocycle preferably cyclopentyl
  • R represents a hydrogen atom, a C C , preferably C C 4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or is linked to R as defined above.
  • alkyl group e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl
  • R and R each independently represent a hydrogen atom or a C ⁇ -C 6 , preferably
  • alkyl group e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl,
  • R and R each independently represent a hydrogen atom or a C j -Cg, preferably C1-C 4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by a Ci-Cg, preferably C1-C4, alkoxycarbonyl substituent group.
  • alkyl group e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl
  • Ci-Cg preferably C1-C4, alkoxycarbonyl substituent group.
  • R represents a hydrogen atom or a C r C 6 , preferably C1-C 4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
  • alkyl group e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl.
  • R represents a hydrogen atom, or a C Cg, preferably C j ⁇ , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, C r Cg, preferably C1-C 4 , alkoxy or C ⁇ -C 6 , preferably C1-C 4 , alkoxycarbonyl.
  • alkyl group e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl
  • carboxyl e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobuty
  • R represents carboxyl, C r C 6 , preferably C C 4 , alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C r C 6 , preferably alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C r C 6 alkoxycarbonylC r C 6 alkyl, preferably C r C 4 alkoxycarbonylC r C 4 a ⁇ yl (e.g.
  • R represents C r C 4 alkoxy (especially methoxy), C r C 4 alkylcarbonyl (especially methylcarbonyl or ethylcarbonyl), C 1 -C 4 alkoxycarbonylC ⁇ -C 4 alkyl (particularly methoxycarbonylmethyl or methoxycarbonylethyl), -NHC(O)CH 3 , -C(O)NR 17 R 18 , -NHSO 2 CH 3 or -NHC(O)NR 17 R 1 S .
  • Each R independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, nitro, carboxyl, hydroxyl, C 3 -C 6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C j -Cg, preferably -C 4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C r Cg, preferably C1-C 4 , alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C C 6 , preferably C r C 4 , haloalkyl (e.g. trifluoromethyl),
  • halogen e.g. chlorine, fluorine, bromine or iodine
  • cyano nitro, carboxyl, hydroxyl, C 3 -C 6 cycloalkyl (cycl
  • C 3 -Cg cycloalkylamino e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino
  • C Cg preferably C r C 4
  • alkylthio e.g. methylthio or ethylthio
  • C Cg preferably C1-C 4 , alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C r C 6 , preferably C r C 4 , alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), sulphonamido,
  • alkylcarbonyl e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl
  • C r C 6 preferably C r C 4
  • alkylcarbonylamino e.g. methyl
  • Ci-Cg preferably C1-C 4 , alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), -C(O)NR 21 R 22 , -NR 23 C(O)-(NH) v R 24 , phenyl, or C Cg, preferably C1-C4, alkyl (e.g.
  • Ci-Cg preferably Cj-C , alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl).
  • each R independently represents halogen (particularly chlorine or fluorine), hydroxyl, cyano, C r C alkoxy (especially methoxy), C1-C 4 alkoxycarbonyl (especially methoxycarbonyl), haloalkyl (especially trifluoromethyl), C1-C 4 alkylcarbonyl (particularly methylcarbonyl), phenyl or Ci -C 4 alkyl (e.g. methyl or tert-butyl).
  • halogen particularly chlorine or fluorine
  • hydroxyl cyano
  • C r C alkoxy especially methoxy
  • C1-C 4 alkoxycarbonyl especially methoxycarbonyl
  • haloalkyl especially trifluoromethyl
  • C1-C 4 alkylcarbonyl particularly methylcarbonyl
  • phenyl or Ci -C 4 alkyl e.g. methyl or tert-butyl
  • R and R each independently represent (i) a hydrogen atom, (ii) a 5- to 6-membered saturated or unsaturated ring which may comprise at least one heteroatom (e.g. one, two or three heteroatoms independently) chosen from nitrogen, oxygen and sulphur (such as cyclopentyl, cyclohexyl, pyrolyl, imidazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl or furanyl), the ring being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g.
  • Ci-C preferably C r C 4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g.
  • halogen e.g. fluorine, chlorine, bromine or i
  • R represents a hydrogen atom or a Ci -Cg, preferably C1-C 4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or, more preferably, Ci-Cg, preferably C1-C 4 , alkoxycarbonyl, especially methoxycarbonyl,
  • R and R each independently represent a hydrogen atom or a Ci -Cg, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl,
  • n-pentyl or n-hexyl 19 20 n-pentyl or n-hexyl), or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle (preferably pyrrolidinyl or piperidinyl).
  • R 21 and R 22 each independently represent a hydrogen atom or a Ci-Cg, preferably
  • alkyl group e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl
  • a C ⁇ Cg preferably Ci -C
  • alkoxycarbonyl substituent group e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl
  • R 23 represents a hydrogen atom or a C Cg, preferably C1-C 4 , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
  • alkyl group e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl.
  • R represents a hydrogen atom, or a Ci -Cg, preferably Ci -C , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, Ci-Cg, preferably C1-C4, alkoxy or C Cg, preferably C1-C 4 , alkoxycarbonyl.
  • a Ci -Cg preferably Ci -C , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, Ci-Cg, preferably C1-C4, alkoxy or C Cg, preferably
  • Preferred compounds of the invention include:
  • the present invention further provides a process for the preparation of a compound of formula (I) as defined above which comprises, (a) reacting a compound of general formula
  • L represents a hydrogen atom or an activating group (e.g. Li when Q is CH 2 ) and
  • the invention provides a process for the preparation of a compound of formula (F) as hereinbefore defined which comprises, (a) reacting a compound of general formula
  • R, R , R , R and R° are as defined in formula (F), with a compound of general formula (F), with a compound of general formula
  • L represents a hydrogen atom or an activating group (e.g. Li when Q is CH 2 ) and
  • the invention provides a process for the preparation of a compound of formula (I") as hereinbefore defined which comprises, (a) reacting a compound of general formula
  • L represents a hydrogen atom or an activating group (e.g. Li when Q is CH 2 ) and
  • the invention provides a process for the preparation of a compound of formula (F") as hereinbefore defined which comprises, (a) reacting a compound of general formula
  • L represents a hydrogen atom or an activating group (e.g. Li when Q is CH2) and
  • a solvent e.g. an organic solvent such as an alcohol (e.g. methanol or ethanol), a hydrocarbon (e.g. toluene) or acetonitrile at a temperature of, for example, 15°C or above such as a temperature in the range from 20 to 120°C.
  • an organic solvent such as an alcohol (e.g. methanol or ethanol), a hydrocarbon (e.g. toluene) or acetonitrile
  • a temperature of, for example, 15°C or above such as a temperature in the range from 20 to 120°C.
  • the compounds of formula (I), (F), (I") or (F") above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or 7-toluenesulphonate.
  • a pharmaceutically acceptable salt or solvate thereof preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or 7-toluenesulphonate.
  • the compounds of formula (I), (F), (I") or (F") have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially MlP-l ⁇ chemokine receptor) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS).
  • chemokine receptor especially MlP-l ⁇ chemokine receptor
  • COPD chronic obstructive pulmonary disease
  • asthma such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g.
  • bronchitis acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
  • NSCLC non-small cell lung cancer
  • squamous sarcoma squamous sarcoma
  • cystic fibrosis (9) cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and sepsis.
  • the present invention provides a compound of formula (I), (F), (I") or (F"), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
  • the present invention provides the use of a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
  • the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
  • the terms “therapeutic” and “therapeutically” should be construed accordingly.
  • the invention also provides a method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • the invention still further provides a method of treating an airways disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • the daily dosage of the compound of formula (I), (F), (I") or (F") may be in the range from 0.001 mg/kg to 30 mg/kg.
  • the compounds of formula (I), (F), (I") or (F") and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I), (F), (I") or (F") compound salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
  • ⁇ NMR spectra were recorded on Varian Unity Inova 400.
  • the central solvent peak of chloroform-c? ( ⁇ H 7.27 ppm) were used as internal standard.
  • Low resolution mass spectra and accurate mass determination were recorded on a Hewlett- Packard 1100 LC-MS system equipped with APCI /ESI ionisation chambers. All solvents and commercial reagents were laboratory grade and used as received. The nomenclature used for the compounds was generated with ACD/IUPAC Name Pro.
  • a toluene solution of 4-(3,4-difluorophenoxy)piperidine (0.03 ml, 0.5 M) was mixed with a toluene solution of methyl 2-methyl-2- ⁇ [2-(2-oxiranylmethoxy)benzoyl]amino ⁇ - propanoate (0.03 ml, 0.5 M).
  • the mixture was diluted with 0.20 ml toluene and 0.05 ml methanol.
  • the reaction mixture was stirred overnight at 100° C in sealed vials.
  • the product were concentrated in vacuo and used without any purification.
  • Example 8 N-[2-( ⁇ (lR,2S,3R)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl)-2- hydroxycyclopentyl ⁇ oxy)phenyl] acetamide and N-[2-( ⁇ (lS,2S,3R)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl)-2- hydroxy cyclopentyl ⁇ oxy)phenyl] acetamide
  • N- ⁇ 2-(6-oxabicyclo[3.1.0]hex-2-yloxy)phenyl ⁇ acetamide (racemic mixture of the trans and cis diastereoisomers) (87 mg, 373 ⁇ mol, 1.0 equiv.) and 4-(3,4-dichIorophenoxy)piperidine (92 mg, 394 ⁇ mol, 1.06 equiv.) were dissolved in 2 M lithium perchlorate in acetonitrile (3 ml) and heated in a sealed tube over night at 85 °C.
  • Example 170 l-(2- ⁇ 3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy ⁇ -phenyl)-propan-l- one
  • the compound was prepared analogously to Example 197.
  • the compound was prepared analogously to Example 197.
  • the compound was prepared analogously to Example 197.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

The invention provides compounds of general formula (I) wherein Q, R, R?2, R4, R5, R6, R7 and R8¿ are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Description

NOVEL COMPOUNDS
The present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
US 5789402 describes certain indole deriatives which are said to be useful for the treatment of diseases which are caused or affected by disorders of the serotonin-affected neurological systems, particularly those relating to the serotonin 1A receptor and those relating to the uptake of serotonin.
Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP -2).
The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins l and lβ (MlP-lα and MlP-lβ).
Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those previously mentioned.
In accordance with the present invention, there is therefore provided a compound of general formula
Figure imgf000003_0001
wherein,
R represents either a group
Figure imgf000003_0002
or a group
Figure imgf000003_0003
m is 0, 1, 2 or 3; each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
C3-Cg cycloalkyl, C Cg alkoxy, Ci-Cg alkoxycarbonyl, Ci-Cg haloalkyl,
9 10 Cι-C6 haloalkoxy, -NR R , C3-C6 cycloalkylamino, CrC6 alkylthio,
Cj-Cg alkylcarbonyl, Ci-Cg alkylcarbonylamino, sulphonamido (-SO2NH2),
CrC6 alkylsulphonyl, -C(O)NRHR12, -NR13C(O)-(NH)pR14, phenyl, or CrC6 alkyl optionally substituted by carboxyl or Cj-Cg alkoxycarbonyl; p is 0 or 1 ; X represents an oxygen or sulphur atom or a CH2, CH(CH3), OCH2, CH2O, CH2NH, NH or carbonyl group and Y represents a nitrogen atom or a CH or C(OH) group, provided that when X represents an oxygen or sulphur atom or a CH2O, CH2NH or NH group, then
Y represents a CH group;
Z represents a bond or a group (CH2)q where q is 1 or 2;
Z 2 represents a bond or a group CH2, with the proviso that Z 1 and Z2 do not both simultaneously represent a bond;
Q represents an oxygen or sulphur atom or a group CH2 or NH; R represents a group
Figure imgf000004_0001
n is 0, 1 or 2;
3 each R independently represents a CrC6 alkyl, Cι-C6 alkoxycarbonyl, -CH2OH or carboxyl group;
R , R , R and R each independently represent a hydrogen atom or a C^-Cg alkyl group, or R , R , R and R together represent a Cι-C4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R ,
Figure imgf000005_0001
together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;
8 4
R represents a hydrogen atom, a Ci-Cg alkyl group or is linked to R as defined above;
9 10 R and R each independently represent a hydrogen atom or a Cι-C6 alkyl group, or
9 10
R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
11 12
R and R each independently represent a hydrogen atom or a Ci-Cg alkyl group optionally substituted by C C alkoxycarbonyl;
13 R represents a hydrogen atom or a C Cg alkyl group;
14 R represents a hydrogen atom, or a C Cg alkyl group optionally substituted by carboxyl, C Cg alkoxy or Ci-Cg alkoxycarbonyl;
R represents carboxyl, Cι-C6 alkylcarbonyl, Ci-Cg alkoxycarbonyl, CrC6 alkoxycarbonylCrCg alkyl or a group -NR17R18, -NHSO2CH3, -NHC(O)CH3, -C(O)NR17R18, -NHC(O)NR17R18, -OC(O)NR17R18, -OCH2C(O)NR17R18, -NHC(O)OR17' or -OR17"; t is 0, 1, 2 or 3; each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
C3-Cg cycloalkyl, Ci-Cg alkoxy, C Cg alkoxycarbonyl, Cj-Cg haloalkyl,
19 20 Cj-C haloalkoxy, -NR R , C3-C6 cycloalkylamino, CrCg alkylthio,
Cj-Cg alkylcarbonyl, C Cg alkylcarbonylamino, sulphonamido (-SO NH2),
CrC6 alkylsulphonyl, -C(O)NR21R22, -NR23C(O)(NH)vR24, phenyl, or CrC6 alkyl optionally substituted by carboxyl or C Cg alkoxycarbonyl;
17 18
R and R each independently represent (i) a hydrogen atom, (ii) a 5- to 6- membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or (iii) a CrCg alkyl group optionally substituted by at least one substituent selected from halogen, trifluoromethyl, carboxyl, Ci-Cg alkoxycarbonyl and a 5- to 6-membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or
17 1
R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
17' R represents a hydrogen atom, or a Cj-Cg alkyl group optionally substituted by carboxyl or CrCg alkoxycarbonyl;
17" 17 17"
R is defined as for R above except that R does not represent a hydrogen atom;
R 19 and R 20 each independently represent a hydrogen atom or a Cj-Cg alkyl group, or
19 20
R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
R 21 and R 22 each independently represent a hydrogen atom or a C C alkyl group optionally substituted by Cj-Cg alkoxycarbonyl; v is 0 or 1; R 23 represents a hydrogen atom or a Ci-Cg alkyl group; and R represents a hydrogen atom, or a Cj-Cg alkyl group optionally substituted by carboxyl, CpCg alkoxy or C C alkoxycarbonyl;
1 2 provided that when X is an oxygen atom or a group CH2, Y is CH, Z and Z each
2 represent a group CH2 and Q is an oxygen atom, then R is other than an unsubstituted indolyl group; or a pharmaceutically acceptable salt or solvate thereof.
In the context of the present specification, an alkyl substituent group or an alkyl moiety in a substituent group may be linear or branched.
In one aspect of the present invention, there is provided a compound of general formula
Figure imgf000007_0001
wherein,
R represents a group
Figure imgf000007_0002
m is 0, 1, 2 or 3; each R , 1 i .ndependently represents halogen, cyano, nitro, carboxyl, hydroxyl, C3-C6 cycloalkyl, Cj-C alkoxy, Ci-Cg alkoxycarbonyl, Ci-Cg haloalkyl,
Ci-Cg haloalkoxy, -NR , 9^ R10 , C3-Cg cycloalkylamino, Cj-Cg alkylthio,
C Cg alkylcarbonyl, Cι-C6 alkylcarbonylamino, sulphonamido, Ci-Cg alkylsulphonyl,
-C(O)NRUR12, -NR13C(O)-(NH V)pR14, phenyl, or CrC6 alkyl optionally substituted by carboxyl or Ci-Cg alkoxycarbonyl; p is 0 or 1 ;
X represents an oxygen or sulphur atom or a CH2, CH(CH3), OCH2, CH2O, CH2NH,
NH or carbonyl group and Y represents a nitrogen atom or a CH or C(OH) group, provided that when X represents an oxygen or sulphur atom or a CH2O, CH2NH or NH group, then
Y represents a CH group;
Z represents a bond or a group (CH )q where q is 1 or 2;
Z 2 represents a bond or a group CH2, with the proviso that Z 1 and Z2 do not both simultaneously represent a bond;
Q represents an oxygen or sulphur atom or a group CH2 or NH; R represents a group
Figure imgf000007_0003
n is 0, 1 or 2; each R independently represents a CrCg alkyl, Cι-C6 alkoxycarbonyl, -CH2OH or carboxyl group; R , R , R and R each independently represent a hydrogen atom or a Ci -Cg alkyl group, or R , R , R and R together represent a C2-C4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R , R and R each represent a hydrogen atom and R and R together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle; R 8 represents a hydrogen atom, a Ci -C6 alkyl group or is linked to R 4 as defined above;
9 10
R and R each independently represent a hydrogen atom or a Ci-Cg alkyl group, or
9 10
R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle; R 11 and R 12 each independently represent a hydrogen atom or a Ci-Cg alkyl group optionally substituted by CrCg alkoxycarbonyl;
13
R represents a hydrogen atom or a CrCg alkyl group;
R represents a hydrogen atom, or a Ci -C6 alkyl group optionally substituted by carboxyl, C Cg alkoxy or Ci-Cg alkoxycarbonyl; R represents carboxyl, Ci-Cg alkylcarbonyl, C^C alkoxycarbonyl,
CrC6 alkoxycarbonylCi-Cg alkyl or a group -NR17R18, -NHSO2CH3, -NHC(O)CH3, -C(O)NR17R18, -NHC(O)NR17R18, -OC(O)NR17R18, -OCH2C(O)NR17R18, -NHC(O)OR17' or -OR17"; t is O, 1, 2 or 3 eeaacchh RR iinnddeetp. endently represents halogen, cyano, nitro, carboxyl, hydroxyl,
C3-Cg cycloalkyl, CrC6 alkoxy, Cι-C6 alkoxycarbonyl, Cι-C6 haloalkyl, CrCg haloalkoxy, -NR 19 R 20 , C3-C6 cycloalkylamino, C C6 alkylthio,
CrCg alkylcarbonyl, CrC6 alkylcarbonylamino, sulphonamido (-SO2NH2),
CCrrCC66 aallkkyyllssuullpphhoonnyyll,, --CC((OO))NNRR2211RR2222,, --NNRR2233CC((OO))((NNHH))vvRR24, phenyl, or CrC6 alkyl optionally substituted by carboxyl or C C alkoxycarbonyl R and R each independently represent (i) a hydrogen atom, (ii) a 5- to 6- membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or (iii) a Cι-C6 alkyl group optionally substituted by at least one substituent selected from halogen, trifluoromethyl, carboxyl, Ci-Cg alkoxycarbonyl and a 5- to 6-membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or
17 18 R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle; R 17' represents a hydrogen atom,, or a Cj-Cg alkyl group optionally substituted by carboxyl or CrCg alkoxycarbonyl;
R 17" is defined as for R 17 above except that R 17" does not represent a hydrogen atom; R 19 and R 20 each independently represent a hydrogen atom or a C C alkyl group, or
19 20
R and R together with the nitrogen atom to which they are attached form- a 4- to 7- membered saturated heterocycle;
R 21 and R 22 each independently represent a hydrogen atom or a C Cg alkyl group optionally substituted by Cj-Cg alkoxycarbonyl; v is 0 or 1 ;
23 R represents a hydrogen atom or a Ci-Cg alkyl group; and
R represents a hydrogen atom, or a C^Cg alkyl group optionally substituted by carboxyl, Cj-Cg alkoxy or C2-C alkoxycarbonyl; or a pharmaceutically acceptable salt or solvate thereof.
In another aspect of the invention, there is provided a compound of general formula
Figure imgf000009_0001
wherein,
R represents a group
Figure imgf000010_0001
m is 0, 1, 2 or 3;
. 1 . each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
C3-Cg cycloalkyl, Ci-Cg alkoxy, Cι-C6 alkoxycarbonyl, CrCg haloalkyl,
9 10 Cj-C haloalkoxy, -NR R , C3-C6 cycloalkylamino, C Cg alkylthio,
Cj-Cg alkylcarbonyl, C C alkylcarbonylamino, sulphonamido, Cι-C6 alkylsulphonyl,
-C(O)NRnR12, -NR13C(O)-(NH)pR14, phenyl, or CrC6 alkyl optionally substituted by carboxyl or C C alkoxycarbonyl; p is 0 or 1;
X represents an oxygen or sulphur atom or a CH2, CH(CH3), OCH2, CH2O, CH2NH,
NH or carbonyl group and Y represents a nitrogen atom or a CH or C(OH) group, provided that when X represents an oxygen or sulphur atom or a CH2O, CH2NH or NH group, then Y represents a CH group;
Z represents a bond or a group (CH2)q where q is 1 or 2;
2 1 2
Z represents a bond or a group CH2, with the proviso that Z and Z do not both simultaneously represent a bond;
Q represents an oxygen or sulphur atom or a group CH or NH; R represents a group
Figure imgf000011_0001
n is 0, 1 or 2;
,3 . each R independently represents a Ci-Cg alkyl, Ci -Cg alkoxycarbonyl, -CH2OH or carboxyl group;
R , R , R and R each independently represent a hydrogen atom or a C Cg alkyl group, or R , R , R and R together represent a C1-C4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R , R and R each represent a hydrogen atom and R and R together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;
8 4
R represents a hydrogen atom, a Ci-Cg alkyl group or is linked to R as defined above;
9 10
R and R each independently represent a hydrogen atom or a C^-Cg alkyl group, or
9 10
R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
R 11 and R 12 each independently represent a hydrogen atom or a Ci-Cg alkyl group optionally substituted by CrCg alkoxycarbonyl;
, 13
R represents a hydrogen atom or a CrC6 alkyl group; and 14
R represents a hydrogen atom, or a Cj-Cg alkyl group optionally substituted by carboxyl, C Cg alkoxy or CrCg alkoxycarbonyl;
1 2 provided that when X is an oxygen atom or a group CH2, Y is CH, Z and Z each
2 represent a group CH2 and Q is an oxygen atom, then R is other than an unsubstituted indolyl group; or a pharmaceutically acceptable salt or solvate thereof.
In a further aspect of the invention, there is provided a compound of general formula
Figure imgf000012_0001
wherein,
R represents a group
Figure imgf000012_0002
m is 0, 1, 2 or 3; each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
C3-C6 cycloalkyl, Cj-Cg alkoxy, CrC6 alkoxycarbonyl, CrC6 haloalkyl,
9 10 CrC6 haloalkoxy, -NR R , C3-C6 cycloalkylamino, CrCg alkylthio,
CrCg alkylcarbonyl, Cι-C6 alkylcarbonylamino, sulphonamido, CrC6 alkylsulphonyl,
-C(O)NRπR12, -NR13C(O)-(NH) R14, phenyl, or CrC6 alkyl optionally substituted by carboxyl or C Cg alkoxycarbonyl; p is 0 or 1 ;
Q represents an oxygen or sulphur atom or a group CH2 or NH;
R represents a group
Figure imgf000013_0001
4 5 f 7
R , R , R and R each independently represent a hydrogen atom or a Cj-C alkyl group, or R , R , R and R together represent a 0^4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R , R and R each represent a hydrogen atom and R and R together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;
R 8 represents a hydrogen atom, a Ci-Cg alkyl group or is linked to R 4 as defined above;
R 9 and R 10 each independently represent a hydrogen atom or a Ci-Cg alkyl group, or
R 9 and R 10 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
R 11 and R 12 each independently represent a hydrogen atom or a Cι-C6 alkyl group optionally substituted by Cj-Cg alkoxycarbonyl; R 13 represents a hydrogen atom or a Ci -Cg alkyl group; R 14 represents a hydrogen atom, or a Cj-Cg alkyl group optionally substituted by carboxyl, C Cg alkoxy or CrCg alkoxycarbonyl;
R represents carboxyl, CrC6 alkylcarbonyl, CrCg alkoxycarbonyl,
CrC6 alkoxycarbonylCj-Cg alkyl or a group -NR17R18, -NHSO2CH3, -NHC(O)CH3, -C(O)NR17R18, -NHC(O)NR17R18, -OC(O)NR17R18, -OCH2C(O)NR17R18, -NHC(O)OR17' or -OR17"; t is O, 1, 2 or 3; each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl, C3-C6 cycloalkyl, CrC6 alkoxy, CrC6 alkoxycarbonyl, CrCg haloalkyl,
CrCg haloalkoxy, -NR 19 R 20 , C3-C6 cycloalkylamino, C C6 alkylthio, Ci-Cg alkylcarbonyl, CrCg alkylcarbonylamino, sulphonamido (-SO2NH2), CrC6 alkylsulphonyl, -C(O)NR21R22, -NR23C(O)(NH)vR24, phenyl, or CrC6 alkyl optionally substituted by carboxyl or Ci-Cg alkoxycarbonyl;
17 18 R and R each independently represent (i) a hydrogen atom, (ii) a 5- to 6- membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or (iii) a C Cg alkyl group optionally substituted by at least one substituent selected from halogen, trifluoromethyl, carboxyl, C Cg alkoxycarbonyl and a 5- to 6-membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or
R 17 and R 18 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle; R 17' represents a hydrogen atom, or a C Cg alkyl group optionally substituted by carboxyl or Ci -C6 alkoxycarbonyl;
R 17" is defined as for R 17 above except that R 17" does not represent a hydrogen atom;
R 19 and R 20 each independently represent a hydrogen atom or a C^Cg alkyl group, or R 19 and R 20 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
R 21 and R 22 each independently represent a hydrogen atom or a Ci -C6 alkyl group optionally substituted by Cι-C6 alkoxycarbonyl; v is 0 or 1 ;
23 R represents a hydrogen atom or a Ci-Cg alkyl group; and 24
R represents a hydrogen atom, or a Ci -Cg alkyl group optionally substituted by carboxyl, Ci-Cg alkoxy or Ci-Cg alkoxycarbonyl; or a pharmaceutically acceptable salt or solvate thereof.
The integer m is preferably 0, 1 or 2.
Each R independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, nitro, carboxyl, hydroxyl, C3-Cg cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), Ci-Cg, preferably C C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C Cg, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), CrC6, preferably C1-C4, haloalkyl (e.g. trifluoromethyl),
9 10 Ci-Cg, preferably C1-C4, haloalkoxy (e.g. trifluoromethoxy), -NR R ,
C -C6 cycloalkylamino (e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino), C^C , preferably C1-C4, alkylthio (e.g. methylthio or ethylthio), C Cg, preferably C1-C4, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), Ci-Cg, preferably C1-C4, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), sulphonamido,
Ci -Cg, preferably C1-C4, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), -C(O)NRUR12, -NR13C(O)-(NH)pR14, phenyl, or Ci-Cg, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or Cj-Cg, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl).
Most preferably, each R independently represents halogen (particularly chlorine or fluorine), cyano, nitro, Cι-C6 alkoxy (especially methoxy), Cι-C6 alkylcarbonyl (especially methylcarbonyl) or CrCg alkylcarbonylamino (particularly methylcarbonylamino). Preferably X represents an oxygen atom or a CH2, OCH2, CH2O, NH or carbonyl group.
Preferably Y represents a nitrogen atom or CH group.
Preferred combinations of X - Y include O - CH, OCH2 - CH, NH - CH, CH2O - CH, CH2 - N, C(O) - N and CH2 - CH.
1 2
Preferred combinations of Y, Z and Z include:
Figure imgf000016_0001
Q preferably represents an oxygen atom.
3 Each R independently represents a Ci -Cg, preferably -C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C^Cg, preferably CJ-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), -CH2OH or carboxyl
3 ggrroouupp.. IItt iiss pprreeffeerrrreedd tthhaatt RR represents a methyl, methoxycarbonyl, ethoxycarbonyl,
-CH2OH or carboxyl group.
R , R , R and R each independently represent a hydrogen atom or a Cι-C6, preferably Cι-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or R , R , R and R together represent a Ci-C4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle (e.g. cyclohexyl or preferably cyclopentyl), or R , R and R each represent a hydrogen 4 8 atom and R and R together with the carbon atoms to which they are attached form a 5- to
6-membered saturated carbocycle (preferably cyclopentyl).
R represents a hydrogen atom, a C C , preferably C C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or is linked to R as defined above.
9 10
R and R each independently represent a hydrogen atom or a Cι-C6, preferably
C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl,
9 10 n-pentyl or n-hexyl), or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle (preferably pyrrolidinyl or piperidinyl).
11 12
R and R each independently represent a hydrogen atom or a Cj-Cg, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by a Ci-Cg, preferably C1-C4, alkoxycarbonyl substituent group.
13 R represents a hydrogen atom or a CrC6, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
R represents a hydrogen atom, or a C Cg, preferably Cj^, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, CrCg, preferably C1-C4, alkoxy or Cι-C6, preferably C1-C4, alkoxycarbonyl.
R represents carboxyl, CrC6, preferably C C4, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), CrC6, preferably alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), CrC6 alkoxycarbonylCrC6 alkyl, preferably CrC4 alkoxycarbonylCrC4 a^yl (e.g. methoxycarbonylmethyl or methoxycarbonylethyl), or a group -NR17R18, -NHS02CH3, -NHC(O)CH3, -C(O)NR17R18, -NHC(O)NR17R18, -OC(O)NR17R18, -OCH2C(0)NRI 7R18, -NHC(O)OR17' or -OR17".
It is preferred that R represents CrC4 alkoxy (especially methoxy), CrC4 alkylcarbonyl (especially methylcarbonyl or ethylcarbonyl), C1-C4 alkoxycarbonylCι-C4 alkyl (particularly methoxycarbonylmethyl or methoxycarbonylethyl), -NHC(O)CH3, -C(O)NR17R18, -NHSO2CH3 or -NHC(O)NR17R1 S.
Each R independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, nitro, carboxyl, hydroxyl, C3-C6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), Cj-Cg, preferably -C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), CrCg, preferably C1-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C C6, preferably CrC4, haloalkyl (e.g. trifluoromethyl),
19 20 CrCg, preferably CΓC4, haloalkoxy (e.g. trifluoromethoxy), -NR R ,
C3-Cg cycloalkylamino (e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino or cyclohexylamino), C Cg, preferably CrC4, alkylthio (e.g. methylthio or ethylthio),
C Cg, preferably C1-C4, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), CrC6, preferably CrC4, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), sulphonamido,
Ci-Cg, preferably C1-C4, alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyl, n-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), -C(O)NR21R22, -NR23C(O)-(NH)vR24, phenyl, or C Cg, preferably C1-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl. or Ci-Cg, preferably Cj-C , alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl). Preferably, each R independently represents halogen (particularly chlorine or fluorine), hydroxyl, cyano, CrC alkoxy (especially methoxy), C1-C4 alkoxycarbonyl (especially methoxycarbonyl),
Figure imgf000019_0001
haloalkyl (especially trifluoromethyl), C1-C4 alkylcarbonyl (particularly methylcarbonyl), phenyl or Ci -C4 alkyl (e.g. methyl or tert-butyl).
17 18
R and R each independently represent (i) a hydrogen atom, (ii) a 5- to 6-membered saturated or unsaturated ring which may comprise at least one heteroatom (e.g. one, two or three heteroatoms independently) chosen from nitrogen, oxygen and sulphur (such as cyclopentyl, cyclohexyl, pyrolyl, imidazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl or furanyl), the ring being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), methyl and trifluoromethyl, or (iii) a Ci-C , preferably CrC4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifluoromethyl, carboxyl, Cr g, preferably C1-C4, alkoxycarbonyl, especially methoxycarbonyl, and a 5- to 6-membered saturated or unsaturated ring which may comprise at least one heteroatom (e.g. one, two or three heteroatoms independently) chosen from nitrogen, oxygen and sulphur (such as cyclopentyl, cyclohexyl, pyrolyl, imidazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl or furanyl), the ring being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), methyl and trifluoromethyl, or
17 18 RR a anndd RR ttooggeetthheer with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle (preferably pyrrolidinyl or piperidinyl).
17' R represents a hydrogen atom or a Ci -Cg, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl or, more preferably, Ci-Cg, preferably C1-C4, alkoxycarbonyl, especially methoxycarbonyl,
19 20
R and R each independently represent a hydrogen atom or a Ci -Cg, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl,
19 20 n-pentyl or n-hexyl), or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocycle (preferably pyrrolidinyl or piperidinyl).
R 21 and R 22 each independently represent a hydrogen atom or a Ci-Cg, preferably
C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by a C^Cg, preferably Ci -C , alkoxycarbonyl substituent group.
R 23 represents a hydrogen atom or a C Cg, preferably C1-C4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
R represents a hydrogen atom, or a Ci -Cg, preferably Ci -C , alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by carboxyl, Ci-Cg, preferably C1-C4, alkoxy or C Cg, preferably C1-C4, alkoxycarbonyl.
Preferred compounds of the invention include:
2V-(2- {3-[3R,S-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2R,S-hydroxy-propoxy } -phenyl)- acetamide hydrochloride,
N-(5-Chloro-2-{3-[3R,S-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2R,S-hydroxy- propoxy } -phenyl)-acetamide hydrochloride,
N-(2-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]-2-hydroxypropoxy}phenyl)- acetamide, l-(2-Aminophenoxy)-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2-propanol dihydrochloride,
N-(2-{3-[3-(3,4-dichlorophenoxy)-l-pyrrolidinyl)-2-hydroxypropoxy}phenyl)- acetamide hydrochloride, 5 2- {3-[4-(4-Fluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -benzoic acid methyl ester,
2-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-2-methyl-propionic acid methyl ester,
N-[2-({(li?,25',3i?)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl)-2- l o hydroxy cyclopentyl } oxy)phenyl] acetamide,
N-[2-({(lJS',2-5',3i?)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl)-2- hydroxy cyclopentyl } oxy)phenyl] acetamide,
N-[2-({(2,3-trα«5)-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2- hydroxy cyclohexyl } oxy)phenyl] acetamide, 15 N-(5-Chloro-2-{3-[3-(3,4-dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide,
N-(3-Acetyl-2- {3-[3-(3 ,4-dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -5- methyl-phenyl)-acetamide,
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-methyl-0 phenyl)-acetamide,
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-fluoro- phenyl)-acetamide, l-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-3-(lH-indol-7-yloxy)-propan-2-ol,
1 -(7- {3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l -yl]-2-hydroxy-propoxy}-indol-l -yl)-5 ethanone,
N-(4-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-biphenyl-3- yl)-acetamide,
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-fluoro- phenyl)-acetamide, N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide,
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide, N-(5-Chloro-2- {3 - [3 -(4-chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} - phenyl)-acetamide,
N-(3-Acetyl-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -4-methyl- phenyl)-acetamide,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -5-fluoro- phenyl)-acetamide, l-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-3-(lH-indol-7-yloxy)-propan-2-ol,
1 -(7- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -indol- 1 -yl)- ethanone,
N-(4- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -biphenyl-3-yl)- acetamide,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -4-fluoro- phenyl)-acetamide, N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- acetamide
N-(5-Chloro-2- {3-[3-(4-fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } - phenyl)-acetamide,
N-(3-Acetyl-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide,
N-(2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -4-methyl- phenyl)-acetamide, N-(5-Fluoro-2- { 3 -[3 -(4-fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } - phenyl)-acetamide,
1 -[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-3-( 1 H-indol-7-yloxy)-propan-2-ol,
1 -(7- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -indol- 1 -yl)- ethanone,
N-(4- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -biphenyl-3-yl)- acetamide,
N-(4-Fluoro-2- {3-[3-(4-fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } - phenyl)-acetamide, N-(2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -5-methyl- phenyl)-acetamide,
N-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
N-(5-Chloro-2- { 3 - [3 -(3 ,4-difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } - phenyl)-acetamide,
N-(3-Acetyl-2-{3-[3-(3,4-difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide,
N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-methyl- phenyl)-acetamide, N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-fluoro- phenyl)-acetamide, l-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-3-(lH-indol-7-yloxy)-propan-2-ol, l-(7-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-indol-l-yl)- ethanone, N-(4-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-biphenyl-3- yl)-acetamide,
N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-fluoro- phenyl)-acetamide,
N-(2- {3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -5-methyl- phenyl)-acetamide, N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
N-(5-Chloro-2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide, N-(3-Acetyl-2- {3-[4-(3,4-dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide,
N-(2- {3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-4-methyl- phenyl)-acetamide,
N-(2- {3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -5-fluoro- phenyl)-acetamide,
1 -(7- {3-[4-(3,4-Dichloro-phenoxy)-piperidin-l -yl]-2-hydroxy-propoxy}-indol- 1 -yl)- ethanone,
N-(4- {3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -biphenyl-3- yl)-acetamide, N-(2- {3-[4-(3,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy}-4-fluoro- phenyl)-acetamide,
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide,
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
N-(5-Chloro-2- {3-[4-(4-chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} - phenyl)-acetamide,
N-(3-Acetyl-2- {3-[4-(4-chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -5- methyl-phenyl)-acetamide, N-(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -4-methyl- phenyl)-acetamide,
N-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5-fluoro- phenyl)-acetamide,
1 -(7- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -indol- 1 -yl)- ethanone, N-(4-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-biphenyl-3-yl)- acetamide,
N-(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -4-fluoro- phenyl)-acetamide, N-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide,
N-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
N-{5-Chloro-2-[3-(8-chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- propoxy] -phenyl} -acetamide,
N- {3-Acetyl-2-[3-(8-chloro- 1 ,3 ,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- propoxy]-5-methyl-phenyl}-acetamide,
N-{2-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-4- methy 1-phenyl } -acetamide, N-{2-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-5- fluoro-phenyl } -acetamide, l-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-3-(lH-indol-7-yloxy)-propan- 2-ol, l-{7-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- indol- 1 -yl } -ethanone,
N-{4-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- biphenyl-3-yl} -acetamide,
N-{2-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-4- fluoro-phenyl} -acetamide, N-{2-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-5- methyl-phenyl} -acetamide,
N-{2-[3-(8-Chloro-l,3,4,5-tetrahydro-ρyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- phenyl } -acetamide,
N-{5-Chloro-2-[3-(8-fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- propoxy]-phenyl} -acetamide, N-{3-Acetyl-2-[3-(8-fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- propoxy]-5-methyl-phenyl}-acetamide,
N-{2-[3-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-4- methyl-phenyl} -acetamide, N- {5-Fluoro-2-[3-(8-fluoro- 1 ,3,4,5-tefrahydro-pyrido[4,3-b]indol-2-ylV2-hydroxy- propoxy] -phenyl} -acetamide, l-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-3-(lH-indol-7-yloxy)-propan- 2-ol, l-{7-[3-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- indol-1-yl} -ethanone,
N-{4-[3-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- biphenyl-3-yl} -acetamide,
N-{4-Fluoro-2-[3-(8-fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- propoxy]-phenyl} -acetamide, N-{2-[3-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-5- methyl-phenyl} -acetamide,
N-{2-[3-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- phenyl} -acetamide,
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
3-(2- {3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- propionic acid methyl ester,
1 -[4-(3,4-Dichloro-phenoxy)-piperidin- 1 -yl]-3-(2,6-dimethoxy-phenoxy)-propan-2-ol,
1 - [4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl] -3 -(2-methoxy-phenoxy)-propan-2-ol, 2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide,
1 -(2- {3-[4-(3,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- propan-1-one,
1 -(2- {3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy}-phenyl)- ethanone, 3-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester,
1 -(2,6-Dimethoxy-phenoxy)-3-[3-(4-fluoro-phenoxy)-pyrrolidin- 1 -yl]-propan-2-ol,
1 -[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol, (2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -benzoylamino)- acetic acid methyl ester,
(2- {3-[3-(4-Chloro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} - benzoylamino)-acetic acid methyl ester,
2-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- 2-methyl-propionic acid methyl ester,
2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide, l.-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-6-methoxy- phenyl)-ethanone, 1 -(2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)-propan-
1-one, l-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- ethanone,
N-[2-(3-{[l-(3,4-dichlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-4- methylphenyl]acetamide,
3-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester,
1 -[3-(3,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol,
(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-acetic acid methyl ester,
2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide,
1 -(2- {3-[3 -(3 ,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -6-methoxy- phenyl)-ethanone, l-(2-{3-[3-(3,4-Difluoro-ρhenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propan-1-one, l-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- ethanone, N-(2- {3-[4-(3,4-dichloroanilino)-l-piperidinyl]-2-hydroxypropoxy} phenyl)acetamide,
3-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-ρroρoxy} -phenyl)- propionic acid methyl ester,
1 -[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-3-(2,6-dimethoxy-phenoxy)-propan-2-ol, l-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol, (2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -benzoylamino)- acetic acid, methyl ester,
2-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-proρoxy}-benzoylamino)- 2-methyl-propionic acid methyl ester,
2- {3-[3-(4-Chloro-ρhenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-ρropoxy) -N,N-dimethyl- benzamide,
1 -(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -6-methoxy- phenyl)-ethanone,
1 -(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)-propan- 1-one, 1 -(2- {3-[3-(4-Chloro-phenoxy)-ρyrrolidin-l -yl]-2-hydroxy-propoxy} -phenyl)- ethanone,
N-(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
3-(2- {3-[3-(4-Cyano-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- propionic acid methyl ester,
(2- {3-{3-(4-Cyano-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy }-benzoylamino)- acetic acid methyl ester,
2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide, 4- { 1 -[2-Hydroxy-3-(2-propionyl-phenoxy)-propyl]-pyrrolidin-3-yloxy} -benzonjtrile, N-(2- {2-Hydroxy-3-[3-(4-methoxy-phenoxy)-pyrrolidin- 1 -yl]-propoxy} -phenyl)- acetamide,
N-(4-chloro-2- {3-[4-(3 ,4-dichloroanilino)- 1 -piperidinyl]-2- hy droxypropoxy } phenyl)acetamide, 3-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester, l-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol,
(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-acetic acid methyl ester, 2-(2- {3-[3-(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} - benzoylamino)-2-methyl-propionic acid methyl ester,
2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide,
1 -(2- {3-[3-(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -6-methoxy- phenyI)-ethanone,
1 -(2- {3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- propan-1-one,
1 -(2- {3-[3-(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- ethanone, N-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
3 -(2 - {3 -[4-(3 ,4-Difluoro-phenoxy)-piperidin- 1 -yl] -2 -hydroxy-propoxy } -phenyl)- propionic acid methyl ester,
2- {3-[4-(3,4-Difluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide,
1 -(2- {3-[4-(3,4-Difluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- propan-1-one,
(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-proρoxy}-benzoylamino)- acetic acid methyl ester, N-(2- {3-[3-(3,4-Difluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy } - phenyl)-acetamide,
N-(2-{3-[4-(4-Fluoro-phenoxy)-piρeridin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide, 3-(2- {3-[4-(4-Fluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)-propionic acid methyl ester,
1 -(2,6-Dimethoxy-phenoxy)-3-[4-(4-fluoro-phenoxy)-piperidin- 1 -yl]-propan-2-ol,
1 -[4-(4-Fluoro-phenoxy)-piperidin- 1 -yl]-3-(2-methoxy-phenoxy)-ρropan-2-ol, l-(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)-ethanone, 2- {3-[4-(4-Fluoro-phenoxy)-piperidin- 1 -yl]~2-hydroxy-propoxy}-N,N-dimethyl- benzamide, l-(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propan- 1-one,
(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester,
N-(2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- acetamide,
3-(2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- propionic acid methyl ester, 1 -[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol,
1 -(2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- ethanone,
2-(2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} - benzoylamino)-2-methyl-proρionic acid methyl ester, 2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} -N,N- dimethyl-benzamide,
1 -(2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} -6- methoxy-phenyl)-ethanone,
N-(2- {3-[4-(4-Acetylamino-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- acetamide, N-(4- { 1 -[3-(2- Acetyl-phenoxy)-2-hydroxy-propyl]-piperidin-4-yloxy } -phenyl)- acetamide,
JV-(4-cyano-2- {3-[4-(3,4-dichloroanilino)-l -piperidinyl]-2- hydroxypropoxy } phenyl)acetamide, 3-(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- propionic acid methyl ester, l-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol,
1 -(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- ethanone, 2-(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -benzoylamino)-2- methyl-propionic acid methyl ester,
2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide,
1 -(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -6-methoxy- phenyl)-ethanone,
1 -(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)-propan- 1-one,
(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -benzoylamino)- acetic acid methyl ester, N-(2- {3-[3-(4-Chloro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-ρropoxy } -phenyl)- acetamide,
3-(2- {3-[3-(4-Chloro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-proρoxy} -phenyl)- propionic acid methyl ester,
1 -(2- {3-[3-(4-Chloro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- ethanone,
2-{3-[3-(4-Chloro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N- dimethyl-benzamide,
1 -(2- {3-[3-(4-Chloro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- propan-1-one, N-[2-( {( ΪR,2R)-2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyl]- 1 - hydroxycyclopentyl}methoxy)phenyl]acetamide,
Methyl (2S,4R)- 1 - {3-[2-(acetylamino)phenoxy]-2-hydroxypropyl} -4-[(4- chlorobenzyl)oxy]-2-pyrrolidinecarboxylate hydrochloride, N-(2-{3-[4-(3,4-Dichloroanilinb)-l-piperidinyl]-2-hydroxypropoxy}-4- methylphenyl)acetamide,
N-(2- (3-[4-(4-Chloroanilino)- 1 -piperidinyl]-2-hydroxypropoxy}phenyl)acetamide,
N-(4-Chloro-2- {3-[4-(4-chloroanilino)- 1 -piperidinyl]-2-hydroxypropoxy} phenyl)- acetamide, N-(2- {3-[4-(4-Chloroanilino)- 1 -piperidinyl]-2-hydroxypropoxy} -4- cyanophenyl)acetamide,
N-(2- {3-[4-(4-Chloroanilino)- 1 -piperidinyl] -2-hydroxypropoxy} -4- methylphenyl)acetamide,
N-(5-Chloro-2- {3-[4-(4-fluoroanilino)- 1 -piperidinyl]-2- hydroxypropoxy}phenyl)acetamide,
N-(5-Chloro-2- {3-[4-(3 ,4-difluoroanilino)- 1 -piperidinyl]-2- hydroxypropoxy } phenyl)acetamide,
N-(5-Cyano-2-{3-[4-(4-fluoroanilino)-l-piperidinyl]-2-hydroxypropoxy}- phenyl)acetamide, N-(5-Cyano-2-{3-[4-(3,4-difluoroanilino)-l-piperidinyl]-2- hydroxypropoxy}phenyl)acetamide,
N-(2- {3-[4-(4-Fluoroanilino)- 1 -piperidinyl]-2-hydroxypropoxy} -4- methylphenyl)acetamide,
N-(2-{3-[4-(3,4-Difluoroanilino)-l-piperidinyl]-2-hydroxypropoxy}-4- methylphenyl)acetamide,
N-(2- {3-[3(S)-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-(R)-hydroxy-propoxy- phenyl)acetamide,
N-(2- {3-[3 S-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2S-hydroxy-propoxy} -phenyl)- acetamide hydrochloride, N-(2-{3-[3(R)-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-(S)-hydroxy-propoxy- phenyl)acetamide,
N-[5-Chloro-2-({(2S)-3-[(3S)-3-(4-chloro-phenoxy)pyrrolidinyl]-2- hydroxypropyl } oxy)phenyl] acetamide, N-[5-Chloro-2-({(2R)-3-[(3R)-3-(4-chloro-phenoxy)pyrrolidinyl]-2- hydroxypropyl}oxy)phenyl]acetamide,
N-[5-Chloro-2-({(2S)-3-[(3R)-3-(4-chloro-phenoxy)pyrrolidinyl]-2- hydroxypropyl}oxy)phenyl]acetamide,
N-[5-Chloro-2-( {(2R)-3-[(3 S)-3-(4-chloro-phenoxy)pyrrolidinyl]-2- hydroxypropyl} oxy)phenyl]acetamide,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -4,5-difluoro- phenyl)-acetamide,
7Y-{5-Chloro-2-[2-hydroxy-3-(3-phenoxy-pyrrolidin-l-yl)-propoxy]-phenyl}- acetamide, 7y-(5-Chloro-2-{2-hydroxy-3-[3-(4-nitro-phenoxy)-pyrrolidin-l-yl]-propoxy}-phenyl)- acetamide,
7V-(5-Acetyl-2-{3-[3-(3,4-dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide,
4- Acetylamino-3 - { 3 - [3 -(3 ,4-dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } - benzoic acid methyl ester,
N-(3-{3-[3-(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl] -2-hydroxy-propoxy } -naphthalen- 2-yl)-acetamide,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -5-cyano- phenyl)-acetamide, 4-Acetylamino-3-{3-[3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-ρropoxy}- benzoic acid methyl ester,
N-(3 - { 3 - [3 -(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -naphthalen-2 - yl)-acetamide, iV-(5-Cyano-2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide, N-(2- {3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -5- trifluoromethyl-phenyl)-acetamide,
N-(5-Chloro-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide trifluoroacetate, N-(5-Acetyl-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide trifluoroacetate,
7V-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)- methanesulfonamide,
N-(5-Chloro-2-[3-[3,4-dichlorophenoxy)-l-pyrrodinyl]-2-hydroxypropoxy]- phenyl)urea,
1 -(3- {2-[(Aminocarbonyl)amino]phenoxy } -2-hydroxypropyl)-3-(4- chlorophenoxy)pyrrolidinium 2,2,2-trifluoroacetate, l-(3-{2-[(Aminocarbonyl)amino]phenoxy}-2-hydroxypropyl)-3-(3,4- dichlorophenoxy)pyrrolidinium 2,2,2-trifluoroacetate, 1 -(3- {2-[(Aminocarbonyl)amino]-4-chlorophenoxy} -2-hydroxypropyl)-3-(4- chlorophenoxy)pyrrolidinium 2,2,2-trifluoroacetate,
N-{2- {3-[3-(4-Chlorophenoxy)- 1 -pyrrolidinyl]-2-hydroxypropoxy}phenyl)-N- ethylurea hydrochloride,
N-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-7Y- methylurea hydrochloride,
(25',45)-l-{3-[2-(Acetylamino)phenoxy]-2-hydroxypropyl}-4-(4-chlorophenoxy)-2- pyrrolidinecarboxylic acid; compound with trifluoroacetic acid,
Ethyl (25,45 -l-{3-[2-(acetylamino)ρhenoxy]-2-hydroxvproρyl}-4-(3,4- dichlorophenoxy)-2-pyrrolidinecarboxylate; trifluoroacetic acid salt, N-[2-({(2-5,)-3-[(25,4-5)-4-(4-Chlorophenoxy)-2-(hydroxymethyl)pyrrolidinyl]-2- hydroxypropyl}oxy)phenyl] acetamide; trifluoroacetic acid salt,
N-[2-({(2i?)-3-[(2-S',4-S)-4-(4-Chlorophenoxy)-2-(hydroxvmethyl)pyrrolidinyl]-2- hydroxypropyl}oxy)phenyl] acetamide; trifluoroacetic acid salt,
7Y-(2- {3-[3-(4-Chlorophenoxy)-l -pyrrolidinyl]-2-hydroxy-2- methylpropoxy}phenyl)acetamide hydrochloride, N-(2-{(i ,2i?*,35*)-3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide,
N-(2-{(l ?*,2i?,,3.S,*)-3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide, N-(2- {(2R*,3R*)-3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-butoxy } - phenyl)-acetamide,
N-(2- {(l^,2i?*,3 )-3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide,
N-(2-{(2i?*,35*)-3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-butoxy}- phenyl)-acetamide,
N-(2- {(2i?*,3i?*)-3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-butoxy } - phenyl)-acetamide,
N-(2- {(2R*,3-5'*)-3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-butoxy } - phenyl)-acetamide, N-(2-{(l^,2i?*,35*)-3-[4-(3-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide,
N-[5-Chloro-2-({(15,2i?,31S)*-3-[4-(3,4-dichlorophenoxy)-l-piρeridinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide,
N-[4-Fluoro-2-( {(lS,2i?,3,S)*-3-[4-(3,4-dichlorophenoxy)- 1 -piperidinyl]-2- hydroxycyclopentyl} oxy)ρhenyl] acetamide,
N-(2-{3-[4-(3,4-Dichlorobenzyl)-l-piperazinyl]-2-hydroxypropoxy}-phenyl)acetamide dihydrochloride,
N-(2-{3-[4-(3,4-Dichlorobenzyl)-l-piperazinyl]-2-hydroxypropoxy}-4- fluorophenyl)acetamide, N-(2- {3-[4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l -ρiρerazinyl]-2- hydroxypropoxy } phenyl)acetamide,
N-(5-Chloro-2-{3-[4-(3,4-dichlorobenzyl)-l-ρiρerazinyl]-2- hydroxypropoxy } phenyl)acetamide,
N-(5-Chloro-2-{3-[4-(3,4-dichlorobenzyl)-2,5-dimethyl-l-ρiρerazinyl]-2- hydroxypropoxy}phenyl)acetamide, N-(2- {3-[4-(3 ,4-Dichlorobenzyl)-2,5-dimethyl- 1 -piperazinyl]-2-hydroxypropoxy } -4- methylphenyl)acetamide,
N-(2-{3-[4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2-hydroxypropoxy}-4- fiuorophenyl)acetamide, 5 N-(2-{3 [(S*R*)-4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2- hydroxypropoxy } phenyl)acetamide,
N-(2-{3 [(S*R*)-4-(4-CMorobenzyl)-2,5-dimethyl-l-piperazinyl]-2- hydroxypropoxy}phenyl)acetamide,
7V-(5-Chloro-2-{3-[(5*i?*)-4-(3,4-dichlorobenzyl)-2,5-dimethylpiperazinyl]-2- l o hydroxypropoxy } phenyl)acetamide,
7V-(5-Chloro-2-{3-[(>S*i?*)-4-(4-chloroberizyl)-2,5-dimethylpiperazinyl]-2- hydroxypropoxy } phenyl)acetamide,
1 -(5-Chloro-2- {3-[4-(4-chlorobenzoyl)- 1 -piperazinyl]-2-hydroxypropoxy} phenyl)- 1 - ethanone, is JV-(5-Cyano-2- {3-[(S*R *)-4-(3 ,4-dichlorobenzyl)-2,5-dimethylpiperazinyl]-2- hydroxypropoxy}phenyl)acetamide,
N-(2-{3-[(5*i?*)-4-(4-CUorobenzyl)-2,5-dimethylpiperazinyl]-2-hydroxypropoxy}-5- cyanophenyl)acetamide,
N-(5-Chloro-2- {3-[4-(4-chlorobenzyl)- 1 -piperazinyl]-2 -hydroxypropoxy} - 0 phenyl)acetamide,
N-(4-Chloro-2- {3-[4-(4-chlorobenzyl)-2,5-dimethyl- 1 -piperazinyl]-2- hydroxypropoxy}phenyl)acetamide,
N-(2- {3-[4-(4-Chlorobenzoyl)- 1 -piperazinyl]-2-hydroxypropoxy} -5- cyanoρhenyl)acetamide, 25 N-(2- {3-[4-(4-Chlorobenzoyl)- 1 -piperazinyl]-2-hydroxypropoxy} -4- methylphenyl)acetamide,
N-[5-Chloro-2-({(li?,2>S',3i?)-3-[(35)-3-(4-chlorophenoxy)pyrrolidinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide,
N- {2-[(2S)-(3- {(3S)-3-[(4-Chlorophenyl)oxy]- 1 -pyrrolidinyl} -2-hydroxyproρyl)oxy]- 30 4-fiuorophenyl} acetamide, yV-[2-({(2»S)-3-[(31S)-3-(4-Chlorobenzyl)pyrrolidinyl]-2- hydroxypropyl} oxy)phenyl]acetamide hydrochloride,
N-(5-Chloro-2-{3-[3-(4-chloro-benzyl)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide trifluoroacetic acid salt, N-(2- {3-[3-(4-Chlorophenoxy)~ 1 -pyrrolidinyl]-2-hydroxypropoxy } -4-methylphenyl)-
1 -pyrrolidinecarboxamide trifluoroacetate,
N-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}-4- hydroxyphenyl)acetamide trifluoroacetate,
N-[2-( {(2S)-3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyl]-2-hydroxypropyl} oxy)-4- fluorophenyl]acetamide trifluoroacetic acid salt,
N-(2-(3-(4-Chloro-phenoxy)-pyrrolidin-l-yl)-2-hydroxy-propoxy)-4,6-difluoro- phenyl)-acetamide hydrochloride,
7V-[2-( {(2-S)-3-[(2,S,45)-4-(4-Chlorophenoxy)-2-methylpyrrolidinyl]-2- hydroxypropyl}oxy)-4- fluorophenyl] acetamide trifluoroacetic acid salt, 7V-[2-({(25 -3-[(3i?)-3-(4-Chlorobenzyl)pyrrolidinyl]-2- hydroxypropyl } oxy)phenyl] acetamide hydrochloride,
N- {2-[(2R (3- {(3S)-3-[(4-Chlorophenyl)oxy]- 1 -pyrrolidinyl} -2-hydroxyρropyl)oxy]- 4-fluorophenyl} acetamide,
N-[2-({(2S)-3-[(2i?,41S)-4-(4-Chlorophenoxy)-2-methylpyrrolidinyl]-2- hydroxypropyl}oxy) phenyl]acetamide trifluoroacetic acid salt,
N-{2-[(2S)-(3-{(3R)-3-[(4-Chloroρhenyl)oxy]-l-pyrrolidinyl}-2-hydroxypropyl)oxy]- 4-fluorophenyl} acetamide, iV-(2- { 3 - [3 -(4-Chlorophenoxy)- 1 -pyrrolidinyl] -2-hydroxypropoxy } -4-methylphenyl)- TV^N-dimethylurea trifluoroacetate, N-(2- {3-[3-(4-Chloroanilino)- 1 -pyrrolidinyl] -2 -hydroxypropoxy }phenyl)acetamide,
TV- {2-[(3- {3-[(4-Chlorophenyl)oxy]- 1 -pyrrolidinyl} -2-hydroxy- 1 - methylproρyl)oxy]phenyl } acetamide hydrochloride,
7V-(2- {3-[3-(4-Chlorophenoxy)- 1 -pyrrolidinyl]-2-hydroxypropoxy} -4- methoxyphenyl)acetamide hydrochloride, N-(2-[3-(4-Chloro-benzyloxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy)-phenyl)- acetamide trifluoroacetic acid salt,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-2-methyl-propoxy } - phenyl)-acetamide, N-(2- {(1 S,2R,3S)*-3-[(3S)-3-(3 ,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy- cyclopentyloxy}-5-chloro-phenyl)-acetamide (diastereomeric mixture),
N-[2-({(2R,36) *-3-[(3^)-3-(4-Chlorophenoxy)pyrrolidinyl]-2-hydroxybutyl}oxy)-4- methylphenyl] acetamide (diastereomeric mixture),
N-{2-[(3-{4-[(3,4-Dichlorophenyl)oxy]-l-piperidinyl}-2-hydroxy-2- methylpropyl)oxy]-4-fluorophenyl} acetamide hydrochloride,
N-(2-{(15,2i?,35)*-3-[(31S)-3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy- cyclopentyloxy}-4-fluoro-phenyl)-acetamide (diastereomeric mixture),
N-(5-Chloro-2- {3-[3-(3 ,4-difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } - phenyl)-acetamide, N-(5-Chloro-2- {3-[3-(4-fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-ρropoxy} - phenyl)-acetamide,
N-(4-Cyano-2-{3-[4-(3,4-dichloroanilino)-l-piperidinyl]-2- hydroxypropoxy } phenyl)acetamide,
N-(4-Hydroxy-2-{(liS,2i?,3-S)*-3-[(3-S)-3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2- hydroxy-cyclopentyloxy}-phenyl)-acetamide (diastereomeric mixture),
N-(4-Hydroxy-2-{(l1S,2i?,35)-3-[(3.S)-5-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2- hydroxy-cyclopentyloxy}-phenyl)-acetamide,
N-(4-Hydroxy-2-{(li?,2lS,3R)-3-[(J,S -5-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2- hydroxy-cyclopentyloxy}-phenyl)-acetamide, N-[2-( {(l1S',2i?,35)-3-[(31S)-3-(4-Chlorophenoxy)pyrrolidinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide,
. 7Y-[2-({(lR,25',3i?)-3-[(3>S)-3-(4-Chlorophenoxy)pyrrolidinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide,
N-[5-Chloro-2-({(15,2i?,3-5)-3-[(35)-3-(4-chlorophenoxy)pyrrolidinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide, N- {5-Chloro-2-[(( 1 S,2R,3S)*-3- { [ 1 -(4-chlorobenzyl)-4-piperidinyl]amino} -2- hydroxycyclopentyl)oxy]phenyl} acetamide (racemic mixture), and
N-[2-({(21S)-3-[(35)-3-(4-Chlorophenoxy)pyrrolidinyl]-2-hydroxypropyl}oxy)-4- hydroxyphenyl] acetamide.
The present invention further provides a process for the preparation of a compound of formula (I) as defined above which comprises, (a) reacting a compound of general formula
R - H (II) wherein R is as defined in formula (I), with a compound of general formula
wherein Q,
Figure imgf000039_0001
ula (I); or (b) reacting a compound of general formula
Figure imgf000039_0002
wherein R, R , R , R , R and R° are as defined in formula (I), with a compound of general formula
L1 - Q - R2 (V) wherein L represents a hydrogen atom or an activating group (e.g. Li when Q is CH2) and
2 Q and R are as defined in formula (I); and optionally thereafter converting the compound of formula (I) to a further compound of formula (I); and, if desired, forming a pharmaceutically acceptable salt or solvate of the compound of formula (I).
In one aspect, the invention provides a process for the preparation of a compound of formula (F) as hereinbefore defined which comprises, (a) reacting a compound of general formula
R - H (IF) wherein R is as defined in formula (F), with a compound of general formula
Figure imgf000040_0001
wherein Q, R , R , R , R , R and R are as defined in formula (F); or (b) reacting a compound of general formula
Figure imgf000040_0002
wherein R, R , R , R , R and R° are as defined in formula (F), with a compound of general formula
L1 - Q - R2 (V) wherein L represents a hydrogen atom or an activating group (e.g. Li when Q is CH2) and
2 Q and R are as defined in formula (F);
and optionally thereafter converting the compound of formula (F) to a further compound of formula (F); and, if desired, forming a pharmaceutically acceptable salt or solvate of the compound of formula (F). In another aspect, the invention provides a process for the preparation of a compound of formula (I") as hereinbefore defined which comprises, (a) reacting a compound of general formula
R - H (II") wherein R is as defined in formula (I"), with a compound of general formula
Figure imgf000041_0001
wherein Q, R2, R4, R5, R6, R7 and R8 are as defined in formula (I"); or
(b) reacting a compound of general formula
Figure imgf000041_0002
S (Λ 7 R wherein R, R , R ,, RR ,, RR aanndd RR aarree aass ddeefifinneedd iinn f formula (I"), with a compound of general formula
L1 - Q - R2 (V") wherein L represents a hydrogen atom or an activating group (e.g. Li when Q is CH2) and
2 Q and R are as defined in formula (I");
and optionally thereafter converting the compound of formula (I") to a further compound of formula (I"); and, if desired, forming a pharmaceutically acceptable salt or solvate of the compound of formula (I").
In yet another aspect, the invention provides a process for the preparation of a compound of formula (F") as hereinbefore defined which comprises, (a) reacting a compound of general formula
R - H (IF") wherein R is as defined in formula (F"), with a compound of general formula
wherein Q,
Figure imgf000042_0001
ula (!'"); or
(b) reacting a compound of general formula
wherein R, R , R
Figure imgf000042_0002
a (F"), with a compound of general formula
L1 - Q - R2 (V") wherein L represents a hydrogen atom or an activating group (e.g. Li when Q is CH2) and
2
Q and R are as defined in formula (!'");
and optionally thereafter converting the compound of formula (F") to a further compound of formula (Im); and, if desired, forming a pharmaceutically acceptable salt or solvate of the compound of formula (F").
The processes of the invention may conveniently be carried out in a solvent, e.g. an organic solvent such as an alcohol (e.g. methanol or ethanol), a hydrocarbon (e.g. toluene) or acetonitrile at a temperature of, for example, 15°C or above such as a temperature in the range from 20 to 120°C.
Compounds of formulae (II), (IF), (II"), (IF"), (HI), (UT), (HI"), (HF"), (IV), (IV), (IV), (IV"), (V), (V), (V) and (V") are either commercially available, are well known in the literature or may be prepared easily using known techniques. Compounds of formula (I), (F), (I") or (F") can be converted into further compounds of formula (I), (F), (I") or (F") using standard procedures. For example, a compound of formula (I) in which R represents -NHC(O)CH3 can be converted to a further compound of formula (I) in which R represents -NH2 by a hydrolysis reaction in the presence of hydrochloric acid.
It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I), (F), (I") or (F") may involve, at an appropriate stage, the removal of one or more protecting groups.
The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley- Interscience (1991).
The compounds of formula (I), (F), (I") or (F") above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or 7-toluenesulphonate.
Compounds of formula (I), (F), (I") or (F") are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers of the compounds of formula (I), (F), (I") or (F") and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention. Enantiomerically pure forms are particularly desired. The compounds of formula (I), (F), (I") or (F") have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially MlP-lα chemokine receptor) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS).
Examples of these conditions are:
(1) (the respiratory tract) airways diseases including chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
(2) (bone and joints) rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
(3) (skin) psoriasis, atopical dermatitis, contact dermatitis and other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;
(4) (gastrointestinal tract) Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema; (5) (other tissues and systemic disease) multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome and idiopathic thrombocytopenia pupura;
(6) (allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
(7) cancers, especially non-small cell lung cancer (NSCLC) and squamous sarcoma;
(8) diseases in which angiogenesis is associated with raised CXCR2 chemokine. levels (e.g. NSCLC); and
(9) cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and sepsis.
Thus, the present invention provides a compound of formula (I), (F), (I") or (F"), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
In a further aspect, the present invention provides the use of a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly. The invention also provides a method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
The invention still further provides a method of treating an airways disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (I), (F), (I") or (F") may be in the range from 0.001 mg/kg to 30 mg/kg.
The compounds of formula (I), (F), (I") or (F") and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I), (F), (I") or (F") compound salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
The present invention also provides a pharmaceutical composition comprising a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier. The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), (F), (I") or (F"), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
The invention will now be further explained by reference to the following illustrative examples, in which Η NMR spectra were recorded on Varian Unity Inova 400. The central solvent peak of chloroform-c? (δH 7.27 ppm) were used as internal standard. Low resolution mass spectra and accurate mass determination were recorded on a Hewlett- Packard 1100 LC-MS system equipped with APCI /ESI ionisation chambers. All solvents and commercial reagents were laboratory grade and used as received. The nomenclature used for the compounds was generated with ACD/IUPAC Name Pro.
Example 1 iV-(2-{3-[3R,S-(4-Chloro-phenoxy)-pyrroUdin-l-yl]-2R,S-hydroxy-propoxy}-phenyl)- acetamide hydrochloride
(i) 3-Hydroxy-pyrrolidine-l-carboxylic acid tert-butyl ester
A solution of pyrrolidin-3-ol (16.25g, 186.5 mmol) and di-tert-butyl-dicarbonate (40.7g, 186.5 mmol) in dry THF (50 ml) under nitrogen was stirred over night. Concentration at reduced pressure and purification by flash chromatography on silica (EtOAc : heptane, 7 : 3) gave 31.9 g (91 %) of the subtitle compound. 'H-NMR (400MHz, DMSO-rfd): δ 4.87 (d, IH, J = 3.4 Hz), 4.21 (bs, IH), 3.31-3.22 (m, 3H), 3.10 (d, IH, J - 11.5 Hz), 1.83 (m, IH), 1.72 (m, IH), 1.39 (s, 9H). APCI-MS: m/z 132 [MH+-56]
(ii) 3-(4-Chloro-phenoxy)-pyrrolidine
3 -Hydroxy-pyrrolidine-1 -carboxyhc acid tert butyl ester (2.1g, 9.9 mmol) and triphenyl phosphine (2.59g, 9.9 mmol) were dissolved in dry THF (35 ml) under nitrogen. The solution was cooled to 0°C and 4-chlorophenol (1.28g, 9.9 mmol) dissolved in dry THF (10 ml) was added followed by diethyl azodicarboxylate (DEAD) (1.55 ml, 9:9 mmol). After 15 minutes the ice bath was removed and the reaction was stirred overnight.
The reaction mixture was concentrated under reduced pressure and the residue was stirred with ether. The solid triphenyl phosphine oxide was filtered off. The solution was washed three times with sodium hydroxide (IM) and concentrated. The BOC-protected product was purified by flash chromatography on silica using EtOAc/ heptane as eluant. It was dissolved in dichloromethane (35 ml) and trifluoroacetic acid (17 ml). The reaction mixture was stirred at room temperature overnight, concentrated and purified by flash chromatography on silica (MeOH:CHCl3:NH3, 100:100:1) to give the subtitle compound (1.72g, 88%).
'H-NMR (400MHz, DMSO-ύ ): δ 7.30 (d, 2H, J = 8.9 Hz), 6.91 (d, 2H, J = 8.9 Hz), 4.82 (m, IH), 3.03 (dd, IH, J = 12.3, 5.4 Hz), 2.82 (m, 3H), 1.99 (m, IH), 1.72 (m, IH). APCI-MS: m/z 198 [MH+]
(ϋi) iV-(2-{3-[3R,S-(4-Chloro-phenoxy)-pyrrolidm-l-yl]-2R,S-hydroxy-propoxy}- phenyl)-acetamide hydrochloride
A solution of 3-(4-Chloro-phenoxy)-pyrrolidine (0.059 g, 0.298 mmol) and N-acetyl-2- (2,3-epoxyρropoxy)aniline (0.062 g, 0.299 mmol) in EtOH (1.5 ml, 99.5%) was stirred for 3 hours at 75°C in a sealed vial. The solvent was evaporated after completion of the reaction and the residue was purified on silica (CH2Cl2:MeOH, 98:2 to 97:3) to give 88 mg of the free amine of the title compound. The amine was dissolved in MeOH : water 1 : 1 (30 ml), and the solution was acidified with 2M hydrochloric acid. The methanol was evaporated and the residual water solution was lyophilized to give 92 mg (70%) of the title compound as a white solid.
APCI-MS : m z 405.2, 407.2 [MH+, isotope pattern]
Example 2
7Y-(5-Chloro-2-{3-[3R,S-(4-Chloro-phenoxy)-pyrroIidin-l-yI]-2R,S-hydroxy-propoxy}- phenyl)-acetamide hydrochloride
(i) 7Y-(5-Chloro-2-hydroxy-phenyl)-acetamide
A solution of 4-amino-2-chlorophenol (2.0g, 13.9 mmol) and acetic anhydride (1.77g, 17.3 mmol) in water (40 ml) was stirred vigorously for 5 minutes. The reaction mixture was then heated with stirring to 60°C for 30 minutes, and was then allowed to cool. A pink solid was formed and the precipitate was collected by filtration, washed twice with water, and dried to give 1.8g (70%) of the subtitle compound.
'H-NMR (400 MHz, DMSO-rf ): δ 10.09 (IH, s); 9.25 (IH, bs); 7.93 (IH, s); 6.93 (IH, dd, J8.8, 2.7 Hz); 6.84 (IH, d, J8.6 Hz); 2.09 (3H, s) APCI-MS: m/z 186.0 [MH+]
(ii) N-(5-Chloro-2-oxiranylmethoxy-phenyl)-acetamide
A solution of N-(5-Chloro-2-hydroxy-phenyl)-acetamide (0.499 g, 2.68 mmol), K2CO3 (0.60 g, 4.35 mmol) and epibromohydrin (0.405 g, 2.95 mmol) in DMF (5 ml) was heated with stirring at 50°C for 2 hours. The mixture was then partitioned between EtOAc and water 40+40 ml. The organic phase was washed twice with water and once with brine and finally concentrated in vacuo to give a crude product. The crude product was purified on silica (heptane : EtOAc, 1 : 1), to give 0.43 g (66%) of a white solid. 'H-NMR (400MHz, CDC13): δ 8.46 (IH, d, J2.3 Hz); 7.90 (IH, bs); 6.98 (IH, dd, J8.7, 2.4 Hz); 6.83 (IH, d, J8.8 Hz); 4.36 (IH, dd, J 11.5, 2.4 Hz); 3.94 (IH, dd, J 11.6, 6.0 Hz); 3.41-3.36 (IH, m); 2.97 (IH, dd, J4.7, 4.2 Hz); 2.80 (IH, dd, J4.6, 2.6 Hz); 2.23 (3H, s)
(iϋ) N-(5-Chloro-2-{3-[3R,S-(4-Chloro-phenoxy)-pyrroIidin-l-yl]-2R,S-hydroxy- propoxy}-phenyl)-acetamide hydrochloride
Prepared by a process analogous to that described in Example 1, step (iii).
Example 3 /y-(2-{3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2-hydroxypropoxy}phenyl)- acetamide
Prepared according to the methods described in Example 1. Purified and isolated as the free amine in 73% yield by C18-column chromatography (H2O:CH3CN, 0. IM NH4OAc buffer, gradient 30% to 95% CH3CN).
APCI-MS m/z: 453, 455 [MH+]
'H NMR (400 MHz, CDC13) : δ 7.32(d, IH), 7.01(d, IH), 6.85-8.80(m, 2H), 6.78-6.69 (m, 3H), 4.31 (m, IH), 4.15-4.09(m, IH), 4.18-3.18(bs, 3H), 2.91(m, IH), 2.71(m, IH), 2.62-2.52(m, 3H), 2.35(m, IH), 2.05-1.93(m, 2H), 1.89-1.77(m, 2H)
Example 4 l-(2-anιinophenoxy)-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2-propanol dihydrochloride
N-(2-{3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2-hydroxypropσxy}phenyl)acetamide (1.418g, 3.13 mmol) was dissolved in 50ml HCl (35%/aq, puriss) and refluxed overnight. The product precipitated and was filtered and dried to give 0.835 g (65%) of the title compound. APCI-MS m/z: 411, 413 [MH+]
'H NMR (400 MHz, CDC13) : δ 8.39-3.31 (m, 2H), 7.3 l(d, IH), 7.01-6.98(m, 3H), 6.94-6.9 l(m, IH), 6.75(dd, IH), 4.3 l(m, IH), 4.12-4.02 (m, 2H), 3.92(dd, IH), 2.90(m, IH), 2.69(m, IH), 2.62-2.51(m, 2H), 2.46(dd, IH), 2.34(m, IH), 2.18(s, 3H), 2.04-1.93(m, 2H), 1.89-1.77(m, 2H).
Example 5
N-(2-{3-[3-(3,4-dichlorophenoxy)-l-pyrrolidinyl)-2-hydroxypropoxy}phenyl)- acetamide hydrochloride
Prepared according to the methods described in Example 1 to give 68mg (68%) of the title compound as a white solid.
APCI-MS m/z: 439, 441 [MH+]
Example 6
2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-benzoic acid methyl ester
(i) 2-Oxiranylmethoxy-benzoic acid methyl ester
Prepared according to the method described in Example 2, step (ii).
'H-NMR: (400 MHz, CDC13): δ 7.81 (IH, dd, J7.7 , 1.7Hz); 7.46 (IH, dt, J7.7 , 1.7 Hz); 7.05-6.98 (2H, m); 4.33 (IH, dd, J 11.3 , 3.0 Hz); 4.11 (IH, dd, J 11.3 , 4.8 Hz); 3.90 (3H, s); 3.43-3.37 (IH, m); 2.93-2.90 (2H, m)
(ii) 2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-benzoic acid methyl ester
Prepared according to the method described in Example 1, step (ii). Isolated as the free amine 'H-NMR: (400 MHz, CDC13): δ 7.81 (IH, dd, J8.1 , 1.8 Hz); 7.46 (IH, dt, J7.8 , 1.7 Hz); 7.03-6.91 (4H, m); 6.86-6.82 (2H, m); 4.28-4.10 (3H, m); 4.08-4.00 (IH, m); 3.88 (3H, s); 2.92-2-84 (IH, m); 2.83-2.76 (IH, m); 2.66-2.53 (2H, m); 2.46 (IH, t, J 10.2 Hz); 2.36 ( 1 H, t, J 10.2 Hz); 2.02-1.92 (2H, m); 1.86-1.74 (2H, m); 1.63 (lH, bs) APCI-MS: m/z 404.2 [MH+]
Example 7
2-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-2-methyl-propionic acid methyl ester
(i) Methyl 2-[(2-hydroxybenzoyl)amino]-2-methylpropanoate
To a solution of 2-(chlorocarbonyl)phenyl acetate (20 mmol, 3.96g) in toluene (50ml) were iV-ethyl-iV^N-diisopropylamine (22 mmol, 2.84g) and 2-methylalanine (22 mmol, 2.27g) added. After stirring the reaction mixture at room temperature overnight, the mixture was diluted with 250ml toluene and was washed with 1.8% HCl/aq (250 ml) and sat. NaCl/aq (250 ml). The organic phase was dried over Na2SO4 and concentrated under reduced pressure. The residue was dissolved in MeOH (50mL) and 3 drops of cone. H2SO4 were added. The mixture was refluxed for 2 hours and concentrated under reduced pressure. The residue was dissolved in 250mL EtOAc and washed with sat.NaHCO3/aq (250 ml) and sat. NaCl/aq (250 ml). The organic phase was dried over Na2SO4 and concentrated at reduced pressure. The resulting crude material was used without further purification. APCI-MS m/z: 238 [MH+]
(ii) Methyl 2-methyl-2-{[2-(2-oxiranylmethoxy)benzoyl]amino}propanoate
A solution of methyl 2-[(2-hydroxybenzoyl)amino]-2-methylpropanoate, K2CO3 (20 mmol, 2.68g) and 2-(chloromethyl)oxirane (22 mmol, 2.03g) in acetonitrile (60 ml) was stirred at reflux temperature overnight. The reaction mixture was diluted with EtOAc and washed with 1.8%> HCl/aq (250 ml) and sat. NaCl/aq (250 ml). The organic phase was dried over Na2SO4 and concentrated at reduced pressure. The residue was purified on C18-column (H2O:CH3CN, 0.1M NH4OAc buffer, gradient 10% to 95% CH3CN) to give the subtitle compound (244mg, 5% yield, two steps).
APCI-MS m/z: 294 [MH+] Η NMR (400 MHz, CDC13) : δ 8.40(s, IH), 8.14 (dd, IH), 7,41 (dt, IH), 7.07 (t, IH), 6.90 (d, IH), 4,44 (dd, IH), 4.07 (dd, IH), 3.74 (s, 3H) , 3.45 (m, IH) , 2.94 (dd, IH), 2.84 (dd, IH), 1.64 (d, 6H)
(iii) 2-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- benzoyIamino)-2-methyl-propionic acid methyl ester
A toluene solution of 4-(3,4-difluorophenoxy)piperidine (0.03 ml, 0.5 M) was mixed with a toluene solution of methyl 2-methyl-2-{[2-(2-oxiranylmethoxy)benzoyl]amino}- propanoate (0.03 ml, 0.5 M). The mixture was diluted with 0.20 ml toluene and 0.05 ml methanol. The reaction mixture was stirred overnight at 100° C in sealed vials. The product were concentrated in vacuo and used without any purification.
APCI-MS m/z: 507 [MH+]
'H NMR (400 MHz, CDC13) : δ 8.13(s, IH) , 7.90 (dd, IH), 7.33 (dt, IH), 7.07-6.96 (m, 2H), 6.89 (d, IH), 6.73-6.68 (m, IH), 6.58-6.55 (m, IH), 4.77-4.72 (m, IH), 4.49 (bs, IH), 4.20-4.13 (m, 2H), 3.69 (s, 3H), 3.58-3.44 (m, 2H), 3.39-3.26 (m, 4H), 2.54-2.40 (m, 2H), 2.13-2.04 (m, 2H), 1.60 (d, 6H)
Example 8 N-[2-({(lR,2S,3R)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl)-2- hydroxycyclopentyl}oxy)phenyl] acetamide and N-[2-({(lS,2S,3R)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl)-2- hydroxy cyclopentyl} oxy)phenyl] acetamide
(i) N-[2-(2-cycIopenten-l-yloxy)phenyl]acetamide To a suspension of sodium hydride (60 proc. in paraffin; 297 mg, 7.43 mmol, 1.1 equiv.) in DMF (3 ml) a solution of 2-acetamido-phenol (1.02 g, 6.75 mmol, 1.0 equiv.) in DMF (12 ml) was added dropwise at 0°C. After 30 minutes chlorocyclopent-2-ene (R. Moffett. Organic Synthesis, Wiley: New York 1963, Collect. Vol. IV, p.238-241) (762 mg, 0.76 ml, 7.43 mmol, 1.1 equiv.) was added by a syringe and stirring was continued overnight. Aqueous work-up followed by flash chromatography on silica gel (heptane/ethyl acetate, 2:1 continued to 1:1) afforded 992 mg (68 %) of the subtitle compound as a dark, yellow oil.
'H-NMR (400 MHz, CDC13): δ 8.35 (IH, d, J 8.0Hz), 7.73 (IH, bs), 7.00 (IH, td, J 7.9, 1.5Hz), 6.90-6.95 (2H, m), 6.17 (IH, m), 5.95 (IH, m), 5.36 (IH, d, J 5.9Hz), 2.59 (IH, m), 2.38 (2H, m), 2.17 (3H, s), 1.97 (IH, m). MS-ESI+ : m/z 218.1 [MH+].
(ii) iV-{2-(6-oxabicyclo[3.1.0]hex-2-yloxy)phenyl}acetamide
To an ice bath cooled solution of iV-[2-(2-cyclopenten-l-yloxy)phenyl]acetamide (149 mg, 686 μmol, 1.0 equiv.) in dichloromethane (4 ml) An-chloroperbenzoic acid (85 proc; 146 μmol, 1.1 equiv.) was added. After stirring overnight with slowly warming up to an ambient temperature the reaction mixture was diluted by terώutyl(methyl)ether, washed successively by a sat. sodium bisulfate solution, 5 proc. sodium hydroxide and brine and dried over sodium sulfate. Evaporation of the solvent and flash chromatography on silica gel (ethyl acetate heptane, 2:3 continued to ethyl acetate) yielded 93 mg (58 %) of the subtitle compound as a mixture of the trans, (minor) and the cis (major) diastereoisomeric epoxides as a pale yellow oil. The cis/trans ratio was determined as 2:1 by Η-NMR.
'H-NMR (400 MHz, CDC13): δ 8.39 (IH [A], m), 8.34 (IH [B], d, J 8.2Hz), 7.91 (IH [A], bs), 7.59 (IH, [B], bs), 6.92-7.25 (3H [A] + 3H [B], m), 4.89 (IH [B], d, J 5.2Hz), 4.77 (IH [A], td, J 8.0, 1.3Hz), 3.66 (IH [B], m), 3.64 (IH [B], m), 3.60 (IH, [A], m), 3.54 (IH [A], m), 2.23 (IH [B], d, J 8.4Hz), 2.21 (3H [A], s), 2.19 (3H [B], s), 2.10 (2H [A], m), 1.72- 1.92 (m), 1.53-1.63 (m) (2H [A] + 3H [B]). {K=trans, B=cis) MS-ESI+: m/z 234.1 [MH+].
(iii) N-[2-({(lR,2-S,3R)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl)-2- hydrox c clopentyl} oxy)phenyl] acetamide and N-[2-({(lS,2S,3i?)*-3~[4-(3,4-dichlorophenoxy)-l-piperidmyl)-2- hydroxy cyclopentyl} oxy)phenyl] acetamide
N-{2-(6-oxabicyclo[3.1.0]hex-2-yloxy)phenyl} acetamide (racemic mixture of the trans and cis diastereoisomers) (87 mg, 373 μmol, 1.0 equiv.) and 4-(3,4-dichIorophenoxy)piperidine (92 mg, 394 μmol, 1.06 equiv.) were dissolved in 2 M lithium perchlorate in acetonitrile (3 ml) and heated in a sealed tube over night at 85 °C. Aqueous work-up and flash chromatography of the crude on silica gel (heptane/ethyl acetate/methanol/ammonia = 1:3:0:0 continued to 0:90:10:1 to 0:80:20:3) led to the separation of two diastereoisomeric addition products to give 24 mg (14 %) of the (1S,2S,3R) diastereoisomer (first eluted) and 75 mg (42 %) of the second eluted (IR,2S,3R) diastereoisomer.
For (IS,2S,3R) diastereoisomer:
'H-NMR (400 MHz, CDC13): δ 8.27 (IH, dd, J 7.6, 1.7Hz), 7.91 (IH, s), 7.29 (IH, d, J 8.9Hz), 6.88-7.00 (4H, m), 6.73 (IH, dd, J 8.9, 2.8Hz), 4.45 (IH, m), 4.28 (IH, hept, J 3.6Hz), 4.18 (IH, dd, J 7.1, 4.6Hz), 2.87 (3H, m), 2.71 (IH, q, J 7.5Hz), 2.15 (3H, s), 2.11 (lH5 m), 1.78-2.02 (7H, m). MS-APCI+: m/z 479.1 [MH+].
For (ΪR,2S,3R) diastereoisomer:
'H-NMR (400 MHz, CDC13): δ 8.20-8.25 (2H, m), 7.29 (IH, d, J 8.9Hz), 6.91-7.00 (4H, m), 6,74 (IH, dd, J 8.9, 2.8Hz), 4.46 (IH, bq, J 4.8Hz), 4,29 (IH, m), 4.13 (IH, d, J 7.2Hz), 2.95 (2H, ), 2.84 (2H, m), 2.50 (2H, m), 2.15 (3H, s), 1.93-2.07 (5H, m), 1.82 (2H, m), 1.58 (lH, m). MS-APCI+ : m z 479.1 [MH+].
Example 9 iV-[2-({(2,3-trα«5)-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2- hydroxy cyclohexyl} oxy)phenyl] acetamide
(i) iV-[2-(2-cyclohexen-l-yloxy)phenyl] acetamide 2-Cyclohexenol (491 mg, 0.49 ml, 5.00 mmol, 1.0 equiv.), 2-acetamidophenol (756 mg, 5.00 mmol, 1.0 equiv.) and triphenylphosphine (1.44 g, 5..50 mmol, LI equiv.) were dissolved in THF (10 ml) and kept at ambient temperature by a water bath. After dropwise addition of diethyl azodicarbonic acid (871 mg, 0.78 ml, 5.00 mmol, 1.0 equiv.), dissolved in THF (3 ml), the reaction mixture was stirred over night. Extractive work-up and flash chromatography on silica gel (heptane/tertbutyl(methyl)ether = 1:1) afforded 224 mg (19 %) the title compound as a yellow oil.
MS-ESI+: m/z 232.2 [MH+].
(ii) N-[2-(7-oxabicyclo[4.1.0]hept-2-yloxy)phenyl]acetamide
To a solution of 7Y-[2-(2-cyclohexen-l-yloxy)phenyl] acetamide (76 mg, 329 μmol, 1.0 equiv.) in dichloromethane (5 ml) m-chlorobenzoic acid (85 proz.; 121 mg, 559 μmol, 1.7 equiv.) was added at 0°C. Stirring was continued overnight while the reaction mixture was allowed to warm up slowly to room temperature. The heterogenous mixture was diluted with ethyl acetate and washed with sat. sodium sulfite, 5 % sodium hydroxide and brine. Drying over sodium sulfate, evaporation of the solvent and flash chromatography on silica gel provided 59 mg (73 %) of the title compound as a mixture of the diastereoisomers (ratio A:B = trans:cis = 5:3 [Η-NMR]).
'H-NMR (400 MHz, CDC13): δ 8.35 (IH [A] + IH [B], m), 8.02 (IH [A], bs), 7.70
(IH [B], bs), 6.95-7.04 (3H [A] + 3H [B], m), 4.62 (IH [A], dd, J 8.4, 5.5, 2.1Hz), 4.55 (IH [B], dd, J 7.5, 6.7Hz), 3.30-3.36 (2H [A] + IH [B], m), 3.19 (IH [B], t, J 3.6Hz), 1.26-2.23 (10H [A] + 10H [B], m).
LC/MS-ESI+: m/z 248.1 [MH+ (A)], 248.2 [MH+ (B)]. (iii) N-[2-({(2,3-ϊrαns)-3-[4-(3,4-dichlorophenoxy)-l-piperidinyI]-2- hydroxy cyclohexyl} oxy)phenyl] acetamide
The diastereoisomeric mixture of 7Y-[2-(7-oxabicyclo[4.1.0]hept-2-yloxy)phenyl]acetamide (59 mg, 239 μmol, 1.0 equiv.) and 4-(3,4-dichlorophenoxy)piperidine (56 mg, 239 μmol, 1.0 equiv.) were dissolved in 2 M lithium perchlorate in acetonitrile (2 ml) and heated in a sealed tube over night at 85 °C. Aqueous work-up and flash chromatography on silica gel (heptane/ethyl acetate/methanol = 50:100:3) gave 86 mg (75 %) as a yellow oil in a diastereoisomeric ratio of 69:31 = A:B (Η-NMR). No separation of the diastereoisomers on reversed phase columns could be observed. The relative stereochemistry of the major and minor diastereoisomers, respectively, could not be assigned due to the complex spectrum of the mixture.
'H-NMR (400 MHz, CDC13): δ 9.48 (IH [A], bs), 9.25 (IH [B], bs), 8.46 (IH [A] + IH [B], t, J 9.1Hz), 7.22-7.32 (2H [A] + IH [B], m), 6.93-7.08 (4H [A] + 5H [B], m),
6.72-6.76 (IH [A] + IH [B], m), 4.08-4.30 (3H [A] + 3H [B], m), 3.55-3.64 (2H [A] + IH [B], m), 2.96-3.07 (2H [A] + 2H [B], m), 2.71 (2H [A] + 3H [B], m), 2.19 (3H [A], s), 2.16 (3H [B], s), 1.47-2.37 (10 H [A] + 10H [B], m). MS-ESI+: m/z 493.1 [MH+ (A, B)].
The following compounds were prepared by routes analogous to those described in the previous Examples.
Example 10 N-(5-Chloro-2-{3-[3-(3,4-dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide
APCI-MS: m/z 473.1 475.1 [MH+]
Example 11 N-(3-Acetyl-2-{3-[3-(3,4-dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide
APCI-MS: m/z 495.1 497.1 [MH+]
Example 12
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-methyl- phenyl)-acetamide
APCI-MS: m/z 453.1 455.1 [MH+]
Example 13
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-fluoro- phenyl)-acetamide
APCI-MS: m/z 457.1 459.1 [MH+]
Example 14 l-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-3-(lH-indol-7-yloxy)-proρan-2-ol
APCI-MS: m/z 421.1 423.1 [MH+]
Example 15 l-(7-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-indol-l-yl)- ethanone
APCI-MS: m/z 463.1 465.1 [MH+]
Example 16 N-(4-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-biphenyl-3- yl)-acetamide
APCI-MS: m/z 515.1 517.1 [MH+]
Example 17
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-fluoro- phenyl)-acetamide
APCI-MS: m/z 457.1 459.1 [MH+]
Example 18
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide
APCI-MS: m/z 453.1 455.1 [MH+]
Example 19
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 439.1 441.1 [MH+]
Example 20 N-(5-Chloro-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide
APCI-MS: m/z 439.1 441.1 [MET]
Example 21 N-(3-Acetyl-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide
APCI-MS : m/z 461.1 [MH+]
Example 22
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yI]-2-hydroxy-propoxy}-4-methyl- phenyl)-acetamide
APCI-MS: m/z 419.1 [MH+]
Example 23
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-fluoro- phenyl)-acetamide
APCI-MS: m/z 423.1 [MH+]
Example 24 l-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-3-(lH-indol-7-yloxy)-propan-2-ol
APCI-MS: m/z 387.1 [MH+]
Example 25 l-(7-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-indol-l-yl)- ethanone
APCI-MS: m/z 429.1 [MH+]
Example 26 N-(4-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-biphenyl-3-yl)- acetamide
APCI-MS: m/z 481.1 [MET]
Example 27
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-fluoro- phenyl)-acetamide
APCI-MS : m/z 423.1 [MH+]
Example 28
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide
APCI-MS: m/z 419.1 [MH+]
Example 29
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 405.1 [MH+]
Example 30 N-(5-Chloro-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide
APCI-MS: m/z 423.1 [MH+]
Example 31 N-(3-Acetyl-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide
APCI-MS: m/z 445.3 [MH+]
Example 32
N-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-methyl- phenyl)-acetamide
APCI-MS: m/z 403.3 [MH+]
Example 33
N-(5-Fluoro-2-{3-[3-(4-fluoro-phenoxy)-pyrroIidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 407.1 [MH+]
Example 34 l-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-3-(lH-indol-7-yloxy)-propan-2-oI
APCI-MS: m/z 371.1 [MH+]
Example 35 l-(7-{3-[3-(4-Fluoro-phenoxy)-pyrrohdin-l-yl]-2-hydroxy-propoxy}-indol-l-yl)- ethanone
APCI-MS: m/z 413.1 [MH+]
Example 36 N-(4-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-biphenyl-3-yl)- acetamide
APCI-MS: m/z 465.3 [MH+]
Example 37
N-(4-Fluoro-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 407.1 [MH+]
Example 38
N-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide
APCI-MS : m/z 403.1 [MH+]
Example 39
N-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 389.1 [MH+]
Example 40 N-(5-Chloro-2-{3-[3-(3,4-difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide
APCI-MS: m/z 441.1 [MH+]
Example 41 N-(3-Acetyl-2-{3-{3-(3,4-difluoro-phenoxy)-pyrroIidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide
APCI-MS: m z 463.3 [MH~]
Example 42
N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-methyl- phenyl)-acetamide
APCI-MS: m z 421.1 [MH"]
Example 43
N-(2-{3-[3-(3,4-Di luoro-phenoxy)-pyrrolidin-l-yI]-2-hydroxy-propoxy}-5-fluoro- phenyl)-acetamide
APCI-MS: m/z 425.1 [MET]
Example 44 l-[3-(3,4-Difluoro-phenoxy)-pyrroIidin-l-yl]-3-(lH-indoI-7-yloxy)-propan-2-ol
APCI-MS; m/z 389.1 [MH"]
Example 45 l-(7-{3-[3-(3,4-Difluoro-phenoxy)-pyrroUdin-l-yl}-2-hydroxy-propoxy}-indol-l-yl)- ethanone
APCI-MS: m/z 431.1 [MFT]
Example 46 N-(4-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-biphenyl-3- yl)-acetamide
APCI-MS: m/z 483.3 [MH1"]
Example 47
N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yI]-2-hydroxy-propoxy}-4-fluoro- phenyl)-acetamide
APCI-MS: m/z 425.1 [MH4]
Example 48
Nr(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide
APCI-MS: m/z 421.1 [MH*]
Example 49
N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 407.1 [MET]
Example 50 N-(5-Chloro-2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide
APCI-MS: m/z 487.1 489.1 [MH"]
Example 51 N-(3-Acetyl-2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide
APCI-MS: m/z- 509.1 511.1 [MH~]
Example 52
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-4-methyl- phenyl)-acetamide
APCI-MS: m/z 467.1 469.1 [MET]
Example 53
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5-fludro- phenyl)-acetamide
APCI-MS: m/z 471.1 473.1 [Mff]
Comparison Example 54 l-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yI]-3-(lH-indol-7-yloxy)-propan-2-ol
APCI-MS: m/z 435.1 437.1 [MH+]
Example 55 l-(7-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-indol-l-yl)- ethanone
APCI-MS: m/z 477.1 479.1 [MH"]
Example 56 N-(4-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yI]-2-hydroxy-propoxy}-biphenyl-3- yl)-acetamide
APCI-MS: m/z 429.1 431.1 [MET]
Example 57
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-4-fluoro- phenyl)-acetamide
APCI-MS: m/z 471.1 473.1 [MH+]
Example 58
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide
APCI-MS: m/z 467.1 469.1 [MH"]
Example 59
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 453.1 455.1 [MH-]
Example 60 N-(5-Chloro-2-{3-[4-(4-chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 453.1 455.1 [MH"]
Example 61 N-(3-Acetyl-2-{3-[4-(4-chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide
APCI-MS: m/z 475.3 [MH+]
Example 62
N-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-4-methyl-phenyl)- acetamide
APCI-MS: m/z 433.1 [MH+]
Example 63
N-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5-fluoro-phenyl)- acetamide
APCI-MS: m/z 437.1 [MH+]
Comparison Example 64 l-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-3-(lH-indol-7-yloxy)-propan-2-ol
APCI-MS: m/z 401.1 [MH+]
Example 65 l-(7-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-indol-l-yl)- ethanone
APCI-MS: m/z 443.1 [MH+]
Example 66 N-(4-{3-[4-(4-Chloro-phenoxy)-piρeridin-l-yl]-2-hydroxy-propoxy}-biphenyl-3-yl)- acetamide
APCI-MS: m/z 495.3 [MH+]
Example 67
N-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-4-fluoro-phenyl)- acetamide
APCI-MS: m/z 437.1 [MH+]
Example 68
N-(2-{3-[4-(4-Chloro-phenoxy)-piperidm-l-yl]-2-hydroxy-propoxy}-5-methyl-phenyl)- acetamide
APCI-MS: m/z 433.1 [MH+]
Example 69
N-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS: m/z 419.1 [MH+]
Example 70 N-{5-Chloro-2-[3-(8-chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- propoxy]-phenyl}-acetamide
APCI-MS: m/z 448.1 450.1 [MET]
Example 71 N-{3-Acetyl-2-[3-(8-chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indoI-2-yl)-2-hydroxy- propoxy]-5-methyl-phenyl}-acetamide
APCI-MS: m/z 470.1 [MH+]
Example 72
N-{2-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-4- methyl-phenyl}-acetamide
APCI-MS: m/z 428.1 [MH+]
Example 73
N-{2-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-5- fluoro-phenyl} -acetamide
APCI-MS: m/z 432.1 [MH+]
Example 74 l-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-3-(lH-indol-7-yloxy)-propan- 2-ol
APCI-MS: m/z 396.1 [MH"] .
Example 75 l-{7-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- indol-l-yl}-ethanone
APCI-MS: m/z 438.1 [MH"]
Example 76 N-{4-{3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- biphenyl-3-yl}-acetamide
APCI-MS: m/z 490.1 [MH"]
Example 77
N-{2-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-4- fluoro-phenylj-acetamide
APCI-MS: m z 432.1 [MH"]
Example 78
N-{2-[3-(8rChloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propόxy]-5- methyl-phenyl}-acetamide
APCI-MS: m/z 428.1 [MH1
Example 79
N-{2-[3-(8-Chloro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- phenyl}-acetamide
APCI-MS: m z 414.1 [MH+]
Example 80 N-{5-Chloro-2-[3-(8-fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- propoxy] -phenyl} -acetamide
APCI-MS: m/z 432.1 [MH+]
Example 81 N-{3-AcetyI-2-[3-(8-fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- propoxy]-5-methyl-phenyl}-acetamide
APCI-MS: m/z 454.3 [MH"]
Example 82
N-{2-[3-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yI)-2-hydroxy-propoxyJ-4- methy 1-phenyl} -acetamide
APCI-MS: m/z 412.1 [MH"]
Example 83
N-{5-Fluoro-2-[3-(8-fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- propoxy] -phenylj-acetamide
APCI-MS: m/z 416.1 [MET]
Example 84 l-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-3-(lH-indol-7-yloxy)-propan- 2-ol
APCI-MS: m z 380.1 [MET]
Example 85 l-{7-[3-(8-FIuoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- indol-l-yl}-ethanone
APCI-MS: m/z 422.1 [MH"]
Example 86 N-{4-[3-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- biphenyl-3-yl}-acetamide
APCI-MS: m z 474.3 [MET]
Example 87
N-{4-Fluoro-2-[3-(8-fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy- pr opoxy] -phenyl} -acetamide
APCI-MS: m/z 416.1 [MH+]
Example 88
N-{2-[3-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]-5- methyl-phenyl}-acetamide
APCI-MS: m/z 412.1 [MH+]
Example 89
N-{2-[3-(8-Fluoro-l,3,4,5-tetrahydro-pyrido[4,3-b]indol-2-yl)-2-hydroxy-propoxy]- phenylj-acetamide
APCI-MS: m/z 398.1 [MH+]
Example 90 N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS m/z: 453, 455 [MH+]
Example 91 3-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester
APCI-MS m/z: 482, 484 [MH+]
Example 92 l-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-3-(2,6-dimethoxy-phenoxy)-propan-2-ol
APCI-MS m/z: 456, 458 [MH+]
Example 93 l-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-oI
APCI-MS m/z: 426, 428 [MH+]
Example 94
2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m z: 467, 469 [MH+]
Example 95 l-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propan-1-one
APCI-MS m/z: 452, 454[MH+]
Example 96 l-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- ethanone APCI-MS m/z: 438, 440 [MH+]
Example 97 3-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester
APCI-MS m/z: 418 [MH+]
Example 98 l-(2,6-Dimethoxy-phenoxy)-3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-propan-2-oI
APCI-MS m/z: 392 [MH+]
Example 99 l-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol
APCI-MS m/z: 362 [MH+]
Example 100
(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester
APCI-MS m/z: 447 [MH+]
Example 101
(2-{3-[3-(4-Chloro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-acetic acid methyl ester
APCI-MS m/z: 491 [MH+] Example 102
2-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)-2- methyl-propionic acid methyl ester
APCI-MS m/z: 475 [MH+]
Example 103
2-{3-[3-(4-FIuoro-phenoxy)-pyrrolidin-l-yI]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m/z: 403 [MH+]
Example 104 l-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-6-methoxy- phenyl)-ethanone
APCI-MS m/z: 404 [MH+]
Example 105 l-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propan- 1-one
APCI-MS m/z: 388 [MH+]
Example 106 l-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)-ethanone
APCI-MS m/z:374 [MH+] Example 107
N-[2-(3-{[l-(3,4-dichlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-4- methylphenyl] acetamide
APCI-MS: m/z 480[MrT]
Example 108
3-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester
APCI-MS m/z: 436 [MH+]
Example 109 l-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol
APCI-MS m/z: 380 [MH+]
Example 110
(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrroUdm-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester
APCI-MS m/z: 465 [MH+]
Example 111 2-{3-[3-(3,4-Difluoro-phenoxy)-pyrroIidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m/z: 421 [MH+]
Example 112 l-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-6-methoxy- phenyl)-ethanone
APCI-MS m/z: 422 [MH+]
Example 113 l-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propan-1-one
APCI-MS m/z: 406 [MH+]
Example 114 l-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- ethanone
APCI-MS m/z: 392 [MH+]
Example 115 N-(2-{3-[4-(3,4-dicUoroanilino)-l-piperidinyl]-2-hydroxypropoxy}phenyl)acetamide
APCI-MS: m/z 452.1 [MH+]
Example 116
3-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester
APCI-MS m/z: 434 [MH+]
Example 117 l-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-3-(2,6-dimethoxy-phenoxy)-propan-2-ol APCI-MS m/z: 408 [MH+]
Example 118 l-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol
APCI-MS m/z: 378 [MH+]
Example 119 (2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-benzoyIamino)- acetic acid, methyl ester
APCI-MS m/z: 463 [MH+]
Example 120
2-(2-{3-[3-(4-Chloro-phenoxy)-pyrroUdin-l-yl]-2-hydroxy-propoxy}-benzoylamino)-2- methyl-propionic acid methyl ester
APCI-MS m/z: 491 [MH+]
Example 121
2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m/z: 419 [MH+]
Example 122 l-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-6-methoxy- phenyl)-ethanone APCI-MS m z: 420 [MH+]
Example 123 l-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propan- 1-one
APCI-MS m/z: 404 [MH+]
Example 124 l-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)-ethanone
APCI-MS m/z: 390 [MH+]
Example 125 N-(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS m/z: 396 [MH+]
Example 126
3-(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propionic acid methyl ester
APCI-MS m/z: 425 [MH+]
Example 127
(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester
APCI-MS m/z: 454 [MH+] Example 128
2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-l-yI]-2-hydroxy-propoxy}-N,N-dimethyI- benzamide
APCI-MS m/z: 410 [MH+]
Example 129 4-{l-[2-Hydroxy-3-(2-propionyl-phenoxy)-propyI]-pyrrolidin-3-yloxy}-benzonitrile
APCI-MS m/z: 395 [MH+]
Example 130
N-(2-{2-Hydroxy-3-[3-(4-methoxy-phenoxy)-pyrrolidin-l-yl]-propoxy}-phenyl)- acetamide
APCI-MS m/z: 401 [MH+]
Example 131 iV-(4-chloro-2-{3-[4-(3,4-dichloroanilino)-l-piperidinyl]-2- hydroxypropoxy}phenyl)acetamide
APCI-MS: m/z 486[MH+]
Example 132
3-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester
APCI-MS m/z: 468, 470 [MH+] Example 133 l-[3-(3,4-Dichloro-phenoxy)-pyrroIidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol
APCI-MS m/z: 412, 414 [MH+]
Example 134
(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrroUdin-l-yl]-2-hydroxy-propόxy}-benzoylamino)- acetic acid methyl ester
APCI-MS m/z: 497, 499 [MH+]
Example 135
2-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-2-methyl-propionic acid methyl ester
APCI-MS m/z: 525, 527 [MH+]
Example 136
2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m/z: 453, 455 [MH+]
Example 137 l-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-6-methoxy- phenyl)-ethanone
APCI-MS m/z: 454, 456 [MH+]
Example 138 l-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propan-1-one
APCI-MS m/z: 438, 440 [MH+]
Example 139 l-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- ethanone
APCI-MS m/z: 424, 426 [MH+]
Example 140
N-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS m/z: 421 [MH+]
Example 141
3-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester
APCI-MS m/z: 450 [MH+]
Example 142 2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m/z: 435 [MH+]
Example 143 l-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propan-1-one
APCI-MS m/z: 420 [MH+]
Example 144
(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester
APCI-MS m/z: 479 [MH+]
Example 145
N-(2-{3-[3-(3,4-Difluoro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide
APCI-MS m/z: 435 [MH+]
Example 146
N-(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS m/z: 403 [MH+]
Example 147 3-(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propionic acid methyl ester
APCI-MS m/z: 432 [MH+]
Example 148 l-(2,6-Dimethoxy-phenoxy)-3-[4-(4-fluoro-phenoxy)-piperidm-l-yl]-propan-2-ol
APCI-MS m/z: 406 [MH+]
Example 149 l-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol
APCI-MS m/z: 376 [MH+]
Example 150 l-(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)-ethanone
APCI-MS m/z: 388 [MH+]
Example 151
2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m z: 417 [MH+]
Example 152 l-(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propan-l- one
APCI-MS m/z: 402 [MH+]
Example 153
(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester APCI-MS m z: 461 [MH+]
Example 154
N-(2-{3-[3-(4-Fluoro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS m z: 417 [MH+]
Example 155 3-(2-{3-[3-(4-Fluoro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester
APCI-MS m/z: 446 [MH+]
Example 156 l-[3-(4-Fluoro-phenoxymethyl)-piperidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol
APCI-MS m/z:390 [MH+]
Example 157 l-(2-{3-[3-(4-Fluoro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- ethanone
APCI-MS m/z: 402 [MH+]
Example 158
2-(2-{3-[3-(4-Fluoro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-2-methyl-propionic acid methyl ester
APCI-MS m/z: 503 [MH+] Example 159
2-{3-[3-(4-Fluoro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m/z:431 [MH+]
Example 160 l-(2-{3-[3-(4-Fluoro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-6-methoxy- phenyl)-ethanone
APCI-MS m z: 432 [MH+]
Example 161 N-(2-{3-[4-(4-AcetyIammo-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS m/z: 442 [MH+]
Example 162
N-(4-{ 1 - [3-(2-Acetyl-phenoxy)-2-hy dr oxy-propyl] -piperidin-4-yloxy } -phenyl)- acetamide
APCI-MS m/z: 427 [MH+]
Example 163
7V-(4-cyano-2-{3-[4-(3,4-dichloroanilino)-l-piperidinyl]-2- hydroxypropoxy}phenyl)acetamide
APCI-MS: m/z 477[MH+] Example 164
3-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propionic acid methyl ester
APCI-MS m/z: 448 [MH+]
Example 165 l-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-3-(2-methoxy-phenoxy)-propan-2-ol
APCI-MS m/z: 392 [MH+]
Example 166 l-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)-ethanone
APCI-MS m/z: 404 [MH+]
Example 167
2-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)-2- methyl-propionic acid methyl ester
APCI-MS m/z: 505 [MH+]
Example 168 2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m/z: 433 [MH+]
Example 169 l-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-6-methoxy- phenyl)-ethanone
APCI-MS m/z: 434 [MH+]
Example 170 l-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propan-l- one
APCI-MS m/z: 418 [MH+]
Example 171
(2-{3-[4-(4-Chloro-phenoxy)-piperid -l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester
APCI-MS m/z: 477 [MH+]
Example 172
N-(2-{3-[3-(4-Chloro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide
APCI-MS m/z: 433 [MH+]
Example 173 3-(2-{3-[3-(4-Chloro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester
APCI-MS m/z: 462 [MH+]
Example 174 l-(2-{3-[3-(4-Chloro-phenoxymethyI)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyI)- ethanone
APCI-MS m/z: 418 [MH+]
Example 175
2-{3-[3-(4-Chloro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide
APCI-MS m/z: 447 [MH+]
Example 176 l-(2-{3-[3-(4-Chloro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propan-1-one
APCI-MS m/z: 432 [MH+]
Example 177
N-[2-({(lR,2R)-2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-l- hydroxy cyclopentyl} methoxy)phenyl] acetamide
Example 178
Methyl (2S,4R)-l-{3-[2-(acetylamino)phenoxy]-2-hydroxypropyl}-4-[(4- chlorobenzyl)oxy] -2-py rrolidinecarboxylate hydrochloride
Examples 179-189
Starting materials:
A) (3,4-Dichloro-phenyl)-piperidin-4yl-amine In a nitrogen filled reaction vessel 4-oxo-piperidine-l -carboxyhc acid tert-butyl ester (2.46g, 12.3 mmol) and 3,4-dichloro-phenylamine (1.0 g, 6.17 mmol) were dissolved in dichloromethane ( 28 ml) and acetic acid ( 2.12 ml). Sodium triacetoxyborohydride (3.67 g, 17.3 mmol) was added at room temperature. The reaction was stirred over night and then poured into a sodium hydrogencarbonate solution (5%). The water phase was shaken three times with ethyl acetate (EtOAc). The combined organic phase was dried over sodium sulfate, evaporated and purified by flash chromatography (EtOAc : Heptane 3:7 ) giving 1.7 g, 81 % of pure compound. The BOC-protected title compound was dissolved in dichloromethane (26 ml) and trifluoro acetic acid (13 ml) and stirred at room temperature for 3h, evaporated and dissolved in diethyl ether and sodium hydroxide (1 M). The organic layer was separated and the water phase washed twice with ether. The combined organic layer was washed with a small portion of brine, dried over sodium sulfate and evaporated to give 1.15g (76%) of the title compound. H-NMR (400MHz, DMSO-d6): δ 7.20 (d, IH, J = 8.9 Hz), 6.73 (d, IH, J = 2.7 Hz), 6.54 (dd, IH, J = 8.8, 2.7 Hz), 5.95 (d, IH, J = 8.1 Hz), 3.22 (m, IH), 2.91 (bd, 2H, J = 12.6 Hz), 2.51 (m, 2H), 2.02 (bs, IH), 1.81 (bd, 2H, J = 12.4 Hz), 1.18 (m). APCI-MS: m/z 245 [M+]
B) (4-Chloro-phenyl)-piperidin-4yl-amine
Was synthesised in the same way as (A) from 4-oxo-piperidine-l -carboxyhc acid tert- butyl ester (3.59 g, 18.0 mmol), 4-chloro-phenylamine (1.15 g, 9.0 mmol) and sodium triacetoxyborhydride (5.34 g, 25.2 mmol) in dichloromethane ( 40 ml) and acetic acid ( 3.1 ml). The deprotection was run in dichloromethane (37 ml) and trifluoro acetic acid (18 ml). Yield 1.5 g, 79 %
!H-NMR (400MHz, DMSO-d6): δ 7.04 (d, 2H, J = 8.9 Hz), 6.55 (d, 2H, J = 8.9 Hz), 5.62 (d, IH, J = 8.1 Hz), 3.18 (m, IH), 2.92 (bd, 2H, J = 12.6 Hz), 2.50 (m, 2H), 1.99 (bs, IH), 1.82 (d, 2H, J = 12.7 Hz), 1.18 (m, 2H). APCI-MS: m/z 211 [MH+] C) (4-Fluoro-phenyl)-piperidin-4yl-amine
Was synthesised in the same way as (A) from 4-oxo-piperidine-l -carboxyhc acid tert- butyl ester (3.59 g, 18.0 mmol), 4-fluoro-phenylamine (1.0 g, 9.0 mmol) and sodium triacetoxyborhydride (5.34 g, 25.2 mmol) in dichloromethane ( 40 ml) and acetic acid ( 3.1 ml). The deprotection was run in dichloromethane (37 ml) and trifluoro acetic acid (18 ml). Yield 1.1 g, 63 % H-NMR (400MHz, DMSO-d6): δ 6.85 (t, 2H, J = 9.0 Hz), 6.51 (dd, 2H, J = 9.1, 4.6 Hz), 5.27 (d, IH, J = 8.2 Hz), 3.13 (m, IH), 2.89 (bd, 2H, J = 12.5 Hz), 2.48 (m, 2H), 1.80 (bd, 2H, J = 12.3 Hz), 1.14 (m, 2H). APCI-MS: m/z 195 [MH+]
D) (3,4-Difluoro-phenyl)-piperidin-4yl-amine Was synthesised in the same* way as (A) from 4-oxo-piperidine-l -carboxyhc acid tert- butyl ester (3.59 g, 18.0 mmol), 3,4-difluoro-phenylamine (1.16 g, 9.0 mmol) and sodium triacetoxyborohydride (5.34 g, 25.2 mmol) in dichloromethane ( 40 ml) and acetic acid (3.1 ml). The deprotection was run in dichloromethane (37 ml) and trifluoro acetic acid (18 ml). Yield 1.26 g, 66 % H-NMR (400MHz, DMSO-d6): δ 7.05 (dt, IH, J = 10.8, 9.2 Hz), 6.50 (ddd, IH, J = 14.1, 7.0, 2.8 Hz), 6.32 (bd, IH, J = 9.20 Hz), 5.64 (d, IH, J = 8.14 Hz), 3.17 (m, IH), 2.90 (bd, 2H, J = 12.6 Hz), 2.50 ( , 2H), 2.00 (bs, IH), 1.81 (bd, 2H, J = 12.6 Hz), 1.16 (m, 2H) APCI-MS: m/z 213 [MH+]
Example 179
N-(2-{3-[4-(3,4-Dichloroanilino)-l-piperidinyl]-2-hydroxypropoxy}-4- methylphenyl)acetamide
APCI-MS: m/z 466[MH+] Example 180 N-(2-{3-[4-(4-Chloroanilino)-l-piperidinyl]-2-hydroxypropoxy}phenyl)acetamide
APCI-MS: m/z 418[MH+]
Example 181
N-(4-Chloro-2-{3-[4-(4-chloroanilino)-l-piperidinyl]-2-hydroxypropoxy}phenyl)- acetamide
APCI-MS: m/z 452[MH+]
Example 182
N-(2-{3-[4-(4-Chloroanilino)-l-piperidinyl]-2-hydroxypropoxy}-4- cyanophenyl)acetamide
APCI-MS : m/z 443 [MH+]
Example 183 N-(2-{3-[4-(4-Chloroanilino)-l-piperidinyl]-2-hydroxypropoxy}-4- methylphenyl)acetamide
APCI-MS: m/z 432[MH+]
Example 184
N-(5-Chloro-2-{3-[4-(4-fluoroanilino)-l-piperidinyl]-2- hydroxypropoxy} phenyl)acetamide
APCI-MS: m/z 436[MH+] Example 185
N-(5-Chloro-2-{3-[4-(3,4-difluoroanilino)-l-piperidinyl]-2- hydroxypropoxy}phenyl)acetamide
APCI-MS: m/z 454[MH+]
Example 186
N-(5-Cyano-2-{3-[4-(4-fluoroanilino)-l-piperidinyl]-2-hydroxypropoxy}- phenyl)acetamide
APCI-MS: m/z 427[MH+]
Example 187
N-(5-Cyano-2-{3-[4-(3,4-difluoroanilino)-l-piperidinyl]-2- hydroxypropoxy}phenyl)acetamide
APCI-MS: m/z 445[MH+]
Example 188 N-(2-{3-[4-(4-Fluoroanilino)-l-piperidinyl]-2-hydroxypropoxy}-4- methylphenyl)acetamide
APCI-MS: m/z 416[MH+]
Example 189
N-(2-{3-[4-(3,4-Difluoroanilino)-l-piperidinyl]-2-hydroxypropoxy}-4- methylphenyl) acetamide
APCI-MS: m/z 434[MH+] Example 190
N-(2-{3-[3(S)-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-(R)-hydroxy-propoxy- phenyl)acetamide
i) 3-(S)-(4-Chloro-phenoxy)-pyrrolidine CF3COOH
To a solution of triphenyl phosphine (4.2 g, 16.02 mmol) in THF (75 mL) was added diethyl azodicarboxalate (2.52 mL) at 0 °C, after 15 min 4-chlorophenol (2.05 g, 16.02 mmol) was added and after another 10 min 3 -hydroxy-pyrrolidine-1 -carboxyhc acid tert- butyl ester (3.0 g, 16.02 mmol) in THF (20 mL) was added slowly. After addition was complete the ice bath was removed and the reaction mixture was kept at room temperature overnight. The solvent was removed in vacuo and the residue was stirred with diethyl ether, the solid triphenyl phosphine was filtered off. The residue was purified by flash chromatography (0-0.5% MeOH in CHC13) to give the subtitled compound (3.65 g, 76%) which was dissolved in dichloromethane (60 mL) and trifluoroacetic acid (15 mL) was added. The reaction mixture was kept at room temperature for 30 min. The solvent was removed invacuo. The residue was dissolved in dichloromethane, diethylether and hexane were added. The solid was filtered off to give the subtitled compound 3.70 g, 97%.
'H-NMR (CDC13, 400 MHz): δ 10.20 (s, IH), 9.99 (s, IH), 7.25 (d, J 8.8 Hz, 2H), 6.78 (d, J 8.8 Hz, 2H), 4.99 (m, IH), 3.41 (m, 4H), 2.30 (m IH), 2.20 (m, IH). APCI-MS: m/z 198 (MH+).
ϋ) N-(2-{3- [3 (S)-(4-Chloro-phenoxy)-pyrrolidin-l -yl] -2-(R)-hydr oxy-propoxy- phenyl)acetamide A mixture of 3-(S)-(4-chloro-phenoxy)-pyrrolidine.CF3COOH (312 mg, 1.0 mmol), N-acetyl-2-(2,3-epoxypropoxy)aniline (207 mg, 1.0 mmol), K2CO3 (560 mg) in EtOH (10 mL) was stirred at 65 °C for 4 h. The solvent was removed in vacuo. The residue was partitioned between ethyl acetate and water. The organic layer was washed with aqueous NHC1 solution, then with water. The organic layer was dried over Na2SO4, filtered, concentrated. The residue was purified by flash chromatography (0-3% MeOH in CHC13) to give a mixture of diastereomers (310 mg, 77%). The diastereomers were seperated by HPLC to give N-(2-{3-[3(S)-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-(R)-hydroxy-propoxy- phenol)acetamide (57 mg)
'H-NMR (CDC13, 400 MHz): δ 8.36 (m, IH), 8.25 (s, IH), 7.25 (m, 2H), 6.99 (m, 2H), 6.93 (m, IH), 6.75 (m, 2H), 4.80 (m, IH), 4.08 (m, 2H), 3.96 (m, IH), 3.11 (dd, J 5.9 10.5 Hz, IH), 3.01 (m, IH), 2.82 (m, 2H), 2.59 (m, IH), 2.51 (dd, J 3.2, 12.0 Hz, IH), 2.29 (m, IH), 2.19 (s, 3H), 2.01 (m, IH). APCI-MS: m/z 405 (MH+).
Example 191
N-(2-{3-[3S-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2S-hydroxy-propoxy}-phenyl)- acetamide hydrochloride
The reaction was performed analogously to Example 190.
'H-NMR (CDCI3. 400 MHz): δ 8.35 (m,' IH), 8.26 (s, IH), 7.24 (m, 2H), 6.99 (m, 2H), 6.92 (m, IH), 6.75 (m, 2H), 4.80 (m, IH), 4.12 (m, 2H), 3.95 (m, IH), 2.95 (m, 2H), 2.80 (m, 3H), 2.52 (dd, 3.4, 12.2 Hz, IH), 2.30 (m, IH), 2.19 (s, 3H), 2.01 (m, IH). APCI-MS: m/z 405 (MH+).
Example 192
N-(2-{3-[3(R)-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-(S)-hydroxy-propoxy- phenyl)acetamide
The reaction was performed analogously to Example 190.
'H-NMR (CDCI3, 400 MHz): δ 8.36 (m, IH), 8.25 (s, IH), 7.25 (m, 2H), 6.99 (m, 2H), 6.93 (m, IH), 6.75 (m, 2H), 4.80 (m, IH), 4.08 (m, 2H), 3.96 (m, IH), 3.11 (dd, J 5.9 10.5 Hz, IH), 3.01 (m, IH), 2.82 (m, 2H), 2.59 (m, IH), 2.51 (dd, J 3.2, 12.0 Hz, IH), 2.29 (m, IH), 2.19 (s, 3H), 2.01 (m, IH). APCI-MS: m/z 405 (MH+).
Example 193
N-[5-Chloro-2-({(2S)-3-[(3S)-3-(4-chloro-phenoxy)pyrroUdinyl]-2- hydroxypropyl} oxy)phenyl] acetamide
The reaction was performed analogously to Example 190.
'H-NMR (CDC13, 400 MHz): δ 8.45 (m, IH), 8.36 (br. S, IH), 7.23 (m, 2H), 6.95 (m, IH), 6.85 (m, IH), 6.75 (m, 2H), 4.80 (m, IH), 4.07 (m, 2H), 3.91 (m, IH), 2.95 (m, 2H), 2.80 (m, 3H), 2.49 (dd, J 3.2, 12.0 Hz, IH), 2.30 (m, IH), 2.19.(s, 3H), 2.03 (m, IH). APCI-MS: m/z 439 (MH+).
Example 194 N-[5-Chloro-2-({(2R)-3-[(3R)-3-(4-chIoro-phenoxy)pyrroIidinyl]-2- hy dr oxypropy 1} oxy)phenyl] acetamide
The reaction was performed analogous to Example 190.
'H-NMR (CDC13, 400 MHz): δ 8.45 (m, IH), 8.36 (br. S, IH), 7.23 (m, 2H), 6.95 (m, IH), 6.85 (m, IH), 6.75 (m, 2H), 4.80 (m, IH), 4.07 (m, 2H), 3.91 (m, IH), 2.95 (m, 2H), 2.80 (m, 3H), 2.49 (dd, J 3.2, 12.0 Hz, IH), 2.30 (m, IH), 2.19 (s, 3H), 2.03 (m, IH). APCI-MS: m z 439 (MH+).
Example 195
N-[5-Chloro-2-({(2S)-3-[(3R)-3-(4-chloro-phenoxy)pyrroUdinyl]-2- hydroxypropyl} oxy)phenyl] acetamide
The reaction was performed analogously to Example 190. 'H-NMR (CDCI3, 400 MHz): δ 8.45 (m, IH), 8.34 (br. S, IH), 7.22 (m, 2H), 6.94 (m, IH), 6.85 (m, IH), 6.75 (m, 2H), 4.80 (m, IH), 4.08 (m, 2H), 3.90 (m, IH), 3.11 (dd, J 5.9, 10.5 Hz, IH), 3.02 (m, IH), 2.81 (m, 2H), 2.58 (m IH), 2.49 (dd, J 3.5, 12.1 Hz, IH), 2.30 (m, lH), 2.18 (s, 3H), 2.01 (m, IH). APCI-MS : m/z 439 (MH+).
Example 196
N-[5-Chloro-2-({(2R)-3-[(3S)-3-(4-chloro-phenoxy)pyrrolidinyl]-2- hy droxy propy 1} oxy)phenyl] acetamide
The reaction was performed analogous to Example 190.
'H-NMR (CDCI3, 400 MHz): δ 8.45 (m, IH), 8.34 (br. S, IH), 7.22 (m, 2H), 6.94 (m, IH), 6.85 (m, IH), 6.75 (m, 2H), 4.80 (m, IH), 4.08 (m, 2H), 3.90 (m, IH), 3.11 (dd, J 5.9, 10.5 Hz, IH), 3.02 (m, IH), 2.81 (m, 2H), 2.58 ( IH), 2.49 (dd, J 3.5, 12.1 Hz, IH), 2.30 (m, lH), 2.18 (s, 3H), 2.01 (m, IH). APCI-MS : m/z 439 (MH+).
Example 197 -V-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4,5-difluoro- phenyl)-acetamide
i) 4,5-Difluoro-2-nitro-phenol
In a flask was dissolved 3,4-Difluorophenol (3.10 g, 23.7 mmole) in acetic acid (15 ml). To the stirred solution was added dropwise a solution of fuming HNO3 (1.25 g, 29.7 mmole) in acetic acid (6 ml). The temperature was kept under 50°C during the entire addition. After completed addition, the mixture was stirred for another hour. The reaction mixture was then poured onto ice- water, giving precipitation of a yellowish solid. The solid was collected by filtration, and dried. The solid was purified on silica (Heptane : EtOAc 5:1), giving the sub-title compound (2.05 g, 50%) as a yellow oil, which crystallizes on standing.
'H-NMR (400 MHz, CDC13) δ: 10.61 (IH, s); 8.00 (IH, dd, J9.6 8.2 Hz); 7.00 (IH, dd, J 10.4 6.8Hz)
ϋ) N-(4,5-Difluoro-2-hydroxy-phenyl)-acetamide
In a flask was added the product obtained in i) (0.59 g, 3.37 mmole), and acetic acid (10 ml). The solution was heated with stirring to 90°C, and Tin (powder, 1.60 g, 13.5 mmole) was added. The flask was sealed and heated with stirring for another hour, and the hot solution was filtered through celite. The filter was then washed with another 10 ml of hot acetic acid. To the filtrate was added water (25 ml) and acetic anhydride (0.5 ml, 5.29 mmole), and the resulting mixture was heated with stirring at 60°C for 20 minutes. The mixture was allowed to cool, and was partitioned between EtOAc and water. The organic phase was collected and washed with water and brine. The organic phase was evaporated to give the 0.63 g (100%) of the sub-title compound as a solid.
'H-NMR (400 MHz, OMSO-d6) δ: 10.25 (IH, s); 9.31 (IH, bs); 7.88 (IH, dd, J 12.8 7.9 Hz); 6.83 (IH, dd, J 12.1 7.7 Hz); 2.08 (3H, s)
iii) N-(4,5-Difluoro-2-oxiranylmethoxy-phenyl)-acetamide
In a vial was added the compound obtained in ii) (0.4 g, 2.137 mmole), epibromohydrine (0.35 g, 2.55 mmole), K2CO3 (0.6 g, 4.4 mmole) and DMF (2 ml). The vial was sealed and heated with stirring (2 hours, 60°C). The mixture was then partitioned between EtOAc and water, and the organic phase was washed twice with water and once with brine, and was finally evaporated to give a brown solid. The crude epoxide was purified on silica, to give 0.27 g (52%) of the sub-title compound as a slightly pink solid. 'H-NMR (400 MHz, CDC13) δ: 8.37 (IH, dd, J 12.2 8.8 Hz); 7.85 (IH, bs); 6.78 (IH, dd, J 11.2 7.1 Hz); 4.34 (IH, dd, 11.5 2.2 Hz); 3.90 (IH, dd, 1 1.6 6.3 Hz); 3.40-3.36 (lH, m); 2.98 (lH t, J4.5 Hz); 2.81 (IH, dd, J4.7 6.3 Hz); 2.22 (3H, s)
iv) iV-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4,5-difluoro- phenyl)-acetamide
In a vial was added the compound obtained in iii) (0.059 g, 0.24 mmole), 3-(4- chlorophenoxy)-pyrrolidine (0.048 g, 0.24 mmole) and ethanol (2 ml, 99.5%). The vial was sealed and the content was heated with stirring to 75°C for 2 hours. The crude solution was evaporated and the obtained oil purified on silica to the title compound which was lyophilized as the hydrochloride. The title compound was obtained as a white solid (0.075 g, 65%). The compound was a mixture of four stereoisomers, which had an effect on the NMR-spectra.
'H-NMR (400 MHz, DMSO-^) δ: 10.78-10.30 (IH, m); 9.30 (IH, s); 8.07 (IH, dd, J 12.8 9.3 Hz); 7.40-7.34 (2H, m); 7.23 (IH, dd, J 12.7 7.5 Hz); 7.05-6.99 (2H, m); 6.19 (IH, bs); 5.23-5.11 (IH, m); 4.35 (IH, bs); 4.08-3.97 (1.5H, m), 3.96-3.90 (IH, m); 3.84-3.70 (1.5H, m); 3.63-3.23 (4H, m); 2.66-2.00 (5H, m)
APCI-MS : m/z 411.1 [MH+]
Example 198 N-{5-Chloro-2-[2-hydroxy-3-(3-phenoxy-pyrrolidin-l-yl)-propoxy]-phenyl}-acetamide
The compound was prepared analogously to Example 197.
'H-NMR (400 MHz, DMSO-J ) δ: 10.80-10.36 (IH, m); 9.26 (IH, s); 8.14 (IH, s); 7.32 (2H, t, J8.35 Hz); 7.11-6.95 (5H, m); 6.31-6.02 (IH, m); 5.24-5.12 (IH, m); 4.37 (IH, bs); 4.10-3.97 (1.5H, m); 3.95-3.88 (IH, m) 3.84-3.68 (1.5H, m); 3.64-3.26 (4H, m); 2.65-2.52 (0.5H, m); 2.35-2.02 (4.5H, m) APCI-MS: m/z 405.2 [MH+]
Example 199 N-(5-Chloro-2-{2-hydroxy-3-[3-(4-nitro-phenoxy)-pyrrolidin-l-yl]-propoxy}-phenyl)- acetamide
The compound was prepared analogously to Example 197.
'H-NMR (400 MHz, DMSO-ύtø) δ: 10.95-10.48 (IH, m); 9.26 (IH, s); 8.24 (2H, d, J9.6 Hz); 8.13 (IH, bs); 7.23-7.17 (2H, m); 7.12-7.02 (2H, m); 6.20 (lH, bs); 5.43-5.30 (IH, m); 4.38 (IH, m); 4.18-4.06 (0.5H, m); 4.05-3.97 (IH, m); 3.95-3.87 (IH, m); 3.86-3.72 (1.5H, m); 3.69-3.27 (4H, m); 2.73-2.60 (0.5H, m); 2.46-2.08 (4.5H, m)
APCI-MS: m/z 450.1 [MH+]
Example 200
Λr-(5-Acetyl-2-{3-[3-(3,4-dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide
The compound was prepared analogously to Example 197.
APCI-MS: m/z 481.2, 483.2 [MH+]
Example 201
4-Acetylamino-3-{3-[3-(3,4-dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- benzoic acid methyl ester
The compound was prepared analogously to Example 197. APCI-MS: m/z 497.1, 499.2 [MH+]
Example 202
N-(3-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-naphthalen- 2-yl)-acetamide
The compound was prepared analogously to Example 197.
APCI-MS: m/z 489.2, 491.2 [MH+]
Example 203
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-cyano-phenyl)- acetamide
The title compound was prepared according to the method in Example 197. APCI-MS: m/z 430.2 [MH+]
Example 204
4-Acetylamino-3-{3-[3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- benzoic acid methyl ester
The compound was prepared analogously to Example 197.
APCI-MS: m/z 463.2 [MH+]
Example 205 iV-(3-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-naphthalen-2- yl)-acetamide
The title compound was prepared according to the method in Example 197. APCI-MS: m z 455.2 [MH+]
Example 206 N-(5-Cyano-2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide
The title compound was prepared according to the method in Example 197.
APCI-MS: m/z 478.2 480.1 [MH+]
Example 207
Nr(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5- trifluoromethyl-phenyl)-acetamide
The title compound was prepared according to the method in Example 197.
APCI-MS: m/z 521.1 523.2 [MH+]
Example 208
N-(5-Chloro-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide trifluoroacetate
The title compound was prepared according to the method in Example 197.
APCI-MS: m/z 423.1, 424.9 [MET]
Example 209
N-(5-Acetyl-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide trifluoroacetate i) N-(5-Acetyl-2-oxiranyImetoxy-fenyl)-acetamide
To a solution of 4-acetyI-2-nitrophenol (0.50g, 2.76mmol) in THF (20 ml) was added 10% Pd/C (0.15g). The resultant mixture was hydrogenated with H2 at 1 arm for 5 hours and was then filtered through celite and evaporated to give 0.63g of a red oil. Water (20 ml) and acetic anhydride (0.35g, 3.44mmol) was added and the mixture was stirred vigorously for 5 minutes. The reaction mixture was then heated with stirring to 60°C for 30 minutes, and was then allowed to cool. A red solid was formed and the precipitate was collected by filtration, washed with water and dried to give 0.27g (1.40mmol) of N-(5-Acetyl-2- hydroxy-phenyl)-acetamide. This was dissolved in DMF (5ml). K2CO3 (0.34g, 2.45mmol) and epibromohydrin (0.2 lg, 1.54mmol) was added and the resulting mixture was heated with stirring at 50°C for 3 hours. The mixture was partitioned between EtOAc and water 40+40ml. The organic phase was washed twice with water and once with brine and finally concentrated in vacuo to give a red oil. The crude product was purified on silica (Heptane/EtOAc, 1:2-1 :4) to give 110 mg (16%) of the subtitle compound. H-NMR (400MHz, CDC13): δ 9.03 (IH, d, J1.9Hz), 7.81 (IH, bs), 7.74 (IH, dd, J8.6, 2.3Hz), 6.96. (IH, d, J8.6Hz), 4.48 (IH, dd, J11.3, 2.4Hz) 4.00 (IH, dd, J11.4, 6.4Hz), 3.45- 3.40 (IH, m), 2.99 (IH, t, J4.4Hz), 2.79 (IH, dd, J4.7, 2.6 Hz), 2.59 (3H, s), 2.26 (3H, s).
ii) N-(5-Acetyl-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide trifluoroacetate
The title compound was prepared according to the method described in Example 197.
APCI-MS : m/z 447, 449 [MH+]
Example 210
N-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)- methanesulfonamide i) l-(2-Aminophenoxy)-3-[3-(4-chlorophenoxy)-l-pyrroIidinyI]-2-propanol dihydrochloride
A mixture of N-(2-{3-[3-(4-chlorophenoxy)-l-pyrrolidinyl]-2- hydroxypropoxy}phenyl)acetarnide (0.95 g, 2.34 mmol) and concentrated hydrochloric acid (25 mL) was heated (100 -105 °C) for 3 hours then allowed to stand at room temperature overnight. The mixture was concentrated at reduced pressure to a third of its volume basified with saturated sodium hydrogen carbonate. The resulting suspension was extracted twice with ethyl acetate. The organic extracts were dried, the solvent was evaporated at reduced pressure to give a pale brown oil. This oil was dissolved in a minimum amount of methanol, diluted with ethyl ether and the product precipitated by addition of HCl-saturated ethyl ether. The product was filtered to afford the subtitle product (0.93 g, 91.2%).
APCI-MS : m/z 363 [MH+] for the free base.
ϋ) Λr-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)- methanesulfonamide
Methanesulfonyl chloride (35 mg, 0.3 mmol) was added to cold (0 C), stirred mixture of the above amine (110 mg, 0.25 mmol) and pyridine (0.4 mL) in dry dichloromethane (10 mL). The mixture was then stirred at room temperature for 1.5 hour then concentrated. The residue was partitioned between ethyl acetate and water. The organic phase was concentrated and the residue was purified by flash chromatography (silica gel, dichloromethane-methanol, 25:1) to afford the title compound (68 mg, 61.8%) as a foam.
'H-NMR (400MHz, CDC13): δ 7.51 (dd, IH, J= 1.4 and 8.0 Hz), 7.22 (m, 2H), 7,10 (m, IH), 7.68 (m. IH), 6.92 (d, IH, J= 9.0 Hz), 6.76 (m, 2H), 5.78 (very bs, IH), 4.80 (m, IH), 4.20 (m, IH), 4.08 (m, IH), 3.98 (m,lH), 3.16 (m, IH), 3.01 (m, IH), 2.96 (s, 3H), 2.89 (m, 2H), 2.74 (m, M), 2.68 (dd, IH, J= 4.0 and 12.2 Hz), 2.3 (m, IH), and 2.02 (m, IH). 13C-NMR,400 MHz, CDC13): δ 155.9, 149.4, 129.4, 126.9, 125.8, 125.77, 125.75, 122:29, 122.26, 12217, 115.5, 1 13.52, 113.50, 76.52, 76.49, 72.15, 72.09, 67.18, 67.08, 60.24, 60.07, 57.96, 57.94, 53.18, 52.98, 39.1, 31.92, 31.90.
APCI-MS: m/z 441[MH+].
Example 211
N-(5-Chloro-2-[3-[3,4-dichlorophenoxy)-l-pyrrodinyl]-2-hydroxypropoxy]- phenyl)urea
i) N-(5-Chloro-2-hydroxyphenyl)urea
A solution of potassium cyanate (6.14 g, 75.6 mmol) in water (50 mL) was added dropwise to a stirred suspension of 2-amino-4-chlorophenol (5.00 g, 34.8 mmol) in a mixture of acetic acid (350 mL) and water (250 mL) and the resulting solution was stirred at room temperature for 3 hours. The reaction mixture was extracted three times with ethyl ether. The ether extracts were combined and concentrated to a thick oil. A 10% solution of sodium hydrogen carbonate (250 mL) was added to the above oil. The solid product was filtered and washed several times with water and recrystallized (toluene containing a little methanol) to afford the subtitle compound (3.27 g, 50.4%)
'H-NMR (400MHz, DMSO-cK): δ 10.1 (s, IH), 8.07 (d, IH, J=2.2 Hz), 8.04 (s, IH), 6.75- 6.78 (m, 2H), 6.29 (bs, 2H).
13C-NMR: 5156.0, 144.1, 130.0, 122.5, 120.2, 117.5, 115.2.
ii) N-[5-Chloro-2-(2-oxiranylmethoxy)phenyl]urea
A suspension of N-(5-chloro-2-hydroxyphenyl)urea (53 mg, 0.28 mmol), cesium carbonate (92 mg, 0.28 mmol) and epibromohydrine (49 mg, 0.36 mmol) in dry DMF (0.6 mL) was stirred at room temperature for 24 hours. The mixture was then partitioned between ethyl acetate and water. The organic phase was washed with water three times, dried and concentrated to a solid residue. This crude product was recrystallized (ethyl ether and heptane to afford the subtitle compound (18 mg, 26.5%).
'H-NMR (400MHz, DMSO-ΛT): δ 8.20 (d, IH, J=2.2 Hz), 8.00 (s, IH), 7.00 (d, IH, J=8.8 Hz), 6.88 (dd, IH, J= 2.4 and 8.6 Hz), 6.40 (bs, 2H), 4.40 (dd, IH, J= 2.2 and 12.0 Hz), 3.90 (dd, IH, J= 6.6 and 12.0 Hz), 3.37 (m, IH), 2.88 (t, IH, H= 4.8 Hz), 2.74 (m, IH).
iii) N-(5-Chloro-2-[3-[3,4-dichlorophenoxy)-l-pyrrodinyl]-2-hydroxypropoxy]- phenyl)urea A solution of the subtitle compound (ii) (16 mg, 0.07 mmol) and 3-(3,4- dichlorophenoxy)ρyrrolidine (17 mg, 0.07 mmol) in absolute ethanol (1 mL) for 2 hours. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (dichloromethane-methanol, 15:1) to afford the title compound (11 mg, 33%).
'H-NMR (400MHz, DMSO-cfø): δ 8.18 (d, IH, J= 2.6 Hz), 7.94 (s, IH), 7.5 (d, IH, J= 0.0Hz), 7.16 (d, IH, J= 2.1 Hz), 6.82-6.98 (m, 3H), 6.33 (bs, 2H), 4.98 (m, IH), 4.90 (m, IH), 3.85-4.07 (m, 3H), 2.63-2.93 (m, 5H), 2.21-2.30 (m, IH), 1.74 (m, IH).
APCI-MS : m/z 198 [MH+]
Example 212 l-(3-{2-[(Ammocarbonyl)amino]phenoxy}-2-hydroxypropyl)-3-(4- chlorophenoxy)pyrrolidinium 2,2,2-trifluoroacetate
i) N-(2-Hydroxyphenyl)urea
A solution of potassium cyanate (3.94 g, 48.6 mmol) in water (30 mL) was added during 15 min. to suspension of 2-aminophenol (2.41 g, 22.1 mmol) in 50% aqueous acetic acid (160 mL). The resulting solution was allowed to stand at room temperature overnight and then extracted with ethyl ether (3 times). The combined organic extracts was concentrated to small volume and poured into cold saturated aqueous sodium hydrogen carbonate. The solid was filtered and washed with water to afford the subtitle compound (1.61 g, 47.9%).
'H-NMR (400MHz, DMSO-d6): δ 9.88 (s, IH), 7.97 (s, IH), 7.80 (bd, IH), 6.77 (m, 1 H), 6.68 (m, IH), 6.17 (s, 2H),
ϋ) N-[2-(2-Oxiranylmethoxy)phenyl]urea
A solution of epibromohydrin (0.94 g, 6.84 mmol) in dry DMF (2mL) was added dropwise to a stirred suspension of iV-(2-hydroxyphenyl)urea (0.65 g, 4.27 mmol) and cesium carbonate (2.22 g, 6.84 mmol) in DMF (8 mL). After 2 hours the mixture was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate and the combined organic phase was washed with water (3 times), dried and concentrated. The semi-solid residue was disssolved in dichloromethane/ethyl ether, filtered and heptane was added to turbidity. After standing at room temperature overnight, the solid was filtered to afford the subtitle compound (0.28 g, 32%).
'H-NMR (400MHz, DMSO-d6): δ 8.07(m, IH), 7.82 (s, IH), 6.97 (m, IH), 6.85 (m, 2H), 6.24 (bs, 2H), 4.37 (dd, IH, J=2,5 and 11.6 Hz), 3.89 (dd, IH, J=6.4 and 11.6 Hz), 3.38 (m, IH), 2.87 (t, IH, J=4.6 Hz), 2.75 (dd, IH, J=2.6 and 5.2 Hz).
APCI-MS: m/z 209 [MH+].
iii) l-(3-{2-[(Aminocarbonyl)amino]phenoxy}-2-hydroxypropyl)-3-(4- ch!orophenoxy)pyrrolidinium 2,2,2-trifluoroacetate
A solution of 7V-[2-(2-oxiranylmethoxy)phenyl]urea (78 mg, 0.37 mmol) and 3-(4- chlorophenoxy)pyrrolidine (70 mg, 0.36 mmol) in absolute ethanol (4 mL) was heated at reflux for 2.5 hours. The mixture was then concentrated and the residue was purified by HPLC to afford the title compound (102 mg, 54.5%). 'H-NMR (400MHz, DMSO-d6+ D2O): δ 7.98 (bd, IH, J=7.2 Hz), 7.36 (d, 2H, J=8.8 Hz), 6.95-7.02 (m, 3H), 6.88 (m, 2H), 5.15 (bd, IH). 4.26 (m, IH). The remaining 10 aliphatic protons appear as complicated overlapping multiplets between δ 2.04 and 4.04.
APCI-MS: m/z 406 [MH+] and 408 [MH++2] for the free base.
Example 213 l-(3-{2-[(Aminocarbonyl)amino]phenoxy}-2-hydroxypropyl)-3-(3,4- dichlorophenoxy)pyrroIidinium 2,2,2-trifluoroacetate
A solution of N-[2-(2-oxiranylmethoxy)phenyl]urea (Described under example 22, step ii; 69 mg, 0.33 mmol) and 3-(3,4-dichlorophenoxy)pyrrolidine (77 mg, 0.33 mmol) in absolute ethanol (4.5 mL) was heated at 70°C for 2 hours. The residue after evaporation of the solvent was purified by HPLC to afford the title compound (133 mg, 72.3%).
'H-NMR (400MHz, DMSO-d5+ D2O): δ 7.96 (bd, IH, J=7.4 Hz), 7.54 (bd, IH, J=9.0 Hz), 7.27 (bs, IH), 6.84-7.00 (m, 4H), 5.20 (bd, IH), 4.26 (m, IH). The remaining 10 aliphatic protons appear as complicated overlapping multiplets between δ 2.05 and 4.03.
APCI-MS: m/z 439.9 [M] and 442 [M+2] for the free base.
Example 214 l-(3-{2-[(Aminocarbonyl)amino]-4-chlorophenoxy}-2-hydroxypropyl)-3-(4- chlorophenoxy)pyrrolidinium 2,2,2-trifluoroacetate
A solution of N-[2-(2-oxiranylmethoxy)phenyl]urea (described under Example 212, step ii; 47 mg, 0.22 mmol) and 3-(4-chlorophenoxy)pyrrolidine (41 mg, 0.2 mmol) in absolute ethanol (3 mL) was heated at 70°C for 1.5 hours. The solvent was then evaporated and the residue was purified by HPLC to afford the title compound (67 mg, 60.9%). 'H-NMR (400MHz, CD3OD): δ 8.04(s, IH), 7.31 (d, 2H, J=8.6 Hz), 6.94-6.98 (m, 4H), 5.20 (bs, IH), 4.40 (m, IH). The remaining 10 aliphatic protons appear as complicated overlapping multiplets between δ 2.25 and 4.13.
APCI-MS : m/z 440.1 [M] and 442.1 [M+2] for the free base.
Example 215
N-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-iV- ethylurea hydrochloride
An ether solution of N-(2-{3-[3-(4-chlorophenoxy)-l-pyrrolidinyl]-2- hydroxypropoxy}phenyl)urea [obtained from the hydrochloride (1 lOmg, 0.25mmol) by treatment with IM NaOH and extraction with ether] was treated with ethyl isocyanate (16μl, 0.2mmol) in a sealed vial for 15h at ambient temperature. After evaporation and purification by flash chromatography on silica (EtOAc/MeOH 100/5) the appropriate fractions were acidified with IM HCl and lyophilized from acetic acid to give the title compound as a white amorphous solid (35mg, 37%). The substance is a mixture of two diastereomeric pairs.
APCI-MS: m/z 434 [MH+]
Example 216
N-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-iV- methylurea hydrochloride
To a solution of iV-(2-{3-[3-(4-chlorophenoxy)-l-pyrrolidinyl]-2- hydroxypropoxy}phenyl)urea [obtained from the hydrochloride (44mg, O.lmmol) by treatement with IM NaOH and extraction with ether] in DCM (3ml) di(tert-butyϊ) tricarbonate (26mg, O.lmmol) was added, and the solution was set aside for 15 min. Methylamine (2M in DCM, lOOμl, 0.2mmol) was added and the solution was left to stand over night. After evaporation the crude product was purified by preparative RP-HPLC using acetonitrile and water containing 0.1% TFA as mobil phase. The appropriate fraction was concentrated in vacuo and extracted with IM NaOH and ether. The residue from the organic phase was acidified with IM HCl and lyophilized from acetic acid to afford the title compound as a white amorphous solid (15mg, 30%). The substance is a mixture of two diastereomeric pairs.
APCI-MS: m/z 420 [MH4]
Example 217
(2S,4S)-l-{3-[2-(Acetylamino)phenoxy]-2-hydroxypropyl}-4-(4-chlorophenoxy)-2- pyrrolidinecarboxylic acid; compound with trifluoroacetic acid
(i) Methyl (2S,4S)-l-{3-[2-(acetylamino)phenoxy]-2-hydroxypropyl}-4-(4- chlorophenoxy)-2-pyrrolidinecarboxylate hydrochloride
Methyl (25',4-S)-4-(4-chlorophenoxy)-2-pyrrolidinecarboxylate (370mg, l.Ommol) and /V- [2-(2-oxiranylmethoxy)phenyl]acetamide (207mg, l.Ommol) dissolved in tert-butanol (7ml) was stirred in a sealed vial at 100°C over night. Workup of the crude material by flash chromatography on silica (DCM/MeOH 100/2), acidification of the appropriate fractions with IM HCl and lyophilization from acetic acid afforded the subtitled compound as a white amorphous solid (360mg, 72%). The substance is a diastereomeric mixture.
APCI-MS : m/z 463 [MH+]
ii) (2S,4iS -l-{3-[2-(Acetylamino)phenoxy]-2-hydroxypropyl}-4-(4-chlorophenoxy)-2- pyrrolidinecarboxylic acid; compound with trifluoroacetic acid
Compound (i) (50mg, O.lmmol) was dissolved in acetonitrile (2ml) and water (3ml). Lithium hydroxide hydrate (8mg, 0.2mmol) dissolved in water (0.5ml) was added. The reaction was complete after 0.5h as determined by analytical HPLC. The mixture was acidified with TFA and purified by preparative RP-HPLC using acetonitrile and water containing 0.1 % TFA as mobile phase. The appropriate fraction was concentrated in vacuo and the residue lyophilized from acetic acid to give the title compound as a white amorphous solid (27mg, 48%). The substance is a diastereomeric mixture.
APCI-MS: m/z 449 [MH+], 431 [MH+, lactone, minor amount]
Example 218
Ethyl (2S,4S)-l-{3-[2-(acetylamino)phenoxy]-2-hydroxypropyl}-4-(3,4- dichlorophenoxy)-2-pyrrolidinecarboxylate; trifluoroacetic acid salt
i) Methyl (2S,4S)-4-(3,4-dichlorophenoxy)-2-pyrrolidinecarboxylate
The compound was prepared by analogy with Example 217(h) from N-Boc-rø-4-hydroxy- L-proline methylester and 3,4-dichlorophenol.
'H-NMR (400MHz, DMSO-^): δ 9.64 (bs, 2H); 7.58 (d, IH); 7.25 (d, IH); . 6.94 (dd, IH); 5.24 (m, IH); 4.66 (dd, IH); 3.76 (s, 3H); 3.55 (dd, IH); 3.47 (d, IH); 2.67-2.58 (m, IH); 2.38 (d, IH)
APCI-MS : m/z 290, 292 [MH+, isotope pattern]
ii) Ethyl (2S,4S)-l-{3-[2-(acetylamino)phenoxy]-2-hydroxypropyl}-4-(3,4- dichlorophenoxy)-2-pyrroIidinecarboxylate; trifluoroacetic acid salt
The compound was prepared by analogy with Example 217 from compound i) (404mg, 1.Ommol) and N-[2-(2-oxiranylmethoxy)phenyl]acetamide (207mg, 1.Ommol), with the exception that ethanol was used as solvent. Reesterification occurred, and after work-up and purification the title compound was isolated as a white solid (209mg, 33%). The substance is a diastereomeric mixture.
APCI-MS: m/z 511, 513 [MH+, isotope pattern] Example 219
7V-[2-({(2S)-3-[(2S,4S)-4-(4-Chlorophenoxy)-2-(hydroxymethyl)pyrroUdinyl]-2- hydroxypropyl}oxy)phenyl] acetamide; trifluoroacetic acid salt and N-[2-({(2R)-3-[(2S,4S)-4-(4-Chlorophenoxy)-2-(hydroxymethyl)pyrroUdinyl]-2- hydroxypropyI}oxy)phenyl] acetamide; trifluoroacetic acid salt
i) [(2S,4S)-4-(4-Chlorophenoxy)pyrrolidinyl]methanol
Methyl (21S,,4iS)-4-(4-chlorophenoxy)-2-pyrrolidinecarboxylate (prepared from cz.y-4-hydroxy-L-proline methylester according to Example 217ii)) (850 mg, 3.32 mmol) in dry THF (20 ml) was added during 40 min to a mixture of lithium aluminiumhydride (505 mg, 13.3 mmol) in dry THF (10 ml) at 0°C under an argon atmosphere. After stirring overnight at room temperature sodium sulfate decahydrate (lg) was added, followed by dropwise addition of water (0.5 ml), sodium hydroxide (15% w/v, 0.5 ml) and water (1.5 ml). Filtration and evaporation gave a syrup which was purified by flash chromatography on silica gel (dichloromethane/methanol/concentrated ammonia 100/20/1) to give the subtitle compounds (0.60 g, 79%). H-NMR (400 MHz, CDC13): δ 7.22 (m, 2H), 6.78 (m, 2H), 4.79 (m, IH), 3.62 (m, 2H), 3.39 (m, IH), 3.23 (bd, IH), 3.14 (dd, IH, J5.0 Hz, 12.2 Hz), 2.28 (m, IH), 1.72 (m, IH).
MS-APCI+: m z 228 [MH4]
ii) N-[2-({(2S)-3-[(2S,4S)-4-(4-Chlorophenoxy)-2-(hydroxymethyl)pyrroUdinyl]-2- hydroxypropyl} oxy)phenyl] acetamide; trifluoroacetic acid salt and
N-[2-({(2R)-3-[(2S,4S)-4-(4-Chlorophenoxy)-2-(hydroxymethyl)pyrroUdinyl]-2- hydroxypropyl}oxy)phenyl] acetamide; trifluoroacetic acid salt
[(25,4,S)-4-(4-Chloroρhenoxy)ρvrrolidinyl]methanol (380 mg, 1.67 mmol) and N-[2-(2- oxiranylmethoxy)phenyl]acetamide (414 mg, 2.00 mmol) were dissolved in tert-butanol (5 ml) and stirred in a sealed vial at 100°C for 3h. The solution was concentrated and the residue was purified by flash chromatography on silica gel (dichloromethane/methanol 13/1) followed by preparative RP-HPLC using acetonitrile/water containing 0.1% trifluoroacetic acid as mobile phase. The appropriate fractions were lyophilized to give the title compounds (epimer A: 248 mg, 27 %, epimer B: 115 mg, 13 %; stereochemistry at epimeric centre not determined).
Epimer A:
1H-NMR (400 MHz,MeOD): δ 7.82 (dd, IH, J 1.3 Hz, 8.0 Hz), 7.31 (m, 2H), 7.14 (m, IH), 7.04 (m, IH), 6.96 (m, 3H), 5.20 (m, IH), 4.40 (m, IH), 4.11 (bd, 2H), 3.79-4.05 (m, 5H), 3.73 (dd, 1H, J5.2 Hz, 12.5 Hz), 3.43 (dd, 1H, J2.6 Hz, 13.0 Hz), 2.80 (m, IH), 2.18 (s, 3H), 2.12 (m, IH). MS-APCI+: m/z 435 [MH4] Epimer B:
1H-NMR (400 MHz,MeOD): δ 7.79 (dd, IH, J 1.3 Hz, 7.9 Hz), 7.32 (m, 2H), 7.14 (m, IH), 7.04 (m, IH), 6.97 (m, 3H), 5.18 (m, IH), 4.49 (m, IH), 3.83-4.19 (m, 7H), 3.69 (dd, 1H, J4.8 Hz, 13.2 Hz), 3.34 (m, IH), 2.72 (m, IH), 2.18 (s, 3H), 2.07 (m, IH). MS-APCI+: m z 435 [MH4]
Example 220 iV-(2-{3-[3-(4-ChIorophenoxy)-l-pyrroIidinyI]-2-hydroxy-2- methylpropoxy}phenyl)acetamide hydrochloride
i) N-{2-[(2-Methyl-2-propenyl)oxy]phenyl} acetamide
The compound (1.74 g, 85 %) was prepared from 3-chloro-2-methylpropene (1.09 g, 11.9 mmol) and 2-acetamidophenol (1.50 g, 9.92 mmol) analogously to that described in Example 8(1). 1 H-NMR (400 MHz, CDC13): δ 8.36 (dd, IH, J 1.7 Hz, 7.8 Hz), 7.80 (bs, IH), 6.98 (m. 2H), 6.87 (dd, IH, J 1.6 Hz. 7.9 Hz), 5.08 (s, IH), 5.04 (s, IH), 4.51 (s, 2H), 2.21 (s, 3H), 1.85 (s, 3H).
ϋ) N-{2-[(2-Methyl-2-oxiranyl)methoxy]phenyl}acetamide
The compound (0.56 g, 65 %) was prepared from N-{2-[(2-methyl-2- propenyl)oxy]phenyl} acetamide (800 mg, 3.90 mmol) and m-chloroperbenzoic acid (80 %, 1.10 g, 5.22 mmol) analogously to that described in Example 8 (ii).
]H-NMR (400 MHz, CDC13): δ 8.36 (m, IH), 8.01 (bs, IH), 7.01 (m, 2H), 6.91 (m, IH), 4.07 (m, 2H), 2.96 (d, IH, J4.8 Hz), 2.79 (d, IH, J4.8 Hz), 2.22 (s, 3H), 1.49 (s, 3H).
iii) /V-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxy-2- methy lpropoxy } phenyl) acetamide hydrochloride
The title compound (255 mg, 110 %) was prepared from N-{2-[(2-methyl-2- oxiranyl)methoxy]phenyl} acetamide (123 mg, 0.557 mmol) and 3-(4- chlorophenoxy)pyrrolidine (100 mg, 0.506 mmol) analogously to that described in Example 1 (iii).
!H-NMR (400 MHz, MeOD): δ 7.61 (m, IH), 7.29 (m, 2H), 7.18 (m, IH), 7.10 (m, IH), 6.96 (m, 3H), 5.18 (m, IH), 3.91-4.22 (m, 4H), 3.37-3.76 (m, 4H), 2.66 (m, lA H), 2.37 (m, IH), 2.25 (m, Vi H), 2.15 (m, 3H), 1.45 (m, 3H). MS-APCI+: m/z 419 [MET]
General procedures and preparation of starting materials for Examples 221-230
Preparation of the epoxides:
A) iV-(2-{[(2S*,3S*)-3-Methyloxiranyl]methoxy}phenyl)acetamide i) N-{2-[(E)-l-Propenyloxy]phenyl}acetamide
A heterogenic mixture of commercially available l-chloro-2-butene (Aldrich, predominantly trans) (453 mg, 0.49 mL, 5.00 mmol), 2-acetamidophenol (756 mg, 5.00 mmol) and potassium carbonate (691 mg, 5.00 mmol) in aceton (10 ml) was heated to reflux over night. After evaporation of the solvent the residue was taken up by ethylacetate and water. Washing of the organic phase with water, 5-proz. sodium hyroxide and brine and evaporation of the solvent afforded the crude which was purified by flash chromatography on silica gel (heptane/EtOAc = 3:2). Yield: 732 mg (71 %) of a brownish yellow solϊd.Trans: cis = 81 : 19 (ratio determined by Η-NMR; 400MHz, CDC13):
MS-APCI+ : m z 206.1 [MH+].
ii) M-chloroperbenzoic acid (70-proz.; 270 mg, 1.92 mmol, 2.0 equiv.) was added to a ice bath cooled solution of compound i) (112 mg, 546 μmol) dissolved in dichloromethane (3 ml) and stirred without further cooling over night. After addition of ethylacetate the mixture was washed with sat. sodium sulfite, 5-proz. sodium hyroxide and brine. Drying over sodium sulfate, evaporation of the solvent and flash chromatography on silica gel afforded 86 mg (71 %) of the product as a beige solid in a trans:cis-ratio of 83:17 as determined by 'H-NMR.
'H-NMR (400MHz, CDC13; only the signals of the major isomer are given): δ 8.35 (IH, m), 7.90 (IH, br.s), 7.00 (2H, m), 6.88 (IH, m), 4.30 (IH, dd, J 11.4, 2.5Hz), 3.96 (IH, dd, J 11.4, 5.7Hz), 3.08 (2H, m), 2.21 (3H, s), 1.40 (3H, d, J 5.2Hz).
MS-APCI+ : m/z 222.1 [MH+].
B) /V-(2-{[(2S,3R)-3-Methyloxiranyl]methoxy}phenyl)acetamide
i) N-[2-(2-Butynyloxy)phenyl] acetamide A mixture of l-bromo-2-butine (1.39 g (10.4 mmol), 2-acetamidophenol (1.58 mg, 10".4 mmol), anhydrous potassium carbonate (1.44 g, 10.4 mmol) and sodium iodide (30 mg) in butanone (50 ml) was heated over night to reflux. After that the reaction mixture was filtrated, the filtrate was evaporated and the resulting residue was taken up by ethyl acetate. The obtained solution was washed with 5-proz. sodium hydroxide, brine and water, dried over sodium sulfate and evaporated. The crude was recrystallized out of heptane/MTB (1:1) yielding in 1.57 g (74 %) of a light brown needles.
MS-APCI+ : m/z 204.1 [MH+].
ii) N-{2-[(Z)-2-Butenyloxy]phenyl}acetamide
A mixture of the alkyne i) (357 mg, 1.76 mmol) and 5-% Pd/BaSO4 (22 mg) in pyridine (2.0 mL) was hydrogenated for 2h 30min under atmospheric pressure at room temperature. At this point the starting material was completely consumed, but some overreduction to the corresponding alkane was observed by LC MS. The reaction mixture was filtered on celite which was thoroughly washed with ethylacetate. Thereafter the filtrate was washed with 1 N HCl to acidic reaction and finally washed neutral with brine. Drying over sodium sulfate, evaporation of the solvent yielded in 318 mg (88 %) crude which contained beside the desired Z-olefϊn also some E-olefine and corresponding alkane as biproducts. The ratio as determined by Η-NMR (400MHz, CDC13) was E : Z : alkane = 83 : 10 : 7. The crude was used in the next step without further purification.
MS-APCI+ : m/z 206.1 [MH+].
iii) The olefine ii) (310 mg, 1.51 mmol)was dissolved in dichloromethane (10 ml) and m-chloroperbenzoic acid (80-proz.; 587 mg, 2.72 mmol, 1.8 equiv.) was added at 0°C. Stirring over night at ambient temperature was followed by evaporation of the solvent and taking up the resulting residue with ethylacetate, washing with sat. sodium sulfite, 5-% sodium hydroxide and brine and drying over sodium sulfate. Evaporation of the solvent and flash chromatography on silica gel (ethylacetate/heptane = 2:1 continued to ethylacetate) gave 269 mg (81 %) of the epoxide in a E:Z-ratio of 82:18 (determined by Η- NMR) as a white powder.
'H-NMR (400MHz, CDC13; only the signals of the major isomer are given): δ 8.37 (IH, dd, J 7.5, 2.1Hz), 7.81 (IH, br.s), 7.02 (2H, m), 6.91 (IH, dd, J 7.4, 1.7Hz), 4.32 (IH, dd, J 11.1, 3.6Hz), 4.03 (IH, dd, J 1 1.1, 6.9Hz), 3.33 (IH, dt, J 7.0, 4.0Hz), 3.24 (IH, dt, J 9.9, 5.5Hz), 2.21 (3H, s), 1.38 (3H, d, J 5.7Hz).
MS-APCI+ : m/z 222.1 [MH+].
C) N-{2-[(lR,2S,5R)*-6-Oxabicyclo[3.1.0]hex-2-yloxy]phenyI}acetamide
i) (2-Cyclopenten-l-yIoxy)(trϋsopropyl)silane
A solution of 2-cycloρentenol (K. Alder, F. H. Flock, Chem. Ber. 1956, 89, 1732.) (2.31 g, 27.5 mmol), (triisopropyl)chlorsilane (5.30 g, 5.9 mL, 27.5 mmol), imidazole (2.06 g, 30.2 mmol) in DMF (50 mL) was stirred at room temperature for 3h and for an additional hour at 50° C. Then the solution was diluted with ethylacetate, washed 4 times with water and dried over sodium sulfate. Evaporation of the solvent yielded in 6.32 g (96 %) of the silylether 513/13 as a colourless liquid. No major impurities were visible in the Η-NMR- spectrum.
'H-NMR (400MHz, CDC13): δ 5.88 (IH, m), 5.76 (IH, m), 4.98 (IH, m), 2.48 (IH, m), 2.27-2.17 (2H, m), 1.70 (IH, m), 1.12-1.05 (21H, m).
ϋ) Triisopropyl[(lR,2R,5R)*-6-oxabicyclo[3.1.0]hex-2-yloxy]silane
M-chloroperbenzoic acid (70-%.; 5.41 g, 21.9 mmol, 1.7 equiv.) was added to a ice bath cooled solution of compound i) (3.10 g, 12.9 mmol) dissolved in dichloromethane (25 ml) and stirred without further cooling additional 90 min. After filtration of the reaction mixture, evaporation of the filtrate the residue was dissolved in ethylacetate, washed with sat. sodium sulfite, 5-proz. sodium hydroxide and brine and dried over sodium sulfate. Evaporation of the solvent afforded the crude as a mixture of the diastereomeric epoxides in trans/ cis-raήo of 78:22 (Η-NMR). Separation by flash chromatography on silica gel (heptane/ethylacetate = 95:5 continued to 90:10) afforded 1.65 g (50 %) of the desired fr-α/z.s'-epoxide (IR,2R,5R)* as the first eluated diastereomer. The total yield of both diastereomeric epoxides was 2.86 g (87 %).
Η-NMR (400MHz, CDC13): δ 4.39 (IH, d, J 3.4Hz), 3.54 (IH, d, J 2.5Hz), 3.37 (IH, d, J 2.5Hz), 1.94 (IH, m), 1.84 (dtd, J 13.7, 9.3, 1.1Hz), 1.60-1.55 (2H, m), 1.13-1.04 (21H, m).
iii) (lS,2R,5R)*-6-Oxabicyclo[3.1.0]hexan-2-ol
To a solution of the silylether ii) (280 mg, 1.09 mmol) in THF (2.0 mL) tefrabutylammonium fluorid (1.0 M in THF; 1.2 mL, 1.20 mmol) was added. After stirring for 3 h at room temperature the mixture was diluted with ethylacetate, washed with brine and dried over sodium sulfate. Chromatographic filtration on silica gel (heptane/ter utylmethylether 2: 1 continued to ethylacetate) afforded 79 mg (72 %) as a pale yellow oil.
'H-NMR (400MHz, CDC13): δ 4.36 (IH, d, J 5.1Hz), 3.55 (IH, s), 3.42 (IH, d, J 1.5Hz), 1.99 (IH, m), 1.84 (IH, dddd, J 13.9, 10.1, 9.0, 1.1Hz), 1.69-1.53 (3H, m).
iv) The title compound was prepared according to the general protocol (I) below.
'H-NMR (400MHz, CDC13): δ 8.38 (IH, m), 7.91 (IH, br.s), 7.02-6.98 (2H, m), 6.94 (IH, m), 4.78 (IH, td, J 8.0, 1.2Hz), 3.61 (IH, m), 3.54 (IH, d, J 2.7Hz), 2.21 (3H, s), 2.21 (IH, m), 2.10 (IH, dt, J 12.8, 12.0Hz), 1.76 (IH, dtd, J 14.3, 10.4, 1.4Hz), 1.58 (IH, m).
MS-APCI+ : m/z 234.1 [MH+].
General protocol (I) for the preparation of JV-{2-[(lR,2S,5R)*-6-oxabicyclo[3.1.0]hex- 2-yloxy]phenyl}acetamides Step 1 - Mitsunobu coupling:
To a ice bath cooled solution of the epoxyalcohol 546/16 (1.0 equiv.), triphenylphosphine (1.2 equiv.) and a 2-nitrophenol (1.0 equiv.) in dry THF (2 mL/mmol) diethyl diazodicarboxylic acid (1.2 equiv.) was added dropwise. Stirring was continued over night without further cooling. Aqueous, basic workup, followed by flash chromatography on silica gel (typical eluant: heptane/ethyl acetate = 1:1) afforded the 2-nitrophenolic esters which contained often an equimolar amount of the biproduct diethyl 1,2- hydrazinedicarboxylate.
Step 2 - hydrogenation:
A mixture of 2-nitrophenolic esters as obtained from step 1, diwopropyl(ethyl)amine (2.0 equiv.), acetic acid anhydrate (2.0 equiv.) and 5-proz. Pt C (lO.mg/mmol) in ethyl acetate (10 mL/mmol) was hydrogenated for lh under atmospheric pressure at room temperature. In the case of non-halogenated aromates Pd/C and shorter reaction times, typically about 5 min, could be applied. Thereafter, the catalysator was filtered off by a celite filled filterfunnel and washed with ethanol. The filtrate was evaporated and the remaimng residue was subjected an aqueous, basic work-up. Subsequent flash chromatography on silica gel (typical eluant: ethyl acetate/heptane = 2:1) afforded the respective acetamides in typical yields of 50-70 % (2 steps).
D) N-{5-Chloro-2-[(lR,2S,5R)*-6-oxabicyclo [3.1.0] hex-2-yloxy] phenyl} acetamide
Preparation according to protocol (I).
'H-NMR (400MHz, CDC13): δ 8.47 (IH, d, J 2.5Hz), 7.89 (IH, br.s), 6.97 (IH, dd, J 8.8, 2.5Hz), 6.85 (IH, d, J 8.8Hz), 4.74 (IH, td, J 8.0, 1.3Hz), 3.58 (IH, m), 3.56 (IH, m), 2.21 (IH, m), 2.21 (3H, s), 2.09 (dt, J 13.0, 7.4Hz), 1.76 (IH, dtd, J 14.3, 10.1, 1.3Hz), 1.56 (lH, m). MS-APCI+ : m z 268.0 [MH+].
E) N-{4-Fluoro-2-[(lR,2S,5R)*-6-oxabicyclo[3.1.0]hex-2-yloxy]phenyl}acetamide
Preparation according to protocol (I).
'H-NMR (400MHz, CDC13): δ 8.23 (IH, dd, J 10.7, 2.8Hz), 7.99 (IH, br.s), 6.89 (IH, dd, J 9.0, 5.5Hz), 6.69 (IH, ddd, J 11.1, 9.0, 3.1Hz), 4.70 (IH, t, J 7.8Hz), 3.56 (2H, s), 2.21 (IH, dd, J 14.7, 8.4Hz), 2.21 (3H, s), 2.08 (IH, dt, J 13.0, 8.2Hz), 1.75 (IH, dtm, J 14.3, 9.5Hz).
MS-APCI+ : m/z 252.1 [MH+].
General protocol (II) for the addition of aminocycles to substituted 2- (aryloxymethyl)oxiranes
Equimolar amounts of aminocycle and epoxide, dissolved in a saturated solution of LiClO4 in acetonitrile (lml/lOOμmol), were heated to 100°C in a sealed tube. Typical reaction times ranged from 3h for open chained epoxides to 18h for oxabicyclo[3.1.0]hexanes. After cooling down to ambient temperature the reaction mixture was diluted with ethyl acetate and subjected to an aqueous work-up. The crude products were usually obtained in quantitative yields and were purified by flash chromatography on silica gel (typical eluants: ethyl acetate/methanol = 80:20).
The Examples 221-230 below were prepared according to the general protocols (I) and (II).
Example 221
N-(2-{(lS*,2R*,3S*)-3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide 'H-NMR (400MHz, CDC13): δ 8.20 (IH, d, J 7.4Hz), 8.07 (IH, br.s), 7.21 (2H, m), 7.01- 6.96 (2H, m), 6.92 (IH, dm, J 7.4Hz), 6.77 (2H, dm, J 8.8Hz), 4.77 (IH, m), 4,54 (IH, br.q, J 4.8Hz), 4.15 (IH, m), 3.04-2.91 (3H, m), 2.81 (IH, q, J 6.8Hz), 2.62 (IH, quint, J 7.3Hz), 2.29 (IH, m), 2.16 (3H, s), 2.13-1.90 (5H, m), 1.63 (IH, m).
MS-APC1+ : m/z 431.2 [MH+].
Example 222 N-(2-{(lR*,2R*,3S*)-3-[3-(4-Chloro-phenoxy)-pyrroUdin-l-yl]-2-hydroxy- cyclopentyloxy}-phenyI)-acetamide
'H-NMR (400MHz, CDC13): δ 8.26 (IH, m), 7.90 (IH, br.d, J 9.5Hz), 7.20 (2H, m), 6.97 (2H, m), 6.88 (IH, br.d, J 7.3Hz), 6.76 (2H, m), 4.76 (IH, m), 4.50 (IH, m), 4.21 (IH, dt, J 14.1, 5.5Hz), 3.00-2.89 (3H, m), 2.67-2.54 (2H, m), 2.28 (IH, m), 2.15 (3H, s), 2.11 (IH, m), 1.97 (2H, m), 1.87 (2H, m).
MS-APCI+ : m/z 431.2 [MH+].
Example 223
/V-(2-{(2R*,3R*)-3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yI]-2-hydroxy-butoxy}- phenyl)-acetamide
'H-NMR (400MHz, CDC13): δ 8.27 ((IH, dd, J 7.6, 1.6Hz), 8.07 (IH, br.s), 7.30 (IH, d, J 8.8Hz), 7.04-6.92 (4H, m), 6.74 (IH, dd, J 8.8, 2.9Hz), 4.26 (IH, m), 4.23 (IH, dd J 9.9, 2.7Hz), 4.06 (IH, m), 3.96 (IH, dd, J 9.9, 8.0Hz), 2.86-2.72 (3H, m), 2.58 (IH, m), 2.47 (IH, m), 2.18 (3H, s), 1.99 (2H, m), 1.80 (2H, m), 1.12 (3H, d, J 6.9Hz).
MS-APCI+ : m/z 469.1 [MH+]. Example 224
N-(2-{(lS*,2R*,3S*)-3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide
Η-NMR (400MHz, CDC13): δ 8.26 (IH, m), 8.20 (IH, br.s), 7.19 (2H, m), 7.02 (2H, m), 6.95 (IH, m), 6.84 (2H, m), 4.49 (IH, q, J 5.2Hz), 4.31 (IH, m), 4.15 (IH, m), 2.95 (2H, q, J 7.8Hz), 2.87 (IH, m), 2.51 (2H, br.q, J 10.2Hz), 2.19 (3H, s), 2.10-1.95 (5H, m), 1.86 (2H, m), 1.60 (lH, m).
MS-APCI+ : m/z 445.0 [MH+].
Example 225
N-(2-{(2R*,3S*)-3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-butoxy}- phenyl)-acetamide
'H-NMR (400MHz, CDC13): δ 8.47 (IH, br.s), 8.36 (IH, dd, J 7.2, 1.3Hz), 7.32 (IH, d, J 9.0), 7.04-6.93 (4H, m), 6.75 (IH, dd, J 9.0, 2.9Hz), 4.34 (IH, m), 4.11 (IH, m), 3.96 (IH, dd, J 10.5, 5.2 Hz), 3.66 (IH, m), 3.00-2.80 (2H, m), 2.71 (2H, m), 2.42 (IH, m), 2.19 (3H, s), 2.05 (IH, m), 1.94-1.81 (2H, m), 1.08 (3H, d, J 6.7Hz).
MS-APCI+ : m/z 466.9 [MH+].
Example 226 iV-(2-{(2R*,3R*)-3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-butoxy}-phenyl)- acetamide
'H-NMR (400MHz, CDC13): δ 8.34 (IH, t , J 4.5Hz), 8.18 (IH, br.s), 7.22 (2H, m), 6.99 (2H, m), 6.93 (IH, m), 6.76 (2H, m), 4.78 (IH, m), 4.20 (IH, m), 4.07 (IH, dt, J 10.1, 2.9 Hz), 3.95 (IH, dd, J 10.1, 8.2Hz), 3.15 (0.5H, dd, J 10.7, 6.1Hz), 2.97-2.94 (1.5H, m), 2.89 (0.5H, q, J 7.6Hz), 2.82 (0.5H, dd, J 10.5, 2.5Hz), 2.73 (0.5H, qm, J 7.5Hz), 2.65 (0.5H, m), 2.58 (IH, m), 2.26 (IH, m), 2.01 (IH, m), 1.09 (3H, appears as dd, J 6.7, 1.7Hz).
MS-APCI+ : m/z 419.1 [MH+].
Example 227
N-(2-{(2R*,3S*)-3-[3-(4-Chloro-phenoxy)-pyrroUdin-l-yl]-2-hydroxy-butoxy}-phenyl)- acetamide
'H-NMR (400MHz, CDC13): δ 8.48 (IH, m), 8.37 (IH, m), 7.22 (2H, m), 7.04-6.93 (3H, m), 6.77 (2H, m), 4.80 (IH, m), 4.12 (IH, m), 3.97 (I H, dd, J 10.5, 5.3Hz), 3.65 (IH, m), 3.09 (0.5H, dd, J 10.3, 6.0Hz), 3.06-2.99 (1.5H, m), 2.94 (0.5H, q, J 8.0Hz), 2.87-2.67 (2.5H, m), 2.25 (IH, m), 2.02 (IH, m), 1.05 (3H, appears as dd, J 6.7, 5.2Hz).
MS-APCI+ : m/z 418.9 [MH+].
Example 228
N-(2-{(lS*,2R*,35*)-3-[4-(3-Chloro-phenoxy)-piperidin-l-yI]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide
'H-NMR (400MHz, CDC13): δ 8.25 (IH, ), 8.17 (IH, br.s), 7.18 (IH, t, J 8.1Hz), 7.01 (2H, m), 6.97-6.90 (3H, m), 6.79 (IH, dm, J 9.0Hz), 4.48 (IH, q, J 5.5Hz), 4.34 (IH, hept, J 3.5Hz), 4.15 (IH, dd, J 7.2, 5.5Hz), 2.95 (2H, q, J 7.4Hz), 2.87 (IH, m), 2.52 (2H, br.q), J 9.6Hz), 2.19 (3H, s), 2.09-1.94 (6H, m), 1.86 (2H, m), 1.59 (IH, m).
MS-APCI+ : m z 445.1 [MH+].
Example 229
N-[5-ChIoro-2-({(lS,2R,3S)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2- hydroxy cyclopentyl} oxy)phenyl] acetamide 'H-NMR (400MHz, CDC13): δ 8.38 (2H, m), 7.31 (IH, d, J 8.7Hz), 6.99 (IH, d, J 8.8Hz), 6.95 (IH, dd, J 8.8, 2.6Hz), 6.86 (IH, d, J 8.8Hz), 6.75 (IH, dd, J 8.8, 2.9Hz), 4.38 (IH, q, J 4.0Hz), 4.31 (IH, hept, J 3.7Hz), 4.10 (IH, dd, J «7, 6Hz), 3.00 (IH, q, J 7.1Hz), 2.91- 2.82 (IH, m), 2.53 (2H, m), 2.17 (3H, s), 2.08-1.93 (5H, m), 1.85 (2H, m), 1.60 (IH, m).
MS-APCI+ : m/z 513.1 [MH+].
Example 230 N-[4-Fluoro-2-({(lS,2R,3S)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2- hydroxy cyclopentyl} oxy)phenyl] acetamide
'H-NMR (400MHz, CDC13): δ 8.58 (IH, br.s), 8.19 (IH, dd, J 10.9, 3.2Hz), 7.31 (l.H,..d, J 8.8Hz), 7.00 (IH, d, J 2.9Hz), 6.89 (IH, dd, J 9.0, 5.2Hz), 6.75 (IH, dd, J 9.0, 2.9Hz), 6.67 (IH, td, J 8.8, 3.1Hz), 4.35-4.29 (2H, m), 4.09 (IH, dd, J 7.8, 5.0Hz), 3.04 (IH, q, J 7.8Hz), 2.88 (2H, m), 2.54 (2H, m), 2.18 (3H, s), 2.08 (5H, m), 1.85 (2H, m), 1.61 (IH, m).
MS-APCI+ : m/z 497.2 [MH+].
Preparation of starting materials for Examples 231-248
A) (S*R*)-l-(3,4-Dichloro-benzyl)-2,5-dimethyl-piperazine
A solution of 1 ,2-dichloro-4-chloromethyl-benzene (1.1ml 7.89 mmol) in DMF (5 ml) was added to 2,5-dimethyl-piperazine (l.Og, 8.77 mmol) dissolved in DMF (25 ml). The reaction was stirred over night, poured into a mixture of EtOAc and sodium carbonate (5%). The water phase was washed twice with EtOAc and the combined organic phase once with brine, and dried over sodium sulfate. After evaporation the crude was dissolved in methanol. The dibensylated piperazine does not dissolve. The filtrate was filtered through a short silica column, using methanol as eluant and evaporated to give the pure product. Yield 812mg, 38% 'H-NMR (400MHz, DMSO-J6): δ 7.56 (d, IH, J = 8.1 Hz), 7.52 (d, IH, J = 1.8 Hz), 7.20 (dd, IH, J = 8.2, 1.8 Hz), 3.97 (d, IH, J = 14.1 Hz), 3.04 (d, IH, J = 14.2 Hz), 2.76 (dd, IH, J = 11.9, 3.0 Hz), 2.59 (m), 2.48 (dd, IH, J = 11.9, 2.6 Hz), 2.37 (t, IH, J = 10.8 Hz), 2.12 (m), 1.89 (s), 1.57 (t, IH, J = 10.4 Hz), 1.00 (d, IH, J = 6.1 Hz), 0.82 (d, IH, J = 6.3 Hz).
APCI-MS: m z 273 [M4]
B) (S*R*)-l-(4-Chloro-benzyl)-2,5-dimethyI-piperazine Was synthesized in the same way as A) from l-chloro-4-chloromethyl-benzene (1.27 g, 7.89 mmol) and 2,5-dimethyl-piperazine (l.Og, 8.77 mmol) in DMF. Yield 701 mg, 37%
'H-NMR (400MHz, DMSO-Λ5): δ 7.36 (d, 2H, J = 8.4 Hz), 7.30 (d, 2H, J = 8.4 Hz),_3.97 (d, IH, J = 13.9 Hz), 3.01 (d, IH, J = 13.8 Hz), 2.75 (dd, IH, J = 11.9, 3.0 Hz), 2.57 (m, IH, J = 10.8, 2.6 Hz), 2.47 (dd, IH, J = 10.9, 2.6 Hz), 2.36 (dd, IH, J = 11.6, 10.1 Hz), 2.10 (m, IH), 1.88 (bs, IH), 1.53 (t, IH, J = 10.5 Hz), 1.01 (d, 3H, J = 6.1 Hz), 0.80 (d, 3H, J = 6.4 Hz).
APCI-MS: m z 239 [MH4]
C) l-(3,4-Chlorobenzyl)piperazine
3,4-chlorobenzyl chloride (170mg, 0.872mmol) was added to a solution of piperazine (150mg, 1.74mmol) and tri ethyl amine(lml) in DMF (10ml) at room temperature. After 2hrs the solution was concentrated in vacuo. The resulting residue was triturated under ether and the obtained solid was washed with water and then dissolved in methanol and co- evaporated with toluene to give the product, 89mg, as a solid.
APCI-MS: m/z 245, 247[MH+] 'HNMR (400MHz, CD3OD) δ 7.41 (d, IH, J=2.0 Hz), 7.37 (d, IH, J=8.2 Hz), 7.13 (dd,lH, J=8.2, J=2.0 Hz), 3.5 (s, 2H), 3.05 (m, 4H). 2.57 (m, 4H)
D) l-(4-ChIorobenzyl)piperazine
Was prepared by analogy to C) above.
Example 231
N-(2-{3-[4-(3,4-Dichlorobenzyl)-l-piperazinyl]-2-hydroxypropoxy}-phenyl)acetamide dihydrochloride
A solution of N-acetyl-2-(2,3-epoxypropoxy)aniline (87.53mg, 0.422mmol) and l-(3,4- chlorobenzyl)piperazine in ethanol (10ml 99.5%) was refluxed for 3hrs. The solvent was distilled off under reduced pressure and the resulting residue was purified by silica gel column chromatography (dichloromethane/methanol 20: 1) to give the title compound as a gum. Addition of 1.0M ethereal HCl solution gave a white solid product 78mg (40%).
APCI-MS: m/z 452, 454[MH+]
'HNMR (400MHz, CD3OD) δ 8.0 (IH, dd, J=1.53Hz, J=8.01Hz), 7.5 (IH, d, J=1.91Hz), 7.45 (IH d, J=8.2Hz), 7.23 (IH, dd, J=6.1Hz, J=2.1Hz), 6.89-7.08(4H, m), 4.15(1H, m), 3.9-4.1(2H, m), 3.48(2H, S) 2.45-2.60(10H, m), 2.17(3H, S).
Examples 232-248 were synthesized according to Example 231 with the starting materials A) to D) above.
Example 232 iV-(2-{3-[4-(3,4-Dichlorobenzyl)-l-piperazinyl]-2-hydroxypropoxy}-4- fluorophenyl)acetamide APCI-MS: m z 470[MH+]
Example 233
Λr-(2-{3-[4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2- hydroxypropoxy}phenyl)acetamide
APCI-MS: m/z 480[MH+]
Example 234 iV-(5-Chloro-2-{3-[4-(3,4-dichlorobenzyl)-l-piperazinyl]-2- hydroxypropoxy} phenyl)acetamide
APCI-MS: m/z 486[MH+]
Example 235 iV-(5-Chloro-2-{3-[4-(3,4-dichlorobenzyl)-2,5-dimethyl-l-piperazmyl]-2- hydroxypropoxy} phenyl)acetamide
APCI-MS: m/z 480[MH+]
Example 236 iV-(2-{3-[4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2-hydroxypropoxy}-4- methylphenyl)acetamide
APCI-MS: m/z 494[MH+]
Example 237
N-(2-{3-[4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2-hydroxypropoxy}-4- fluorophenyl)acetamide APCI-MS: m z 498 [MH4]
Example 238
7V-(2-{3 [(S*R*)-4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2- hydroxypropoxy}phenyl)acetamide
APCI-MS: m/z 480[MH+]
Example 239 iV-(2-{3 [(S*R*)-4-(4-Chlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2- hy droxypropoxy} phenyl)acetamide
APCI-MS: m/z 446[MH+]
Example 240
N-(5-ChIoro-2-{3-[(S*R*)-4-(3,4-dichIorobenzyl)-2,5-dimethyIpiperazinyI]-2- hydroxypropoxy}phenyl)acetamide
APCI-MS: m/z 514[MH+]
Example 241
N-(5-Chloro-2-{3-[(S*R*)-4-(4-chlorobenzyl)-2,5-dimethylpiperazinyl]-2- hydroxypropoxy} phenyl)acetamide
APCI-MS: m/z 480[MH+]
Example 242 l-(5-Chloro-2-{3-[4-(4-chlorobenzoyl)-l-piperazinyl]-2-hydroxypropoxy}phenyl)-l- ethanone APCI-MS: m/z 451[MH+]
Example 243
N-(5-Cyano-2-{3-[(S*R*)-4-(3,4-dichlorobenzyl)-2,5-dimethylpiperazinyl]-2- 5 hydroxypropoxy} phenyl) acetamide
APCI-MS: m/z 505[MH+]
Example 244 l o JV-(2-{3-[(S*R *)-4-(4-Chlorobenzyl)-2,5-dimethylpiperazinyl] -2-hydroxypropoxy}-5- cyanophenyl)acetamide
APCI-MS: m/z 471[MH+]
is Example 245
N-(5-Chloro-2-{3-[4-(4-chlorobenzyl)-l-piperazinyl]-2-hydroxypropoxy}- phenyl)acetamide
APCI-MS: m/z 452[MH+] 0
Example 246
N-(4-Chloro-2-{3-[4-(4-chlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2- hydroxypropoxy}phenyl)acetamide 5 APCI-MS: m/z 460[MH+]
Example 247
N-(2-{3-[4-(4-Chlorobenzoyl)-l-piperazinyl]-2-hydroxypropoxy}-5- cyanophenyl)acetamide
30 APCI-MS: m/z 457[MH+]
Example 248
JV-(2-{3-[4-(4-ChIorobenzoyl)-l-piperazinyl]-2-hydroxypropoxy}-4- methylphenyl)acetamide
APCI-MS: m/z 446[MH+]
Example 249 /V-[5-Chloro-2-({(lR,2S,3R)-3-[(3S)-3-(4-chlorophenoxy)pyrroUdinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide
MS-APCI+ : m/z 464.9 [MH+].
Figure imgf000131_0001
Example 250
N-{2-[(2S)-(3-{(3S)-3-[(4-Chlorophenyl)oxy]-l-pyrrolidinyl}-2-hydroxypropyl)oxy]-4- fluorophenyl} acetamide
APCI-MS: m/z 423.1 [M+]
Example 251
N-[2-({(2S)-3-[(3S)-3-(4-Chlorobenzyl)pyrroUdinyl]-2- hydr oxy propyl} oxy)pheny 1] acetamide h drochloride
i) 3-(4-ChlorobenzyI)pyrrolidine
To a solution of 3-(4-chlorobenzyl)-2-pyrrolidinone (420mg, 2mmol) in dry THF (25mL) and under N2 LAH (190mg, 5mmol) was added in portions with stirring over a period of a couple of minutes. The temperature was increased to 60°C and the stirring continued for 2.5h. The mixture was quenched with 200μL water, 200μL 5M NaOH and 600μL water. The solid Li- and Al-salts were filtered off and the filtrate was evaporated to give a colourless oil (387mg, 99%).
APCI-MS: m/z 196, 198 [MH4]
ii) (2S)-l-[3-(4-Chlorobenzyl)-l-pyrrolidinyl]-3-(2-nitrophenoxy)-2-propanoI
A solution of compound (i) (387mg, 2mmol) and (25)-2-[(2-nitrophenoxy)-methyl]oxirane (390mg, 2mmol) in ethanol (6mL) was refluxed until the reaction was complete (2h), as determined by LCMS. The solvent was evaporated to give an orange oil (650mg, 83%) which was used without further purification.
APCI-MS: m/z 391, 393 [MH4]
iii) (2S)-l-(2-Aminophenoxy)-3-[3-(4-chlorobenzyl)-l-pyrrolidinyl]-2-propanol To a solution of compound (ii) (650mg, 1.67mmol) in ethanol (lOmL) at 60°C a mixture of tin(II)chloride dihydrate (2.25g, 1 Ommol) and 35% hydrochloric acid (2.5mL) was added. The temperature increased rapidly to 75°C. The mixture was stirred at 60°C for further 30 min. After evaporation of the solvent the residue was extracted with 5M NaOH and ether. The organic phase was washed with water, dried and evaporated. The residue was purified by RP-HPLC with acetonitrile and water containing 0.1 % TFA as mobile phase. The appropriate fraction was evaporated and the residue extracted with IM NaOH and ether. The subtitle compound was obtained from the organic phase as a colourless oil (400mg, 66%).
APCI-MS: m/z 361, 363 [MH4]
iv) To a solution of compound (iii) (400mg, 1.1 mmol) in DCM (10mL) acetic anhydride (200μL, 2. lmmol) was added and the mixture was left overnight. After evaporation the residue was dissolved in methanol and 1.5M sodiummethoxid in methanol (2mL) was added. The mixture was left for 2h, evaporated and taken up in ether and water. A mixture of the two diastereomers was obtained from the organic phase. The diastereomers were separated by HPLC on a chiral column using a mixture of isohexane, 2-propanol and methanol as mobile phase. The isolated enantiomers were dissolved in methanol (lmL), acidified with IM hydrochloric acid (lmL), diluted with water and lyophilized to give the title compounds as white amorphous solids (156mg and 173mg). The absolute stereoisomerism was not assigned.
APCI-MS: m/z 403, 405 [MH4]
Example 252 iV-(5-Chloro-2-{3-[3-(4-chloro-benzyl)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyI)- acetamide trifluoroacetic acid salt
i) 3-(4-Chloro-benzyI)-pyrrolidin-2-one In a flask was added diisopropylamine (3.22 g, 31.8 mmole) and dry THF (60 ml). The content of the flask was kept under nitrogen, and was then cooled to.-76°C. To the cool solution was dropwise added n-butyllithium (n-BuLi, 32 mmole, 20 ml, 1.6 M in hexane). After completed addition, the solution was stirred for 10 minutes, and a solution of 1- Trimethylsilanyl-pyrrolidin-2-one (5.00 g, 31.8 mmole, prepared according to literature methods) in dry THF (5 ml) was added dropwise. The solution was then stirred for an additional 20 minutes and a solution of 4-Chlorobenzyl chloride (5.13 g, 32 mmole) in THF (5 ml) was added via a syringe during 5 minutes. The resulting mixture was stirred at -76°C for 1 hour, and was then allowed to reach the ambient temperature and was stirred over night. Water (40 ml) was added and the mixture was stirred vigorously for 60 minutes. The phases were separated and the organic phase was washed with brine, and was finally evaporated, giving an oil which crystallized on standing. The solid was triturated with heptane:EtOAc 2:1 and was filtered, giving a partly purified solid. The solid was purified on silica (DCM to DCM : MeOH 99:1 to 98:2 to 97:3 gradient) giving 1.3g (20%) of the sub-title compound. 'H-NMR (400 MHz, CDC13) δ: 7.27 (2H, d, J8.4Hz); 7.16 (2H, d, J8.4Hz); 5.43 (IH", bs): 3.31-3.13 (3H, m); 2.74-2.61 (2H, m); 2.20 -2.12 (IH, m); 1.88-1.77 (IH, m)
ii) 3-(4-Chloro-benzyl)-pyrrolidine In a flask was dissolved the compound obtained in a) (0.20 g, 0.95 mmole), in dry THF (10 ml). LiAlH4 (0.17 g, 4.53 mmole) was added in small portions over 10 minutes. After completed addition, the mixture was heated to 60°C for approximately 3h under nitrogen, and the reaction was monitored by LC-MS, and was quenched after completed reaction. Before quenching, the reaction was allowed to reach the ambient temperature, and water (0.160 ml) was added cautiously drop by drop. NaOH (10%o solution in water, 0.16 ml) was added dropwise, and finally another portion of water (0.48 ml). The mixture was stirred for 1 hour and was then filtered. The filtrate was concentrated in vaccuo giving the sub-title compound (0.18 g, 97%) as a colorless oil.
APCI-MS: m z 196.1 [M+H]
iii) Ar-(5-Chloro-2-{3-[3-(4-chloro-benzyl)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide trifluoroacetic acid salt
The title compound was prepared according to the method described in Example 1 iii) from the compound obtained in ii).
'H-NMR (400 MHz, DMSO) δ: 9.93-9.62 (IH, m); 9.12 (IH, s); 8.11 (IH, s); 7.38 (2H, d, J8.9 Hz); 7.29-7.23 (2H, m); 7.13-7.02 (2H, m); 6.11-6.02 (IH, m); 4.29-4.16 (IH, bs); 4.05-3.95 (IH, m); 3.95-3.87 (IH, m); 3.75-3.50 (2H, m); 3.40-3.22 (3H, m); 2.91-2.65 (3H, m); 2.62-2.52 (IH, m); 2.13 (3H, s); 2.11-1.94 (IH, m); 1.81-1.55 (IH, m)
Example 253
N-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}-4-methylphenyl)-l- pyrrolidinecarboxamide trifluoroacetate i) 2- [(5-Methyl-2-nitrophenoxy) ethyl] oxirane
A mixture of 5-Methyl-2-nitrophenol (7.7g, 50mmol), potassium carbonate (13.8g, O.lmmol) and epibromohydrine (8.25mL, O.lmmol) was dissolved in DMF (lOOmL) and stirred 2-3 h at 100°C under an atmosphere of nitrogen. The mixture was diluted with ether (0.5L) and extracted with water until pH=7.
The organic phase was evaporated and the residue was purified by flash-chromatography on silica (DCM) to give the sub-title compound as a yellow solid (8.65g, 83%).
'H-NMR (400MHz, CDC13): δ 7.80 (d,lH); 6.91 (s,lH); 6.86 (d,lH); 4.39 (dd,lH); 4.15 (dd,lH); 3.43-3.37 (m, IH); 2.93 (dd,lH); 2.89 (dd,lH); 2.42 (s,3H)
ii) l-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-3-(5-methyl-2-nitrophenoxy)-2-propanol
A mixture of compound i) (1.05g, 5. Ommol) and 3-(4-chlorophenoxy)pyrrolidine (988mg, 5. Ommol) in ethanol (12mL) was refluxed for 2h. The solvent was evaporated to give the crude product as an orange oil, which was used without further purification.
APCI-MS : m/z 407, 409 [MH4]
iii) l-(2-Amino-5-methylphenoxy)-3-[3-(4-chlorophenoxy)-l-pyrrolidinyl]-2-propanol To a stirred solution of compound ii) (2.1 g, 5. Ommol) in ethanol (1 OmL) tin(II) chloride dihydrate (5.6g, 25mmol) in 35% hydrochloric acid (6mL) was added at 50°C. An exothermic reaction started and the temperature increased rapidly to 75°C. The mixture was maintained at 60°C for 0.5h. The cooled mixture was alkalized with IM sodium hydroxide (180mL) and extracted with ether, the organic phase washed with water, dried and evaporated to give the subtitle compound as a pale yellow oil (1.34g, 71%).
NMR: Due to a mixture of two diastereomeric pairs integration will result in parts of protons.
Η-NMR (400MHz, CDC13): δ 7.23 (d, 2H); 6.77 (d, 2H); 6.61-6.65 (m, IH); 6.64-6.63 (m, IH); 4.83-4.76 (m, IH); 4.14-4.06 (m, IH); 4.01 (d, 2H); 3.71 (bs, 2H);"3.41 (bs, IH); 3.10 (dd, 0.5H); 3.01-2.90 (m, 1.75H); 2.87-2.70 (m, 2.7H); 2.66-2.57 (m, 1.5H); 2.28 (h, IH); 2.25 (s, 3H); 2.06-1.95 (m, IH)
APCI-MS: 377, 379 [MH4]
iv) iV-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyI]-2-hydroxypropoxy}-4- methylphenyI)-l-pyrrolidinecarboxamide trifluoroacetate
A solution of compound (iii) (75mg, 0.2mmol) and di(tert-butyϊ) tri carbonate (53mg, 0.2mmol) in DCM (3mL) was stirred for lh at ambient temperature. Pyrrolidine (33μL, 0.4mmol) was added and the stirring continued for lh. The reaction was complete as determined by LCMS. TFA (lmL) was added and the solution was left for lh. The volatile parts were evaporated and the crude product purified by preparative RP-HPLC using acetonitrile and water containing 0.1% TFA as mobile phase. The appropriate fraction was concentrated in vacuo and the residue lyophilized to give the title compound as a white amorphous solid (85mg, 72%).
NMR: Due to a mixture of two diastereomeric pairs integration will result in parts of protons. Data are from the free base. 'H-NMR (400MHz, CDC13): δ 8.03 (dd, IH); 7.24 (d, 2H); 6.94 (bs, IH); 6.82-6.74 (m, 2H); 6.78 (d, 2H); 6.73-6.68 (m, IH); 4.85-4.76 (m, IH); 4.11-3.94 (m, 3H); 3.52-3.42 (m, 5.6H); 3.11 (dd, 0.5H); 3.05-2.92 (m, 0.45H); 2.95 (d, IH); 2.87-2.72 (m, 2.5H); 2.62-2.52 (m, 1.4H); 2.37-2.21 ( , 0.7H); 2.29 (s, 3H); 2.08-1.90(m, 4.6H)
APCI-MS: m/z 474, 476 [MH4]
Example 254
N-(2-{3-[3-(4-ChIorophenoxy)-l-pyrroIidinyl]-2-hydroxypropoxy}-4- hydroxyphenyl)acetamide trifluoroacetate To a stirred solution of the free base of compound Example 265 iii) following (128mg, 0.29mmol) in DCM (4mL) under N2 IM boron tribromide in DCM (0.58mL, 0.58mmol) was added at ambient temperature. The heterogeneous mixture was stirred overnight and poured into methanol. After evaporation the crude product was purified by RP-HPLC using acetonitrile and water containing 0.1% TFA as mobile phase. The appropriate fraction was lyophilized to give the title compound as a white amorphous solid (113mg, 73%).
APCI-MS: m/z 421, 423 [MH4]
Example 255
N-[2-({(2S)-3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]-2-hydroxypropyl}oxy)-4- fluorophenyl] acetamide trifluoroacetic acid salt
i) (2S)-2-[(5- Fluoro-2-nitrophenoxy)methyl] oxirane
In a flask was added (R)-glycidol (0.994 g, 13.4 mmole) and triphenylphosphine (3.52 g, 13.4 mmole) and THF (20 ml, dried over molecular sieves), and 5-fluoro-2-nitrophenol (2.10 g, 13.4 mmole). The mixture was stirred until a homogeneous solution was obtained. The solution was cooled in an ice bath and diethylazodicarboxylate (DEAD, 2.11 ml, 13.4 mmole) was added dropwise over a few minutes. After completed addition, the flask was allowed to reach room temperature and stirred for an additional 2 hours. The solvent was removed in vaccuo and to the residue was added chloroform (5-10 ml). The precipitate (PPh3O) was removed by filtration and the solid was washed with an additional amount of chloroform (5-10 ml). The filtrate was added to a flash column (SiO2, Heptane:Ethyl acetate 4:1), and purified to give 2.02 g (71%) of the sub-title compound as a crystalline material after concentration of pure fractions.
'H-NMR (400 MHz, CDC13) δ: 7.97 (IH, dd, J9.3, 6.0 Hz); 6.86 (IH, dd, J 10.0, 2.5 Hz); 6.80-6.74 (IH, m); 4.44 (IH, dd, J 11.4, 2.6 Hz); 4.12 (IH, dd, J 11.2, 5.1 Hz); 3.44-3.38 (IH, m); 2.95 (IH, t, J4.5 Hz); 2.90 (IH, dd, J4.8, 2.6) ii) (2S)-l-[4-(3,4-Dichlorophenoxy)-l-piperidinyl1-3-(5-fluoro-2-nitrophenoxy)-2- propanol
In a vial was added 4-(3,4-dichlorophenoxy)-piperidine (0.123 g, 0.5 mmole) and the compound obtained in i) (0.106 g, 0,5 mmole) and ethanol (99.5%, 3. ml). The vial was sealed and the content was heated with stirring at 65°C for 3 hours, and the reaction was monitored on LC-MS. The vial was allowed to cool and the solvent was evaporated, giving an oil, which was purified on silica (DCM to DCM:MeOH 99:1 to 98:2 to 97:3 as a stepwise gradient). Evaporation of pure fractions gave 0.22 g (96%) of the sub-title compound as an oil.
APCI-MS (m/z): 459.1 [M+H]
iii) iV-[2-({(2S)-3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]-2-hydroxypropyl}oxy)-4- fluorophenyl] acetamide trifluoroacetic acid salt
The compound obtained in ii) (0.22 g, 0.48 mmole) was dissolved in ethanol (99.5%, 7 ml) and heated with stirring to 60°C. A solution of SnCl2 x 2H2O (0.56 g , 5 equivalents) in concentrated hydrochloric acid (0.63 ml) was added and was stirred at 60°C for 1 hour. The mixture was then allowed to cool. The solution was alkalized by the addition of excess 2M NaOH, and the solution was extracted with diethyl ether (3 x 50 ml). The combined ethereal solutions were washed with brine an evaporated. The obtained oil was dissolved in THF (8 ml), and water (8 ml) was added, followed by the addition of acetic anhydride (50 Dl, 0.52 mmole). The mixture was stirred at 40°C for 15 minutes. The organic solvent was removed in vaccuo, and the residue was extracted with EtOAc (3 x 30 ml). The combined organic phases were washed with brine and were then concentrated in vaccuo. The residual oil was purified on preparative HPLC giving 55g (20%, 98% purity) of the title compound as the trifluoro acetate, and as a white solid after lyophilization of pure fractions.
APCI-MS (m/z): 471.0, 472.0, 473.0 and 474.0 [M+H] Example 256
N-(2-(3-(4-Chloro-phenoxy)-pyrrolidin-l-yl)-2-hydroxy-propoxy)-4,6-difluoro- phenyl)-acetamide hydrochloride
i) 3,5-Difluoro-6-nitrophenol
To a stirred solution of 2,3,4-trifluoronitrobenzene (5g, 28.23mmol) in dry methanol (70ml) was added a solution of sodium (0.68, 29.46) in dry methanol (30ml). The solution was stirred until all starting material was consumed (~2h). After concentration water was added and the solution was extracted with ether, dried over NajS ,, filtered and concentrated to a yellow residue (4.65g). To the solution of the yellow residue in dichloromethane (140ml) was added boron tribromide (IM in dichloromethane, 40ml) and stirred at room temperature overnight. Water was then added and the solution stirred for further 30 min. The organic phase was separated and the water phase was extracted with ether. The combined organic phase were dried over Na^O,,, filtered and concentrated in vacuo to give a brownish residue. The residue was taken up into ether and washed with 2M sodium hydroxide and water. The water and sodium hydroxide washings were combined and neutralized with 6M HCl and extracted with ether, dried over Na^O,, and evaporated to give a yellow residue which was purified by flash chromatography on silica gel with EtOAc:Heptan; 1 :2 as eluent to give the desired product 2g, 11.42mmol.
GC-MS: m/z 175(M+)
'HNMR (400MHz, CD3OD) δppm, 6.63-6.68(lH, m), 6.60-6.67(lH, dt)
ii) 2-[(3,5-Difluoro-2-nitrophenoxy)methyl]oxirane
To a mixture of 3,5-diflluoro-6-nitrophenol (lOOmg, 0.571mmol) and potassium carbonate (394mg) in DMF (5ml) was added epibromohydrin (80mg, 0.582mmol) and was stirred at 70°C for 3hr. Water and ethyl acetate were added, the organic phase separated, dried and concentrated. The resulting residue was purified by chromatography (ethyl acetate : heptan 1 :3) to give the desired product as a solid 161mg (0.696mmol). GC-MS: m/z 231 (M+)
iii) l-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-3-(3,5-difluoro-2-nitrophenoxy)-2- propanol
A solution of 3-(4-chlorophenoxy)pyrrolidine and 2-[(3,5-difluoro-2- nitrophenoxy)methyl]oxirane (50mg, 0.216mmol) in ethanol was refluxed for 3hrs. The solvent was distilled off under reduced pressure and the resulting residue purified by silica gel column chromatography (dichloromethane/methanol 20:1) to give 45mg (0.105mmol) of the title compound as solid.
iv) N-(2-(3-(4-Chloro-phenoxy)-pyrrolidin-l-yl)-2-hydroxy-propoxy)-4,6-difluoro- phenyl)-acetamide hydrochloride
Platinum oxide on carbon was added to a solution of l-[3-(4-chlorophenoxy)-l- pyrrolidinyl]-3-(3,5-difluoro-2-nitrophenoxy)-2-propanol (40mg, 0.0932mmol) in ethanol and the mixture was hydrogenated for 4hrs at latin. The mixture was filtered through Celite and washed several times with warm ethanol and the combined filtrate were concentrated in vacuo. To the resulting yellow residue was taken up in dichloromethane and acetic anhydride was added to the solution. The solution was stirred at room temperature for 2hrs then concentrated. Addition of 1.OM ethereal hydrogen chloride solution gave the title product as solid 20mg
APCI-MS: m/z 441 [MH4]
Example 257
Λ^-[2-({(2S)-3-[(2S,4S)-4-(4-Chlorophenoxy)-2-methylpyrroUdinyl]-2- hydroxypropyl}oxy)-4-fluorophenyl] acetamide trifluoroacetic acid salt
The title compound was prepared according to the procedure described in Example 260 following. 'H-NMR (400 MHz, OMSO-d6) δ: 9.89 (IH, bs); 9.05 (IH, s); 7.79 (IH, dd, J8.8, 6.6 Hz); 7.37 (2H, d, J9.6 Hz); 7.00-6.94 (3H, m); 6.75 (IH, dt, J8.6, 2.6 Hz); 6.00 (IH, bs); 5.17-5.10 (IH, m); 4.32-4.20 (IH, ); 4.05 (IH, dd, J 10.1, 4.6 Hz); 3.97 (IH, dd, J9.9, 5.7 Hz); 3.78-3.50 (3H, m); 3.47 (IH, t, J 11.6 Hz); 3.17 (IH, t, J 13.3 Hz); 2.83 (IH, p, J 6.9 Hz); 2.07 (3H, s); 1.90-1.80 (IH, m); 1.42 (3H, d, J6.4 Hz)
Example 258
N-[2-({(2S)-3-[(3R)-3-(4-Chlorobenzyl)pyrrohdinyl]-2- hydroxypropyl} oxy)phenyl]acetamide hydrochloride
Prepared by the method described in Example 251.
Example 259 N-{2-[(2R)- (3-{(3S)-3-[(4-Chlorophenyl)oxy]-l-pyrroUdinyl}-2-hydroxypropyl)oxy]- 4-fluorophenyl} acetamide
APCI-MS: m/z 423.1 [M+]
Example 260
N-[2-({(2S)-3-[(2R,4S)-4-(4-chlorophenoxy)-2-methylpyrrohdinyl]-2- hydroxypropyl}oxy) phenyl] acetamide trifluoroacetic acid salt
i) l-(fert-Butyl) 2-methyl (2S, 4R)-4-hydroxy-l,2-pyrrolidinedicarboxylate In a flask was dissolved (25',4i?)-4-Hydroxy-proline hydrochloride (5.4 g, 30 mmole) in a mixture of THF (200 ml), water (170 ml) and NaOH (30 ml, 2 M in water, 60 mmole). To this emulsion was added di-terf-butyldicarbonate (Boc2O, 6.54 g, 30 mmole), and the mixture was stirred vigorously for 1 hour. Ether (100 ml) was added and the phases were allowed to separate. The aqueous phase was extracted with an additional 100 ml of ether. The aqueous phase was discarded and the combined organic phases were washed with IM HCl (aq.) and potassium carbonate (saturated, aq.) and brine. The extract was dried with Na2SO4 and was concentrated in vaccuo to give a residue, which was purified on silica (Heptane:EtOAc 5:1 to 3:1 to 1 :1 stepwise gradient, spots visualized with L/MeOH). Evaporation of pure fractions were concentrated in vaccuo to give 4.2 g (57%) of the sub- title compound as a colorless oil.
'H-NMR (400 MHz, CDC13) δ: 4.50 (IH, bs); 4.45-4.35 (IH, m); 3.74 (3H, s); 3.64 (IH, dd, J 11.7, 4.3 Hz); 3.59-3.42 (IH, m); 2.35-2.20 (IH, m); 2.14-2.03 (IH, m); 1.97 (IH, dd, J23.3, 3.7 Hz); 1.44 (9H, d, J 18.9 Hz)
ii) l-(fe -Butyl) 2-methyl (2S, 45)-4-(4-chlorophenoxy)-l,2 pyrrolidinedicarboxylate
In a flask was dissolved the compound obtained in i) (2.54 g, 10.3 mmole), triphenylphosphine (2.71 g, 10.3 mmole) and 4-Chlorophenol (1.33 g, 10.3 mmole) in THF (50 ml, dried over molecular sieves) under magnetic stirring. The flask was cooled in an ice bath and, to this stirred solution was added diethylazodicarboxylate (DEAD, 1.8 g, 10.3 mmole) dropwise under a few minutes. The reaction was allowed to stand over night, allowing the ice to melt and the reaction to reach room temperature. The solvents were evaporated and the residue was treated with ether (30 ml), allowing the phosphine oxide to precipitate. The solid was removed by filtration and the filtrate concentrated in vaccuo. The residue was purified on silica (Heptane:EtOAc 8:1 to 6:1 to 3:1, stepwise gradient. Spots on TLC were visualized by Seebach's reagent). Concentration of pure fractions gave 2.51 g (68%o) of the sub-title compound as a colorless viscous oil.
'H-NMR (400 MHz, CDC13) δ: 7.26-7.20 (2H, m); 6.77-6.70 (2H, m); 4.86 (IH. bs); 4.55 (72 H, dd, J8.6, 2.6 Hz); 4.43 (V2 H, dd, J7.6, 3.9 Hz); 3.84-3.60 (5H, m); 2.53-2.36 (2H, m); 1.47 (9H, d, J 18.2 Hz)
iii) te -Butyl (2S,4S)-4-(4-chlorophenoxy)-2-(hydroxymethyl)-l- pyrroϋdinecarboxylate In a flask was dissolved the compound obtained in ii) (0.951 g, 2.67 mmole) in THF (10 ml, dried over sieves). The solution was cooled in an ice bath and LiBH4 (0.09 g, 4.07 mmole) was added. The mixture was stirred over night, allowing the ice to cool, and the solution to reach room temperature. The crude mixture was then partitioned between EtOAc (100 ml) and water (100 ml). The aqueous phase was discarded and the organic solution was washed with 0.5M HCl (aq.), NaHCO3 (sat, aq) and brine. The solution was evaporated to give an oil which seem to be contaminated with inorganic salts. Dissolution in DCM and filtration through Celite® afforded 0.82 g (94%) of the sub-title compound as a colorless oil.
'H-NMR (400 MHz, DMSO-d6) δ: 7.33 (2H, d, J9.5 Hz); 6.95 (2H, d, J9.5); 4.96 (IH, bs); 4.71 (IH, bs); 3.84-3.55 (3H, m); 3.32 (2H, bs); 2.29-2.07 (2H, m); 1.41 (9H, s)
iv) ter-'-Butyl (2S,4S)-4-(4-chlorophenoxy)-2-{[(methylsulfonyl)oxy]methyl}-l- pyrrolidine carboxylate
In a flask was dissolved the compound obtained in iii) (0.82 g, 2.5 mmole) in dichloromethane (10 ml, dried over molecular sieves). The flask was cooled on ice, and triethylamine (0.69 ml, 5.0 mmole) was added from a syringe. Methanesulfonylchloride (0.30 ml, 3.86 mmole) was added dropwise over a few minutes, and the obtained mixture was stirred over night, allowing the ice to melt. To the mixture was added DCM (60 ml), and the solution was washed with IM HCl (aq), NaHCO3 (sat, aq), and brine. The solution was evaporated giving 0.876 g (86%) of the sub-title compound as a yellow oil, which was used in the next step without any further purification.
'H-NMR (400 MHz, OMSO-d6) δ: 7.35 (2H, d, J9.4 Hz); 6.99 (2H, d, J9.4 Hz); 5.07- 5.01 (IH, m); 4.37 (IH, dd, J8.9, 4.2 Hz); 4.20-4.05 (2H, m); 3.71 (IH, dd, J 11.8, 5.0 Hz); 3.32 (2H, s); 3.15 (3H, s); 2.07 (IH, d, J 14.4 Hz); 1.41 (9H, s)
v) tgrf-Butyl (2R,4i-»)-4-(4-chlorophenoxy)-2-methyl-l-pyrrolidinecarboxylate In a flask was dissolved the compound obtained in iv) (0.876 g, 2.16 mmole) in THF ( 10 ml, dried over molecular sieves). The reaction mixture was kept under an inert atmosphere and was then cooled in an ice bath. LiB(Et)3H (IM Lithium triethylborohydride in THF, 9 ml, 9 mmole) was added with a syringe over 15 minutes. The ice bath was removed and the mixture was stirred over night. The crude mixture was partitioned between EtOAc (100 ml) and water (100 ml). The aqueous phase was removed, and the organic phase was washed with IM HCl (aq.), NaHCO3 (sat, aq), and brine. The solution was evaporated and the residue was purified on silica (Heptane:EtOAc 10:1 to 5:1 to 4:1 to 2:1 gradient. TLC spots were visualized by Seebach's reagent), giving 0.401 g (60%) of the sub-title compound as a colorless oil.
'H-NMR (400 MHz, DMSO-c δ: 7.33 (2H, d, J8.7 Hz); 6.96 (2H, d, J8.7 Hz); 5.00- 4.94 (IH, m); 3.89 (IH, bs); 3.64 (IH, dd, J 12.5, 5.2 Hz); 3.38 (IH, d, J 12.2 Hz); 2.41- 2.28 (IH, m); 1.79 (IH, d, J 13.7 Hz); 1.40 (9H, s); 1.23 (3H, d, J6.6 Hz)
vi) (2R,4S)-4-(4-Chlorophenoxy)-2-methylpyrrolidine trifluoroacetic acid salt
In a flask was dissolved the compound obtained in v) (0.390 g, 1.25 mmole) in dichloromethane (DCM, 15 ml). To this solution was added TFA (trifluoroacetic acid, 6 ml) and the mixture was allowed to stand for 3 hours, after which the volatiles were removed in vaccuo. The residue was co-evaporated twice with DCM, giving the sub-title compound as an oil.
APCI-MS (m/z): 212 [M+H]
vii) iV-[2-({(2S)-3- (2R,4S)-4-(4-Chlorophenoxy)-2-methylpyrroIidinyl]-2- hydroxypropyl}oxy) phenyl] acetamide trifluoroacetic acid salt
The title compound was prepared according to the method outlined in Example 255 starting from the material obtained in vi) and (2S)-2-[(2-nitrophenoxy)methyl]oxirane. The compound was obtained in 25% yield. Η-NMR (400 MHz, DMSO-cfø) δ: 9.88 (IH, bs); 9.02 (IH, s); 7.89 (IH, d. J7.7 Hz): 7.37 (2H, d, J7.7 Hz); 7.09-6.88 (5H, m); 6.02 (IH, bs); 5.18-5.11 (IH, m); 4.34-4.22 (IH, m); 4.02 (IH, dd, J 10.2, 4.3 Hz); 3.94 (IH, dd, J9.8, 5.7 Hz); 3.77-3.30 (4H, m); 3.19 (IH, t, J 10.7 Hz); 2.84 (IH, p, J6.7 Hz); 2.09 (3H, s); 1.91-1.81 (IH, m); 1.43 (3H, d, J6.4 Hz)
APCI-MS (m/z): 419.2 [M+H]
Example 261
N-{2-[(2S)-(3-{(3R)-3-[(4-ChlorophenyI)oxy]-l-pyrrolidinyl}-2-hydroxypropyl)oxy]-4- fluorophenyl} acetamide
APCI-MS: m/z 423.1 [M+]
Example 262 iV-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}-4-methylphenyl)- AyV-dimethylurea trifluoroacetate
The title compound was prepared by analogy to the methods described in Example 253 starting from compound iii) (75mg, 0.2mmol) and dimethylamine (2M in THF, 200μL, 0.4mmol). The substance was obtained as a white amorphous solid (73mg, 65%).
'H-NMR (400MHz, UeOU-d4): δ 7.54 (dd, IH); 7.51 (d, 2H); 7.16 and 7.15 (d, 2H); 7.05 (bs, IH); 6.96 (bd, IH); 5.40-5.35 (m, IH); 4.54-4.46 (m, IH); 4.27 (d, 2H); 4.16-3.56 (m, 6H); 3.20 (bs, 6H); 2.84-2.59 (m, IH); 2.59-2.44 (m, IH); 2.50 (s,3H).
APCI-MS : m/z 448, 450 [MH4]
Example 263 N-(2-{3-[3-(4-Chloroanilino)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)acetamide i) fert-Butyl-3-hydroxy-l-pyrrolidinecarboxylate
To a solution of 3 -hydroxy- 1-pyrrolidine (871 mg, 10 mmol) in THF (30 mL) was added di-(tert.butyl) dicarbonate (2.18 g, 10 mmol) in THF (2 mL) and the reaction mixture kept on stirring at room temperature for overnight. The solvent was removed in vacuo and the residue was purified by flash chromatography (0-2% MeOH in CHC13) to give the subtitled compound (1.7g).
'H-NMR (CDC13, 400 MHz): δ 4.45 (m, IH); 3.55-3.25 (m, 4H); 2.18-1.85 (m, 3H); 1.45 (s, 9H). APCI-MS: m/z 166 (M-Boc).
ii) fert-Butyl-2-oxo-l-pyrrolidinecarboxylate
Chromium (vi) oxide (800 mg, 8.0 mmol) was added to pyridine (1.6 L) in CH2C12 (10 mL) and the resulting solution was stirred for 15 min at room temperature. A solution of tert.butyl-3-hydroxy-l-pyrrolidinecarboxylate (374.5 mg, 2.0 mmol) in CH2C12 (5 mL) was added, immediately followed by acetic anhydride and the reaction mixture kept at room temperature for 15 min. After addition of ethyl acetate, decanted and filtered through a short column of silica gel. The filtrate was concentrated to give the subtitled product (193 mg) and was used directly in the next step.
iii) fert-Butyl-3-(4-chIoroaniHno)-l-pyrrolidinecarboxylate
Tert.butyl-2-oxo-l-pyrrolidinecarboxylate (190 mg, 1.02 mmol), 4-chloroaniline (64 mg, 0.5 mmol) and acetic acid (184 mg) were mixed in dichloroethane (5 mL). Sodium triacetoxyborohydride (326.5 mg) was added and the reaction mixture kept on stirring at room temperature for overnight. After addition of aq. NaHCO3 the reaction mixture was diluted by addition of ethyl acetate. Two layers were separated. The organic layer was dried over NajSO^ filtered, concentrated. The residue was purified by flash chromatography (0-15% ethyl acetate in petroleum spirit , 40-60) to give the subtitled product (140 mg). 'H-NMR (CDClj, 400 MHz): δ 7.18 (m, 2H); 6.50 (m, 2H); 3.99 (m, IH); 3.70 (m, 2H); 3.46 ( , 2H); 3.20 ( , IH); 2.18 (m, IH); 1.87 (m, IH); 1.45 (s, 9H). APCI-MS: m/z 197 (M-Boc).
iv) N-(4-Chlorophenyl)-3-pyrroUdmamine (2xCF;,COOH)
To a solution of tert.butyl-3-(4-chloroanilino)-l-pyrrolidinecarboxylate (130 mg, 0.438 mmol) in CH2C12 (5 mL) was added CF3COOH (1 mL). After 30 min the volatiles were removed in vacuo to give the subtitled product (186 mg) and was used directly in the next step.
v) N-(2-{3-[3-(4-ChIoroanilino)-l-pyrrolidmyl]-2-hydroxypropoxy}phenyl)acetamide
A mixture ofN-(4-chlorophenyl)-3-ρyrrolidinamine (2xCF3COOH), (186 mg, 0.438 mmol), N-[2-(2-oxiranylmethoxy)phenyl]acetamide (91 mg, 0.438 mmol) and K2CO3 (200 mg) in ethanol (6 mL) was kept on stirring at 65 °C for 2.5 h. The volatiles were removed in vacuo. The residue was partitioned between ethyl acetate and aq. NH4C1 solution. The organic layer was washed with water, dried over Na^ ,, filtered and concentrated. The residue was purified by flash chromatography (0-3 %> MeOH in CHC13) to give the titled product (70 mg).
'H-NMR (CDClj, 400 MHz): δ 8.35 (m, IH); 8.21 (br.s, IH); 7.12 (m, 2H); 7.01 (m, 2H); 6.92 (m, IH); 6.48 (m, 2H); 4.13-3.92 (m, 4H); 3.84 (br. s, IH); 2.99 (m, IH); 2.87-2.30 (m, 6H); 2.18 (s, 3H); 1.66 (m, IH).
APCI-MS: m/z 446 (MH+).
Example 264
N-{2- (3-{3- (4-Chlorophenyl)oxy]-l-pyrroMdinyl}-2-hydroxy-l- methy lpropyl)oxy] phenyl} acetamide hydrochloride
i) iV-{2-[(l-Methyl-2-propenyl)oxy]phenyI}acetamide The compound (557 mg, 40%) was prepared from 3-chloro-l-butene (747 ml, 7.42 mmol) and 2-acetamidophenol (1.02 g, 6.75 mmol) analogously to that described in Example 8 i). H-NMR (400 MHz, CDC13): δ 8.37 (m, IH), 7.80 (bs, IH), 6.94 (m, 3H). 5.93 (m, IH), 5.25 (m, 2H), 4.84 (m, IH), 2.21 (s, 3H), 1.49 (d, J6.3 Hz, 3H).
ii) iV-{2-[l-(2-Oxiranyl)ethoxylphenyI}acetamide
The compound was prepared from N-{2-[(l-Methyl-2-propenyl)oxy]phenyl} acetamide (549 mg, 2.67 mmol) and m-chloroperbenzoic acid (80 %, 923 mg, 4.28 mmol) analogously to that described in Example 8 (ii). Purification was done on silica gel with petroleum ether/ethyl acetate 10/15 as eluent. This gave separation of the two diastereomeric pairs.
Diastereomer 1: (53 mg, 9%), Rf =0.27
Diastereomer 2: (406 mg, 69 %), Rf =0.20 H-NMR (400 MHz, CDC13): δ 8.39 (m, IH), 8.01 (bs, IH), 7.00 (m, 3H), 3.98 (m, IH),
3.24 (m, IH), 2.94 (t, J4.5 Hz, IH), 2.71 (dd, J2.6 Hz, J4.5 Hz, 1 H), 2.23 (s, 3H), 1.47 (d, J6.3 Hz, 3 H).
ui) iV-{2-[(3-{3-[(4-Chlorophenyl)oxy]-l-pyrrolidinyl}-2-hydroxy-l- methylpropyl)oxy] phenyl} acetamide hydrochloride
The title compound (230 mg, 100 %>) was prepared from N-[2-(l- oxiranylethoxy)phenyl] acetamide diasteromer 2 (123 mg, 0.557 mmol) and 3-(4- chlorophenoxy)pyrrolidine (100 mg, 0.506 mmol) analogously to that described in Example 1 (iii). H-NMR (400 MHz, MeOD): δ 7.86 (m, IH), 7.30 (m, 2H), 7.09 (m, 2H), 6.97 (m, 3H), 5,21 (m, IH), 4,51 (m, IH), 3.83-4.22 (m, 3H), 3.37-3.62 (m, 4H), 2.68 (m, Vi H), 2.38 ( , IH), 2.27 (m, lΛ H), 2.19 (m, 3H), 1.32 (m, 3H). MS-APCI+: m/z 419 [MH÷]
Example 265
N-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}-4- methoxyphenyl)acetamide hydrochloride
i) l-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-3-(5-methoxy-2-nitrophenoxy)-2-propanol
The subtitle compound was prepared in analogy of Example 253 ii) from 2-[(5-methoxy-2-nitrophenoxy)methyl]oxirane (320mg, l.όmmol) and 3-(4-chlorophenoxy)pyrrolidine (365mg, l.όmmol). The crude product was obtained as a yellow oil (580mg) and was used without further purification.
APCI-MS: m/z 423, 425 [MH4]
ϋ) l-(2-Amino-5-methoxyphenoxy)-3-[3-(4-chlorophenoxy)-l-pyrrolidinyl]-2- propanol
The subtitle compound was prepared in analogy of Example 253 iii) from compound i) (290mg, 0.7mmol). The crude compound was obtained as a colourless oil
(233mg, 85%) and was used without further purification.
APCI-MS: m/z 393, 395 [MH4"]
iii) iV-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}-4- methoxyphenyl)acetamide hydrochloride To a solution of compound (ii) (157mg, 0.4mmol) in pyridine (3mL) acetic anhydride (lmL) was added. The mixture was stirred for lh at ambient temperature. After evaporation the residue was dissolved in methanol (mL) and 1.5M sodium methoxide in methanol (lmL) was added. The mixture was left overnight at ambient temperature. After evaporation the residue was taken up in ether and water. The free base of the title compound was obtained from the organic phase as a colourless oil (171mg, 98%). The free base (43mg) was dissolved in methanol (5mL), acidified with IM hydrochloric acid till pH<2, diluted with water (50mL) and lyophilized. The title compound was obtained as a white amorphous solid (30mg, 64%).
APCI-MS: m/z 435, 437 [MH4]
Example 266
N-(2-[3-(4-Chloro-benzyloxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy)-phenyl)-acetamide trifluoroacetic acid salt.
i) 3-(4-Chloro-benzyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester
A solution of tert-butyl 3-hydroxy-l-pyrrolidinecarboxylic acid (0.27 g, 1.44 mmol) in dry THF (4 mL) was added dropwise to a cold (0° C), stirred suspension of sodium hydride (0.078 g, 2.17 mmol, ca. 50% suspension in oil) in THF (10 mL). After 30 min. a solution of 4-chlororbenzyl bromide (0.36 g, 1.74 mmol) in THF (2 mL) was added and the resulting suspension was stirred at R.T. overnight. The reaction mixture was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate and the combined organic phase was washed with saturated aqueous sodium chloride, dried and concentrated. The residue was subjected to flash chromatography (heptane-ethyl acetate, 6:1) to afford the subtitle compound 3-(4-Chloro-benzyloxy)-pyrrolidine-l -carboxyhc acid tert-butyl ester as an oil (0.30 g, 66.8%).
'H-NMR (CDC13): δ 7.30 (m, 4H), 4.49 (bs, 2H), 4.11 (m, IH), 3.45 (m, 4H), 1.90-2.08 (m, 2H), 1.46 (s, 9H).
ii) 3-(4-Chloro-benzyloxy)-pyrrolidine
A solution of 3-(4-Chloro-benzyloxy)-pyrrolidine-l -carboxyhc acid tert-butyl ester (0.28 g, 0.9 mmol) in aqueous 90% formic acid (7.5 mL) was stirred at (0° C) for 30 min. then at room temperature overnight. The solvents were removed under reduced pressure and the residue was treated with saturated aqueous potassium carbonate and extracted twice with n- butanol. The combined organic extracts was concentrated and the residue was purified by flash chromatography (SiO2 , dichloromethane-methanol-ammonium hydroxide, 8:8:1 then 50:10:1) to afford the subtitle compound 3-(4-Chloro-benzyloxy)-pyrrolidine (0.13 g, 70%).
'H-NMR (DMSO-d6): δ 7.32-7.41 (m, 4H), 4.42 (s, 2H), 4.02 (m, IH), 3.18 (bs, 3H), 2.75- 2.86 (m, 3H), 2.68 (m, IH), 1.66-1.81 (m, 2H).
APCI-MS: m/z 212 [MH4].
iii) N-(2-[3-(4-Chloro-benzyloxy)-pyrrolidin-l-yI]-2-hydroxy-propoxy)-phenyl)- acetamide trifluoroacetic acid salt
A solution of 3-(4-chloro-benzyloxy)-pyrrolidine (0.050 g, 0.24 mmol) andN-(2- oxiranylmethoxy-phenyl)-acetamide (0.049 g, 0.24 mmol) in absolute ethanol (3 mL) was heated in a closed vial at 70° C for 2h. The product was purified by HPLC to afford the title compound (0.60 g, 47%).
'H-NMR (CD3OD): δ 7.85 (m, IH), 7.35 (m, 4H), 7.12 (m, IH), 7.02 (d, IH, J= 8 Hz), 6.96 (m, IH), 4.56 (m, 2H), 4.39 (m, 2H), 4.05 (d, 2H, J = 5.9 Hz), 3.85 (m, 2h), 3.48 (m, 4H), 2.10-2.55 (m, 5H).
APCI-MS: m/z 419 [MH4] and 421 [MH+24].
Example 267 N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-2-methyl-propoxy}- phenyl)-acetamide
The compound was prepared by a method analogous to that of Example 270 following.
APCI-MS : m z 419 [MH4"] Example 268
N-(2-{(lS,2i?,3S)i-3-[(3S)-5-(3,4-Difluoro-phenoxy)-pyrroHdin-l-yI]-2-hydroxy- cyclopentyloxy}-5-chloro-phenyl)-acetamide (diastereomeric mixture)
Was prepared by analogy to Example 271 following from N-{5-chloro-2-[(li?,2>S,5i?)*-6- oxabicyclo[3.1.0]hex-2-yloxy]phenyl}acetamide (5.3 mg, 20 μmol) and (3S)-3-(3,4- difluoro-phenoxy)-pyrrolidine (4.0 mg, 20 μmol).
MS-APCI+ : m/z 467 [M+].
Example 269
N-[2-({(2R,3S)*-3-[(3S)-3-(4-Chlorophenoxy)pyrroUdinyl]-2-hydroxybutyl}oxy)-4- methylphenyl] acetamide (diastereomeric mixture)
Was prepared analogies to Example 271 following from N-(4-methyI-2-{[(2-S',3i?)*-3- methyloxiranyl]methoxy}phenyl)acetamide (4.7 mg, 20 μmol) and (3.S)-3-(4-Chloro- phenoxy)-pyrrolidine (4.0 mg, 20 μmol).
MS-APCI+ : m/z 433 [M+].
Example 270
N-{2-[(3-{4-[(3,4-Dichlorophenyl)oxy]-l-piperidinyl}-2-hydroxy-2-methylpropyl)oxy]- 4-fluorophenyl} acetamide hydrochloride
i) N- [4-Fluoro-2-(2-methy l-allyloxy)-phenyl] -acetamide
3-Chloro-2-methylpropene (1.36g, 15 mmol) was added to a mixture of 5-fluoro-2-nitro- phenol (1.57 g, 10 mmol), potassium carbonate (2.76 g, 20 mmol), tetrabutylammonium hydrogen sulfate (0.068 g, 0.2 mmol) and acetonitrile (30 ml), and the mixture was heated under reflux for 18 h. The cold reaction mixture was diluted with toluene and washed with 5 % aqueous potassium carbonate, dried and evaporated. A part of the residue (0.631 g, 3 mmol), sodium dithionite (1.04 g, 6 mmol) in EtOH-THF-H2O (2: 1 : 1, 3 ml) was heated at 75 °C for 4 h. The mixture was portioned between dichloromethane and 15 % aqueous potassium carbonate and the organic solution dried and concentrated. The obtained residue was diluted with methanol (1.5 ml) and reacted with acetic anhydride (1.5 ml) at 50 °C for 2 min and allowed to attend room temperature during 20 min, then pyridine (4 ml) was added and the solution heated again at 50 °C for 3 min, cold and concentrated. The material was purified by silica gel chromatography (light petroleum-ethyl acetate 2:1) to give 95 mg of the subtitle compound.
Η-NMR (300MHz, CDC13): δ 8.28 (dd, IH,), 7.62 (bs, IH), 6.70-6.60 (m, 2H), 5.07 (dd, 2H), 4.49 (s, 2H), 2.20 (s, 3H), 1.84 (s, 3H).
ii) N-(4-Fluoro-2-{ [(2-methyl-2-oxiranyl) methyl] oxy} phenyl)acetamide The subtitle compound was prepared from N-[4-fluoro-2-(2-methyl-allyloxy)-phenyl]- acetamide analogously as described in Example 8 ii).
'H-NMR (300MHz, CDC13): δ 8.31-8.26 (dd, IH,), 7.79 (bs, IH), 6.75-6.65 (m, 2H), 4.14 (d, IH), 3.97 (d, IH), 2.93 (d, IH), 2.80 (d, IH), 2.21 (s, 3H), 1.50 (s, 3H).
APCI-MS: m z 240 [MH4"]
iii) N-{2-[(3-{4-r(3,4-Dichlorophenyl)oxy]-l-piperidinyl}-2-hydroxy-2- methylpropyl)oxy]-4-fluorophenyl} acetamide hydrochloride A solution of 4-(3,4-dichloro-phenoxy)-piperidine (36 mg, 0.146 mmol), N-(4-fluoro-2- {[(2-methyl-2-oxiranyl)methyl]oxy}phenyl)acetamide (35 g, 0.146 mmol) in EtOH (1 ml, 95 %) was stirred for 2.5 hours at 77 °C in a sealed vial. The solvent was evaporated and the residue was purified on silica (dichloromethane-methanol, 15:1, containing 1% of NH4OH (25%) to give 45 mg of the corresponding free amine of the title compound. Η-NMR of the corresponding free amine of the title compound. (400MHz, CDC13): δ 8.26-8.22 (dd, IH), 7.89 (bs, IH), 7.31 (d, IH), 7.01 (d, IH), 6.77- 6.65 (m, 3H), 4.30 (m, IH), 3.80 (dd, 2H), 2.93-2.81 (m, 2H), 2.67 (d, IH), 2.63-2.51 (m, 2H), 2.45 (d, IH), 2.19 (s, 3H), 1.96 (m, 2H), 1.83 (m, 2H), 1.62 (bs, IH), 1.31 (s, 3H).
iv) N-{2-[(3-{4-f(3,4-Dichlorophenyl)oxy]-l-piperidinyl}-2-hydroxy-2- methylpropyl)oxy]-4-fluorophenyl}acetamide hydrochloride
A solution of the free amine in methanol (10 ml) was acidified with HCl (cone, 0.020 ml) to pH 3 and concentrated. The residue was coevaporated three times with toluene to give the title hydrochloride compound as a white powder.
APCI-MS: m/z 485, 487 [MH+]
Example 271 N-(2-{(lS,2R,35)*-3-[(3S)-3-(4-Chloro-phenoxy)-pyrroUdin-l-yl]-2-hydroxy- cyclopentyloxy}-4-fluoro-phenyl)-acetamide (diastereomeric mixture )
N-{4-fluoro-2-[(li?,2-S',5i?)*-6-oxabicyclo[3.1.0]hex-2-yloxy]phenyl}acetamide (5.0 mg, 20 μmol) and (35)-3-(4-Chloro-phenoxy)-pyrrolidine (3.9 mg, 20 μmol) were dissolved in a 2M solution of LiClO4 in acetonitrile (0.2 ml) and heated in a sealed tube to 100°C. Dilution by ethyl acetate, neutral aqueous workup and evaporation of the solvent gave a crude product which was used without further purification.
MS-APCI+ : m/z 449 [M+].
Example 272
N-(5-ChIoro-2-{3-[3-(3,4-difluoro-phenoxy)-pyrrolidin-l-yI]-2-hydroxy-propoxy}- phenyl)-acetamide
APCI-MS : m z 441.1 [MW] Example 273
N-(5-Chloro-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide
APCI-MS: m/z 423.1 [MET]
Example 274
/V-(4-Cyano-2-{3-[4-(3,4-dichloroanilino)-l-piperidinyl]-2- hydroxypropoxy} phenyl)acetamide
APCI-MS: m/z 477[MH+]
Example 275 N-(4-Hydroxy-2-{(lS,2R,3S)*-3-[(3S)-3-(4-chloro-phenoxy)-pyrroUdin-l-yl]-2- hydroxy-cyclopentyloxy}-phenyl)-acetamide (diastereomeric mixture)
i) N-{4-methoxy-2-[(lR,2S,5R)*-6-oxabicyclo[3.1.0]hex-2-yloxy]phenyl}acetamide (32 mg, 122 μmol) and (3iS)-3-(4-Chloro-phenoxy)-pyrrolidine (24 mg, 122 μmol) were dissolved in a 2M solution of LiClO4 in acetonitrile (1 ml) and heated in a sealed tube to 100°C. Dilution by ethylacetate, neutral aqueous workup and evaporation of the solvents gave 62 mg (110%) of the crude addition product which was reacted with bortribromide (IM in CH2C12, 0.37 mL, 371 μmol) in dichloromethane (1 mL) at room temperature over night. The reaction was quenched with methanol (1.0 mL) and all volatile components were evaporated. The remaining crude was subjected to a reversed phase HPLC giving 30 mg (54 %) of the title compound as a diastereomeric mixture.
MS-APCI+ : m/z 447.1 [MH+].
ii) Separation of the diastereomers The above under i) described diastereomeric mixture was subjected to chiral phase HPLC (stationary phase: Chiralpak AD; mobile phase: iso- exane/iso- propanol/methanol/diethylamine = 80:16:4:0.1) with the compound of Example 276 as the first and the compound of Example 277 as the second eluted stereoisomer. The assignment of the absolute configuration of the respective stereoisomer beneath is set by will and exchangeable.
Example 276 N-(4-Hydroxy-2-{(lS,2R,3S)-3-[(3S)-3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy- cyclopentyloxy } -phenyl)-acetamide
'H-NMR (400MHz, CDC13; OH-protons are neglected): δ 8.02 (IH, s), 7.49 (IH, d, J 8.4Hz), 7.17 (2H, d, J 8.9Hz), 6.71 (2H, d, J 8.8Hz), 6.43 (IH, s), 6.34 (IH, d, J 7.2Hz), 4.76 (IH, m), 4.39 (IH, m), 4.09 (IH, m), 3.10-2.95 (3H, m), 2.89 (IH, m), 2.77 (IH, m), 2.24 (IH, m), 2.08 (3H, s), 2.10-1.84 (3H, m), 1.75 (IH, m), 1.59 (IH, m). MS-APCI+ : m/z 447.1 [MH+]. [α]22 = + 49.5 (CH2C2).
Example 277
N-(4-Hydroxy-2-{(lR,2S,3R)-3-[(5S)-3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2- hydroxy-cyclopentyloxy}-phenyl)-acetamide
'H-NMR (400MHz, CDC13; OH-protons are neglected): δ 7.75 (IH, s), 7.60 (IH, d, J 8.4Hz), 7.19 (2H, d, J 8.3Hz), 6.73 (2H, d, J 8.6Hz), 6.57 (IH, s), 6.38 (IH, d, J 8.4Hz), 4.77(1H, m), 4.43 (IH, m), 4.21 (IH, m), 3.09-2.94 (3H, m), 2.79 (IH, m), 2.68 (IH, m), 2.28 (IH, m), 2.08 (3H, s), 2.05-1.90 (3H, m), 1.86 (IH, m), 1.53 (IH, m). MS-APCI+ : m/z 447.1 [MH+]. [α]22 = - 45.2 (CH2C2). The diastereomers of Examples 278 and 279 were prepared by methods analogous to those used to prepare the compounds of Examples 221-230 and separated as described in Example 275 above. The absolute configuration of the respective isomers is assigned by will as mentioned above and therefore exchangeable.
Example 278
N-[2-({(lS,2R,3S)-3-[(3S)-3-(4-Chlorophenoxy)pyrroUdinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide
First eluted isomer.
MS-APCI+ : m z 431.1 [MH+]. [α]22 = + 72.2 (CH2C2).
Example 279
N-[2-({(lR,2S,3R)-3-[(3S)-3-(4-Chlorophenoxy)pyrrohdinyl]-2- hydroxycyclopentyl}oxy)phenyI]acetamide
Second eluted isomer.
MS-APCI+ : m/z 431.1 [MH+]. [ ]22 = - 51.4 (CH2C2).
The diastereomers of Examples 280 and 249 were prepared by methods analogous to those used to prepare the compounds of Examples 221-230 and separated as described in
Example 275 above. The compound of Example 280 is the first eluted isomer whilst the compound of Example 249 is the second eluted isomer. The absolute configuration of the respective isomers is assigned by will as mentioned above and therefore exchangeable.
Example 280 N-[5-Chloro-2-({(lS,2R,3S)-3-[(3S)-3-(4-chlorophenoxy)pyrrolidinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide
MS-APCI+ : m/z 464.9 [MH+]. [ ]22 = + 53.0 (CH2C2).
Example 281
N-{5-ChIoro-2-[((lS,2R,3S)*-3-{[l-(4-chlorobenzyl)-4-piperidinylIamino}-2- hydroxycyclopentyl)oxy]phenyl} acetamide(racemic mixture)
Was prepared by analogy to Example 271 from N-{5-chloro-2-[(li?,25,5i?):t:-6- oxabicyclo[3.1.0]hex-2-yloxy]phenyl} acetamide (5.3 mg, 20 μmol) and l-(4- chlorobenzyl)-4-piperidinamine (4.5 mg, 20 μmol).
MS-APCI+ : m/z 492 [M+].
Example 282
N-[2-({(2S)-3-[(3»S)-3-(4-ChIorophenoxy)pyrrolidinyl]-2-hydroxypropyl}oxy)-4- hydroxyphenyl] acetamide
i) (2S)-2-[(5-Methoxy-2-nitrophenoxy)methyI]oxirane
The subtitle compound was prepared under Mitsunobu conditions from R-(+)-glycidole (198mg, Immol), 5-methoxy-2-nitrophenol (169mg, Immol), triphenylphosphine (263mg, Immol) and DEAD (157μL, Immol) using dry THF as solvent. The crude material was purified by flashchromatography on silica using mixtures of ethylacetate and heptane as mobile phase. The appropriate fractions were pooled to give impure product as white crystals (175mg). The product was contaminated with reduced DEAD in molar ratio 1:1, which is equal to a yield of the desired product of lOOmg, 44%.
'H-NMR (400MHz, CDC13): δ 8.00 (d, IH); 6.60 (d, IH); 6.55 (dd, IH); 6.4 (bs, IH, redDEAD); 4.41 (dd, IH); 4.22 (q, 4H, red.DEAD); 4.13 (dd, IH); 3.89 (s, 3H); 3.44-3.39 (m, IH); 2.95 (dd, IH); 2.92 (dd, IH); 1.29 (t, 6H, redDEAD)
APCI-MS: m z 226 [MH^]
ii) (2S)-l-[(3S)-3-(4-Chlorophenoxy)pyrrolidinyl]-3-(5-methoxy-2-nitrophenoxy)-2- propanol
The subtitle compound was prepared by analogy to Example l(ii) from (i) (169mg, 0.43mg) and (35)-3-(4-chlorophenoxy)pyrrolidine (85mg, 0.43 mmol). The product was obtained as a yellow oil and was used without further purification.
APCI-MS: m/z 423, 425 [MH4"]
iii) (2S)-l-(2-Amino-5-methoxyphenoxy)-3-[(3S)-3-(4-chlorophenoxy)pyrrolidinyl]-2- propanol
The subtitle compound was prepared in analogy of Example 253 iii) from (ii) (0.43mmol). The product obtained (colourless oil, 163mg) was a mixture of the desired product and reduced DEAD in molar ratio 5:1. The substance was used as it was.
'H-NMR (400MHz, CDC13): δ 7.23 (d, 2H); 6.77 (d, 2H); 6.67 (d, IH); 6.49 (d, IH); 6.41 (bs, redDEAD); 6.39 (dd, IH); 4.83-4.77 (m, IH); 4.22 (q, red.DEAD); 4.14-4.07 (m, IH); 4.01 (d, 2H); 3.75 (s, 3H); 3.01-2.91 (m, 2H); 2.88-2.72 (m, 3H); 2.62 (dd, IH); 2.29 (hex, IH); 2.06-1.96 (m, IH); 1.29 (t, redDEAD)
APCI-MS: m/z 393, 395 [MH+]
iv) V-[2-({(2S)-3-[(3S)-3-(4-Chlorophenoxy)pyrrolidinyl]-2-hydroxypropyl}oxy)-4- methoxyphenyl] acetamide
To a solution of compound iii) (157mg) in a mixture of acetonitrile (lO L) and water (2mL) acetic anhydride (lmL) was added and the mixture was stirred at ambient temperature overnight. 1.5M sodiummethoxid in methanol (lmL) was added and the stirring continued for lh. After evaporation the residue was taken up in ether and water. The subtitle product was obtained from the organic phase as a colourless oil (155mg).
'H-NMR (400MHz, CDC13): 5 8.18 (d, IH); 7.95 (bs, IH); 7.24 (d, 2H); 6.78 (d, 2H); 6.56-6.52 (m, 2H); 4.85-4.78 (m, IH); 4.22 (q, red.DEAD); 4.10-4.02 (m, 2H); 4.00-3.92 (m, IH); 3.78 (s, 3H); 3.00-2.91 (m, 2H); 2.87-2.73 (m, 3H); 2.53 (dd, IH); 2.36- 2.25 (m, IH); 2.17 (s, 3H); 2.07-1.99 (m, IH); 1.29 (t, red.DEAD)
APCI-MS: m/z 435, 437 [MH4]
v) iir-[2-({(2S)-3-f(3S)-3-(4-Chlorophenoxy)pyrrolid.nyi]-2-hydroxypropyl}oxy)-4- hydroxyphenyl] acetamide
The title compound was prepared by analogy to Example 254 from iv) (150mg). The product obtained after lyophilization was a white amorphous solid (1 Olmg, 57%>).
'H-NMR (400MHz, CDC13+1 drop DMSO- : δ 8.7 (bs, IH); 8.34 (s, IH); 8.73 (d, IH); 7.18 (d, 2H); 6.73 (d, 2H); 6.40-6.31 (m, 2H); 4.99-4.93 (m, IH); 4.4-1.9 (bm, 6H); 4.31-4.23 (m, IH); 3.88-3.78 (m, 2H); 3.39-3.25 (m, 2H); 2.4-2.2 (m, 2H); 2.07 (s, 3H)
APCI-MS: m/z 421, 423 [MH4]
THP-1 Chemotaxis Assay
Introduction
The assay measured the chemotactic response elicited by MlP-lα chemokine in the human monocytic cell line THP-1. The compounds of the Examples were evaluated by their ability to depress the chemotactic response to a standard concentration of MlP-lα chemokine. Methods
Culture of THP-1 cells
Cells were thawed rapidly at 37°C from frozen aliquots and resuspended in a 25 cm flask containing 5 ml of RPMI-1640 medium supplemented with Glutamax and 10% heat inactivated fetal calf serum without antibiotics (RPMI+10%HIFCS). At day 3 the medium is discarded and replaced with fresh medium.
THP-1 cells are routinely cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal calf serum and glutamax but without antibiotics. Optimal growth of the cells requires that they are passaged every 3 days and that the minimum subculture density is 4x10+5 cells/ml.
Chemotaxis assay Cells were removed from the flask and washed by centrifugation in
RPMI+10%HIFCS+glutamax. The cells were then resuspended at 2x10+7 cells/ml in fresh medium (RPMI+10%oHIFCS+glutamax) to which was added calcein-AM (5 μl of stock solution to 1 ml to give a final concentration of 5x10" M). After gentle mixing the cells were incubated at 37°C in a CO2 incubator for 30 minutes. The cells were then diluted to 50 ml with medium and washed twice by centrifugation at 400xg. Labelled cells were then resuspended at a cell concentration of 1x10+7 cells/ml and incubated with an eeqquuaall vvoolluummee ooff MMllPP--llαα aannttaaggoonniisstt ((1100" M to 10" M final concentration) for 30 minutes at 37°C in a humidified CO2 incubator.
Chemotaxis was performed using Neuroprobe 96-well chemotaxis plates employing 8 μm filters (cat no. 101-8). Thirty microlitres of chemoattractant supplemented with various concentrations of antagonists or vehicle were added to the lower wells of the plate in triplicate. The filter was then carefully positioned on top and then 25μl of cells preincubated with the corresponding concentration of antagonist or vehicle were added to the surface of the filter. The plate was then incubated for 2 hours at 37°C in a humidified CO2 incubator. The cells remaining on the surface were then removed by adsorption and the whole plate was centrifuged at 2000 rpm for 10 minutes. The filter was then removed and the cells that had migrated to the lower wells were quantified by the fluorescence of cell associated calcein-AM. Cell migration was then expressed in fluorescence units after subtraction of the reagent blank and values were standardized to % migration by comparing the fluorescence values with that of a known number of labelled cells. The effect of antagonists was calculated as % inhibition when the number of migrated cells were compared with vehicle.

Claims

C L A I M S
1. A compound of general formula
Figure imgf000163_0001
wherein,
R represents a group
Figure imgf000163_0002
m is 0, 1, 2 or 3; each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl,
C3-C6 cycloalkyl, CrC6 alkoxy, CrC6 alkoxycarbonyl, Cι-C6 haloalkyl,
9 10 CrC6 haloalkoxy, -NR R , C3-C6 cycloalkylamino, CrC6 alkylthio,
Ci-Cg alkylcarbonyl, Ci-Cg alkylcarbonylamino, sulphonamido, C^Cg alkylsulphonyl,
-C(O)NRUR12, -NR13C(O)-(NH)pR14, phenyl, or CrC6 alkyl optionally substituted by carboxyl or Cι-C6 alkoxycarbonyl; p is 0 or 1 ;
X represents an oxygen or sulphur atom or a CH2, CH(CH3), OCH2, CH2O, CH2NH,
NH or carbonyl group and Y represents a nitrogen atom or a CH or C(OH) group, provided that when X represents an oxygen or sulphur atom or a CH2O, CH2NH or NH group, then Y represents a CH group;
Z represents a bond or a group (CH2)q where q is 1 or 2;
2 1 2
Z represents a bond or a group CH2, with the proviso that Z and Z do not both simultaneously represent a bond;
Q represents an oxygen or sulphur atom or a group CH2 or NH; R represents a group
Figure imgf000164_0001
n is 0, 1 or 2;
3 each R independently represents a C Cg alkyl, CrCg alkoxycarbonyl, -CH2OH or carboxyl group;
R , R , R and R each independently represent a hydrogen atom or a Cj-Cg alkyl group, or R , R , R and R together represent a CrC4 alkylene chain linking the two carbon atoms to which they are attached to form a 4- to 7-membered saturated carbocycle, or R , R and R each represent a hydrogen atom and R and R together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle;
R 8 represents a hydrogen atom, a C C6 alkyl group or is linked to R 4 as defined above;
9 10
R and R each independently represent a hydrogen atom or a C C alkyl group, or
9 10 R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
R 11 and R 12 each independently represent a hydrogen atom or a Cι-C6 alkyl group optionally substituted by Cj-Cg alkoxycarbonyl;
R represents a hydrogen atom or a Ci -Cg alkyl group; R represents a hydrogen atom, or a C^-Cg alkyl group optionally substituted by carboxyl, CrCg alkoxy or Ci-Cg alkoxycarbonyl;
R represents carboxyl, C^-C alkylcarbonyl, C Cg alkoxycarbonyl,
CrC6 alkoxycarbonyi -Cg alkyl or a group -NR17R18, -NHSO2CH3, -NHC(O)CH3,
-C(O)NR17R18, -NHC(O)NR17R18, -OC(O)NR17R18, -OCH2C(O)NR17R18, -NHC(O)OR17' or -OR17"; t is O, 1, 2 or 3; each R independently represents halogen, cyano, nitro, carboxyl, hydroxyl, C3-C6 cycloalkyl, C Cg alkoxy, C Cg alkoxycarbonyl, CrC6 haloalkyl.
CrCg haloalkoxy, -NR 19 R 20 , C3-C6 cycloalkylamino, CrC6 alkylfhio, CrCg alkylcarbonyl, CpCg alkylcarbonylamino, sulphonamido (-SO2NH2), CrCg alkylsulphonyl, -C(O)NR21R22, -NR23C(O)(NH)vR24, phenyl, or CrC6 alkyl optionally substituted by carboxyl or Ci -Cg alkoxycarbonyl;
17 18
R and R each independently represent (i) a hydrogen atom, (ii) a 5- to 6- membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or
(iii) a Ci-Cg alkyl group optionally substituted by at least one substituent selected from halogen, trifluoromethyl, carboxyl, C Cg alkoxycarbonyl and a 5- to 6-membered saturated or unsaturated ring which may comprise at least one heteroatom chosen from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent selected from halogen, methyl and trifluoromethyl, or
17 18
R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
17'
R represents a hydrogen atom, or a Ci-Cg alkyl group optionally substituted by carboxyl or C Cg alkoxycarbonyl;
17" 17 17" R is defined as for R above except that R does not represent a hydrogen atom;
19 20
R and R each independently represent a hydrogen atom or a Ci -C6 alkyl group, or
19 20
R and R together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocycle;
21 22
R and R each independently represent a hydrogen atom or a Cj-Cg alkyl group optionally substituted by Ci -Cg alkoxycarbonyl; v is 0 or 1 ;
23 R represents a hydrogen atom or a C Cg alkyl group; and
R represents a hydrogen atom, or a C Cg alkyl group optionally substituted by carboxyl, Cj-Cg alkoxy or Cι-C6 alkoxycarbonyl; or a pharmaceutically acceptable salt or solvate thereof.
2. A compound according to claim 1, wherein X represents an oxygen atom or a CH2, OCH2, CH2O, NH or carbonyl group.
3. A compound according to claim 1 or 2, wherein Y represents a nitrogen atom or CH group.
4. A compound according to any one of claims 1 to 3, wherein Q represents an oxygen atom.
5. A compound according to any one of claims 1 to 4, wherein R represents
Cι-C4 alkoxy, CrC4 alkylcarbonyl, C1-C4 alkoxycarbonylC1-C4 alkyl, -NHC(O)CH3, -C(O)NR17R18, -NHSO2CH3 or -NHC(O)NR17R1S.
6. A compound according to any one of claims 1 to 5, wherein each R independently represents halogen, cyano, hydroxyl, C1-C4 alkoxy, C!-C4 alkoxycarbonyl, C1-C4 haloalkyl, C1-C4 alkylcarbonyl, phenyl or CrC alkyl.
7. A compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as defined in claim 1 being selected from:
N-(2-{3-[3R,S-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2R,S-hydroxy-propoxy}-phenyl)- acetamide hydrochloride,
N-(5-Chloro-2-{3-[3R,S-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2R,S-hydroxy- propoxy } -phenyl)-acetamide hydrochloride, N-(2- (3-[4-(3,4-dichlorophenoxy)-l -piperidinyl]-2-hydroxypropoxy}phenyl)- acetamide,
1 -(2-aminophenoxy)-3-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyl]-2-propanol dihydrochloride,
N-(2- {3-[3-(3 ,4-dichlorophenoxy)- 1 -pyrrolidinyI)-2-hydroxypropoxy} phenyl)- acetamide hydrochloride, 2- {3-[4-(4-Fluoro-phenoxy)-piρeridin- 1 -yl]-2-hydroxy-propoxy } -benzoic acid methyl ester,
2-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-2-methyl-propionic acid methyl ester, N-[2-({(li?,2,S,,3i?)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl)-2- hydroxycyclopentyl}oxy)phenyl]acetamide,
N-[2-({(l^,2JS',3i?)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl)-2- hydroxycyclopentyl}oxy)phenyl]acetamide,
N-[2-( {(2,3-trøRs)-3-[4-(3,4-dichlorophenoxy)- 1 -piperidinyl]-2- hydro xycyclohexyl} oxy)phenyl] acetamide,
N-(5-Chloro-2- {3-[3-(3 ,4-dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } - phenyl)-acetamide,
N-(3-Acetyl-2-{3-[3-(3,4-dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide, N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-methyl- phenyl)-acetamide,
N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-fluoro- phenyl)-acetamide,
N-(4- {3-[3-(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -biphenyl-3- yl)-acetamide,
N-(2- {3-[3-(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -4-fluoro- phenyl)-acetamide,
N-(2- {3-[3-(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -5-methyl- phenyl)-acetamide, N-(2-{3-[3-(3,4-Dichloro-phenoxy)-pj τolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
N-(5-Chloro-2- {3-[3-(4-chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} - phenyl)-acetamide,
N-(3-Acetyl-2- {3-[3-(4-chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -5- methyl-phenyl)-acetamide, N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-methyl- phenyl)-acetamide,
N-(2- (3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -5-fiuoro- phenyl)-acetamide, N-(4-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-biphenyl-3-yl)- acetamide,
N-(2-{3-[3-(4-Chloro-ρhenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-4-fluoro- phenyl)-acetamide,
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide,
N-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)~ acetamide
N-(5-Chloro-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide, N-(3-Acetyl-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5- methyl-phenyl)-acetamide,
N-(2- { 3 - [3 -(4-Fluoro-phenoxy )-pyrrolidin- 1 -yl] -2-hydroxy-propoxy } -4-methyl- phenyl)-acetamide,
N-(5-Fluoro-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide,
N-(4- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -biphenyl-3-yl)- acetamide,
N-(4-Fluoro-2- {3-[3-(4-fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} - phenyl)-acetamide, N-(2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide,
N-(2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- acetamide,
N-(5-Chloro-2- {3-[3-(3 ,4-difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} - phenyl)-acetamide, N-(3-Acetyl-2- {3-[3-(3,4-difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -5- methyl-phenyl)-acetamide,
N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy] -4-methyl- phenyl)-acetamide, N-(2- {3-[3-(3 ,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -5-fluoro- phenyl)-acetamide,
N-(4- {3-[3-(3 ,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -biphenyl-3- yl)-acetamide,
N-(2- {3-[3-(3 J4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -4-fluoro- phenyl)-acetamide,
N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide,
N-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl).- acetamide, N-(5-Chloro-2-{3-[4-(3,4-dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide,
N-(3-Acetyl-2- {3-[4-(3,4-dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -5- methyl-phenyl)-acetamide,
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-4-methyl- phenyfj-acetamide,
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5-fluoro- phenyl)-acetamide,
N-(4-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-proρoxy}-biphenyl-3- yl)-acetamide, , N-(2- {3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -4-fluoro- phenyl)-acetamide,
N-(2- {3- [4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -5-methyl- phenyl)-acetamide,
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-proρoxy}-phenyl)- acetamide, N-(5-Chloro-2-{3-[4-(4-chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide,
N-(3-Acetyl-2- {3-[4-(4-chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -5- methyl-phenyl)-acetamide, N-(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -4-methyl- phenyl)-acetamide,
N-(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -5-fluoro- phenyl)-acetamide,
N-(4- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -biphenyl-3-yl)- acetamide,
N-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-4-fluoro- phenyl)-acetamide,
N-(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5-methyl- phenyl)-acetamide, N-(2-{3-[4-(4-Chloro-phenoxy)-piρeridin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
3-(2- {3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- propionic acid methyl ester,
1 -[4-(3,4-Dichloro-phenoxy)-piperidin- 1 -yl]-3-(2,6-dimethoxy-phenoxy)-propan-2-ol,
1 -[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol,
2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-N,N-dimethyl- benzamide, 1 -(2- {3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- propan-1-one, l-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- ethanone,
3-(2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- propionic acid methyl ester, 1 -(2,6-Dimethoxy-phenoxy)-3-[3-(4-fluoro-phenoxy)-pyrrolidin- 1 -yl]-propan-2-ol, 1 -[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol, (2-{3-[3-(4-Fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester, (2-{3-[3-(4-Chloro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-acetic acid methyl ester,
2-(2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -benzoylamino)- 2-methyl-propionic acid methyl ester,
2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -N,N-dimethyl- benzamide,
. 1 -(2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -6-mefhoxy- phenyl)-ethanone, l-(2-{3-[3-(4-Fluoro-phenoxy)rpyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propan- 1-one, 1 -(2- {3-[3-(4-Fluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- ethanone, iV-[2-(3-{[l-(3,4-dichlorobenzyl)-4-piperidinyl]amino}-2-hydroxypropoxy)-4- methylphenyl] acetamide,
3-(2- {3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- propionic acid methyl ester,
1 -[3-(3,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol, (2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-acetic acid methyl ester,
2- {3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -N,N-dimethyl- benzamide,
1 -(2- {3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -6-methoxy- phenyl)-ethanone, l-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propan-1-one, l-(2-{3-[3-(3,4-Difluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- ethanone,
N-(2- (3-[4-(3,4-dichloroanilino)- 1 -piperidinyl]-2-hydroxypropoxy}phenyl)acetamide, 3-(2-{3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester, l-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-3-(2,6-dimethoxy-phenoxy)-propan-2-ol, 1 -[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol, (2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -benzoylamino)- acetic acid, methyl ester, 2-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -benzoylamino)-
2-methyl-propionic acid methyl ester,
2- {3-[3-(4-Chloro-phenoxy)-pyrroIidin- 1 -yl]-2-hydroxy-propoxy } -N,N-dimethyl- benzamide,
1 -(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -6-methoxy- phenyl)-ethanone,
1 -(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)-propan- 1-one,
1 -(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- ethanone, N-(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
3-(2- {3-[3-(4-Cyano-phenoxy)-ρyrrolidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)- propionic acid methyl ester,
(2-{3-[3-(4-Cyano-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester,
2- {3-[3-(4-Cyano-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -N,N-dimethyl- benzamide,
4-{l-[2-Hydroxy-3-(2-propionyl-phenoxy)-propyl]-pyrrolidin-3-yloxy}-benzonitrile, N-(2- {2-Hydroxy-3-[3-(4-methoxy-phenoxy)-pyrrolidin- 1 -yl]-propoxy} -phenyl)- acetamide, N-(4-chloro-2- |3-[4-(3,4-dichloroanilino)- 1 -piperidinyl] -2- hydroxypropoxy}phenyl)acetamide,
3-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester, 1 -[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l -yl]-3-(2-methoxy-phenoxy)-propan-2-ol,
(2- { 3 - [3 -(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl] -2 -hy droxy-propoxy } - benzoylamino)-acetic acid methyl ester,
2-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- benzoylamino)-2-methyl-propionic acid methyl ester, 2- {3-[3-(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -N,N-dimethyl- benzamide, l-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-6-methoxy- phenyl)-ethanone, l-(2-{3-[3-(3,4-Dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propan-1-one,
1 -(2- {3-[3-(3 ,4-Dichloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propox } -phenyl)- ethanone, • • ~
N-(2- {3-[4-(3 ,4-Difluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- acetamide, 3-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propionic acid methyl ester,
2- {3-[4-(3,4-Difluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -N,N-dimethyl- benzamide, l-(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- propan-1-one,
(2-{3-[4-(3,4-Difluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester,
N-(2- {3-[3-(3 ,4-Difluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy } - phenyl)-acetamide, N-(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide,
3-(2-{3-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)-propionic acid methyl ester, 1 -(2,6-Dimethoxy-phenoxy)-3-[4-(4-fluoro-phenoxy)-piperidin- 1 -yl]-propan-2-ol,
1 -[4-(4-Fluoro-phenoxy)-piperidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol,
1 -(2- {3-[4-(4-Fluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)-ethanone,
2- {3-[4-(4-Fluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -N,N-dimethyl- benzamide, 1 -(2- {3-[4-(4-Fluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)-propan-
1-one,
(2- {3-[4-(4-Fluoro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -benzoylamino)- acetic acid methyl ester,
N-(2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- acetamide,
3-(2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- propionic acid methyl ester,
1 -[3-(4-Fluoro-phenoxymefhyl)-piperidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol, l-(2-{3-[3-(4-Fluoro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-ρropoxy}-phenyl)- ethanone,
2-(2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy } - benzoylamino)-2-methyl-propionic acid methyl ester,
2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy} -N,N- dimethyl-benzamide, 1 -(2- {3-[3-(4-Fluoro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy } -6- methoxy-phenyl)-ethanone,
N-(2- {3-[4-(4-Acetylamino-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- acetamide,
N-(4- { 1 -[3-(2-Acetyl-phenoxy)-2-hydroxy-propyl]-piperidin-4-yloxy} -phenyl)- acetamide, N-(4-cyano-2-{3-[4-(3,4-dichloroanilino)-l-piperidinyl]-2- hydroxypropoxy } phenyl)acetamide,
3-(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- propionic acid methyl ester, 1 -[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-3-(2-methoxy-phenoxy)-propan-2-ol,
1 -(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- ethanone,
2-(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -benzoylamino)-2- methyl-propionic acid methyl ester, 2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -N,N-dimethyl- benzamide,
1 -(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } -6-methoxy- phenyl)-ethanone,
1 -(2- {3-[4-(4-Chloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy} -phenyl)-propan- 1-one,
(2-{3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-benzoylamino)- acetic acid methyl ester,
N-(2-{3-[3-(4-Chloro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide, 3-(2- {3-[3-(4-Chloro-phenoxymethyl)-piperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- propionic acid methyl ester, l-(2-{3-[3-(4-Chloro-phenoxymethyl)-piρeridin-l-yl]-2-hydroxy-proρoxy}-phenyl)- ethanone,
2-{3-[3-(4-Chloro-phenoxymethyl)-piperidin-l-yl]-2-hydroxy-proρoxy}-N,N- dimethyl-benzamide,
1 -(2- {3-[3-(4-Chloro-phenoxymethyl)-ρiperidin- 1 -yl]-2-hydroxy-propoxy } -phenyl)- proρan-1-one,
N-[2-({(li?,2i?)-2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-l- hydroxycyclopentyl}methoxy)phenyl]acetamide, Methyl (2S,4R)~ 1 - {3-[2-(acetylamino)phenoxy]-2 -hydroxypropyl } -4-[(4- chlorobenzyl)oxy]-2-pyrrolidinecarboxylate hydrochloride,
N-(2- {3-[4-(3 ,4-Dichloroanilino)- 1 -piperidinyl]-2-hydroxypropoxy } -4- methylphenyl)acetamide, N-(2- {3-[4-(4-Chloroanilino)- 1 -piperidinyl]-2-hydroxypropoxy }phenyl)acetamide,
N-(4-Chloro-2- {3-[4-(4-chloroanilino)- 1 -piperidinyl]-2-hydroxypropoxy} phenyl)- acetamide,
N-(2- {3-[4-(4-Chloroanilino)- 1 -piperidinyl] -2-hydroxypropox } -4- cyanophenyl)acetamide, N-(2- {3-[4-(4-Chloroanilino)-l -piperidinyl]-2-hydroxypropoxy}-4- methylphenyl)acetamide,
N-(5-Chloro-2- {3-[4-(4-fluoroanilino)- 1 -piperidinyI]-2- hydroxypropoxy } phenyl)acetamide,
N-(5-Chloro-2- {3-[4-(3 ,4-difluoroanilino)- 1 -piperidinyl]-2- hydroxypropoxy} phenyl)acetamide,
N-(5-Cyano-2- {3-[4-(4-fluoroanilino)-l -piperidinyl]-2-hydroxypropoxy}- phenyl)acetamide,
N-(5-Cyano-2- {3-[4-(3,4-difluoroanilino)-l-piperidinyl]-2- hydroxypropoxy } phenyl)acetamide, N-(2- {3-[4-(4-Fluoroanilino)- 1 -piperidinyl]-2 -hydroxypropoxy } -4- methylphenyl)acetamide,
N-(2- {3-[4-(3 ,4-Difluoroanilino)- 1 -piperidinyl]-2-hydroxypropoxy } -4- methylphenyl)acetamide,
N-(2- {3-[3(S)-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-(R)-hydroxy-proρoxy- phenyl)acetamide,
N-(2- {3-[3S-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2S-hydroxy-propoxy}-phenyl)- acetamide hydrochloride,
N-(2- {3-[3(R)-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-(S)-hydroxy-propoxy- phenyl)acetamide, N-[5-Chloro-2-({(2S)-3-[(3S)-3-(4-chloro-phenoxy)pyrrolidinyl]-2- hydroxypropyl } oxy)phenyl]acetamide,
N-[5-Chloro-2-({(2R)-3-[(3R)-3-(4-chloro-phenoxy)pyrrolidinyl]-2- hydroxypropyl}oxy)phenyl]acetamide, N-[5-Chloro-2-({(2S)-3-[(3R)-3-(4-chloro-phenoxy)pyrrolidinyl]-2- hydroxypropyl}oxy)phenyl]acetamide,
N-[5-Chloro-2-({(2R)-3-[(3S)-3-(4-chloro-phenoxy)pyrrolidinyl]-2- hydroxypropyl}oxy)phenyl]acetamide,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } -4,5-difluoro- phenyl)-acetamide,
N-{5-Chloro-2-[2-hydroxy-3-(3-phenoxy-pyrrolidin-l-yl)-propoxy]-phenyl}- acetamide,
N-(5-Chloro-2- {2-hydroxy-3-[3-(4-nitro-phenoxy)-pyrrolidin- 1 -yl]-propoxy } -phenyl)- acetamide, JV-(5-Acetyl-2- {3-[3-(3,4-dichIoro-phenoxy)-pyrrolidin-l -yl]-2-hydroxy-propoxy}- phenyl)-acetamide,
4-Acetylamino-3-{3-[3-(3,4-dichloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- benzoic acid methyl ester,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} -5-cyano- phenyl)-acetamide,
4-Acetylamino-3- {3-[3-(4-chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy } - benzoic acid methyl ester,
N-(5-Cyano-2- {3-[4-(3 ,4-dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-propoxy } - phenyl)-acetamide, N-(2-{3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-propoxy}-5- trifluoromethyl-phenyl)-acetamide,
N-(5-Chloro-2- {3-[3-(4-fluoro-phenoxy)-pyrrolidin- l,-yl]-2-hydroxy-propoxy} - phenyl)-acetamide trifluoroacetate,
N-(5-Acetyl-2-{3-[3-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide trifluoroacetate, 7V-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)- methanesulfonamide,
N-(5-Chloro-2-[3-[3,4-dichlorophenoxy)-l-pyrrodinyl]-2-hydroxyρropoxy]- phenyl)urea, 1 -(3- {2-[(Aminocarbonyl)amino]phenoxy } -2-hydroxypropyl)-3-(4- chlorophenoxy)pyrrolidinium 2,2,2-trifluoroacetate,
1 -(3- {2-[(Aminocarbonyl)amino]phenoxy} -2-hydroxypropyl)-3-(3,4- dichlorophenoxy)pyrrolidinium 2,2,2-trifluoroacetate,
1 -(3- {2-[(Aminocarbonyl)amino]-4-chlorophenoxy } -2-hydroxyρropyl)-3-(4- chlorophenoxy)pyrrolidinium 2,2,2-trifluoroacetate, iV-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-iV- ethylurea hydrochloride,
N-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}phenyl)-iV- methylurea hydrochloride, (2.S',4tS)-l-{3-[2-(Acetylamino)phenoxy]-2-hydroxypropyl}-4-(4-chlorophenoxy)-2- pyrrolidinecarboxylic acid; compound with trifluoroacetic acid,
Ethyl (2 4ό)-l-{3-[2-(acetylamino)phenoxy]-2-hydroxypropyl}-4-(3,4- dichlorophenoxy)-2-pyrrolidinecarboxylate; trifluoroacetic acid salt,
N-[2-({(2-S)-3-[(2-S,45)-4-(4-Chlorophenoxy)-2-(hydroxymethyl)pyrrolidinyl]-2- hydroxypropyl }oxy)phenyl] acetamide; trifluoroacetic acid salt,
N-[2-({(2i?)-3-[(21S,45)-4-(4-Chlorophenoxy)-2-(hydroxymethyl)ρyrrolidinyl]-2- hydroxypropyl}oxy)phenyl]acetamide; trifluoroacetic acid salt,
N-(2-{3-[3-(4-Chloroρhenoxy)-l-ρyrrolidinyl]-2-hydroxy-2- methylpropoxy}phenyl)acetamide hydrochloride, N-(2-{(l-?*,2i?*,3-S,*)-3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide,
N-(2-{(li?*,27-*,3^)-3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide,
N-Q.- {(2R* ,3R*)-3-[4-(3 ,4-Dichloro-phenoxy)-piperidin- 1 -yl]-2-hydroxy-butoxy} - phenyl)-acetamide, N-(2-{(l1S*,2i?*,3^)-3-[4-(4-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy- cyclopentyloxy}-phenyl)-acetamide,
7V-(2-{(2i?*,3 )-3-[4-(3,4-Dichloro-phenoxy)-piperidin-l-yl]-2-hydroxy-butoxy}- phenyl)-acetamide, N-(2-{(2i?*,3i?*)-3-[3-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-butoxy}- phenyl)-acetamide,
N-(2- {(2i?*,3-S*)-3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-butoxy } - phenyl)-acetamide,
N-(2-{(l,_ ,2i?*,35*)-3-[4-(3-Chloro-phenoxy)-piperidin-l-yl]-2-hydroxy- cyclopentyloxy} -phenyl)-acetamide,
N-[5-Chloro-2-({(l,S,2i?,35)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide,
N-[4-Fluoro-2-({(l_ ,2i?,35)*-3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]-2- hydroxy cyclopentyl } oxy)phenyl] acetamide, N-(2-{3-[4-(3,4-Dichlorobenzyl)-l-piperazinyl]-2-hydroxypropoxy}-phenyl)acetamide dihydrochloride,
N-(2-{3-[4-(3,4-Dichlorobenzyl)-l-piperazinyl]-2-hydroxypropoxy}-4- fluorophenyl)acetamide, iV-(2-{3-[4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2- hydroxypropoxy} phenyl)acetamide,
N-(5-Chloro-2-{3-[4-(3,4-dichlorobenzyl)-l-piρerazinyl]-2- hydroxypropoxy}phenyl)acetamide,
N-(5-Chloro-2-{3-[4-(3,4-dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2- hydroxypropoxy } phenyl)acetamide, N-(2- {3-[4-(3 ,4-Dichlorobenzyl)-2,5-dimethyl- 1 -piperazinyl]-2-hydroxypropoxy } -4- methylphenyl)acetamide,
N-(2-{3-[4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2-hydroxypropoxy}-4- fluorophenyl)acetamide,
N-(2-{3 [(S*R*)-4-(3,4-Dichlorobenzyl)-2,5-dimethyl-l-piperazinyl]-2- hydroxypropoxy } phenyι)acetamide, N-(2- {3 [(S*R*)-4-(4-Chlorobenzyl)-2,5-dimethyl- 1 -piρerazinyl]-2- hydroxypropoxy } phenyl)acetamide,
N-(5-Chloro-2- {3-[(S*R *)-4-(3 ,4-dichlorobenzyl)-2,5-dimethylpiperazinyl]-2- hydroxypropoxy } phenyl)acetamide, N-(5-Chloro-2- {3-[(S*R *)-4-(4-chlorobenzyl)-2,5-dimethylpiperazinyl]-2- hydroxypropoxy } phenyl)acetamide,
1 -(5-Chloro-2- {3-[4-(4-chlorobenzoyl)- l-piperazinyl]-2-hydroxypropoxy}phenyl)- 1 - ethanone,
N-(5-Cyano-2-{3-[(,S:|si?*)-4-(3,4-dichlorobenzyl)-2,5-dimethylpiperazinyl]-2- hydroxypropoxy}phenyl)acetamide,
N-(2-{3-[(5*/?:i:)-4-(4-Chlorobenzyl)-2,5-dimethylpiperazinyl]-2-hydroxypropoxy}-5- cyanophenyl)acetamide,
N-(5-Chloro-2- {3-[4-(4-chlorobenzyl)- 1 -piperazinyl]-2-hydroxypropoxy } - phenyl)acetamide, N-(4-Chloro-2- {3-[4-(4-chlorobenzyl)-2,5-dimethyl- 1 -piperazinyl]-2- hydroxypropoxy } phenyl)acetamide,
N-(2- { 3 -[4-(4-Chlorobenzoyl)- 1 -piperazinyl]-2-hydroxypropoxy } -5- cyanophenyl)acetamide,
N-(2- {3-[4-(4-Chlorobenzoyl)- 1 -piperazinyl]-2-hydroxypropoxy } -4- methylphenyl)acetamide,
N-[5-Chloro-2-({(li?,25,3i?)-3-[(31S)-3-(4-chlorophenoxy)pyrrolidinyl]-2- hydroxycyclopentyl}oxy)phenyl]acetamide,
N- {2-[(2S)-(3- {(3S)-3-[(4-Chlorophenyl)oxy]- l-pyrrolidinyl} -2-hydroxypropyl)oxy]- 4-fluorophenyl} acetamide, N-[2-( {(21S)-3-[(3-S)-3-(4-Chlorobenzyl)pyrrolidinyl]-2- hydroxypropyl}oxy)phenyl]acetamide hydrochloride,
N-(5-Chloro-2-{3-[3-(4-chloro-benzyl)-pyrrolidin-l-yl]-2-hydroxy-propoxy}-phenyl)- acetamide trifluoroacetic acid salt,
N-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}-4-methylphenyl)- 1-pyrrolidinecarboxamide trifluoroacetate, iV-(2-{3-[3-(4-Chlorophenoxy)-l-pyrrolidinyl]-2-hydroxypropoxy}-4- hydroxyphenyl)acetamide trifluoroacetate,
N-[2-( {(2S)-3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyl]-2-hydroxypropyl} oxy)-4- fluorophenyl] acetamide trifluoroacetic acid salt, N-(2-(3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl)-2-hydroxy-propoxy)-4,6-difluoro- phenyl)-acetamide hydrochloride,
N-[2-({(2,S)-3-[(25,4 )-4-(4-Chlorophenoxy)-2-methylpyrrolidinyl]-2- hydroxypropyl}oxy)-4-fluorophenyl] acetamide trifluoroacetic acid salt,
N-[2-({(2,S)-3-[(3i?)-3-(4-Chlorobenzyl)pyrrolidinyl]-2- hydroxypropyl} oxy)phenyl] acetamide hydrochloride,
N- (2-[(2R)- (3- {(3 S)-3-[(4-Chlorophenyl)oxy]- 1 -pyrrolidinyl} -2-hydroxypropyl)oxy]- 4-fluorophenyl} acetamide,
N-[2-({(2S)-3-[(2i?,45)-4-(4-Chlorophenoxy)-2-methylpyrrolidinyl]-2- hydroxypropyl}oxy) phenyl]acetamide trifluoroacetic acid salt, N- {2-[(2S)-(3- {(3R)-3-[(4-Chlorophenyl)oxy]- 1 -pyrrolidinyl } -2-hydroxyρroρyl)oxy]-
4-fluorophenyl} acetamide, iV-(2- {3-[3-(4-Chlorophenoxy)- 1 -pyrrolidinyl]-2-hydroxypropoxy } -4-methylphenyl)- N^V-dimethylurea trifluoroacetate,
N-(2-{3-[3-(4-Chloroanilino)-l-pyrrolidinyl]-2 -hydroxypropoxy} phenyl)acetamide, N- {2-[(3- {3-[(4-Chloroρhenyl)oxy]- 1 -pyrrolidinyl} -2-hydroxy- 1 - methylpropyl)oxy]phenyl} acetamide hydrochloride,
N-(2- (3-[3-(4-Chlorophenoxy)- 1 -pyrrolidinyl] -2 -hydroxypropoxy } -4- methoxyphenyl)acetamide hydrochloride,
N-(2-[3-(4-Chloro-benzyloxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy)-phenyl)- acetamide trifluoroacetic acid salt,
N-(2- {3-[3-(4-Chloro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-2-methyl-propoxy } - phenyl)-acetamide,
N-(2- {(1 S,2R,3S)*-3-[(3S)-3-(3 ,4-Difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy- cyclopentyloxy } -5-chloro-phenyl)-acetamide (diastereomeric mixture), N-[2-({(2Jr?,35) *-3-[(35)-3-(4-Chlorophenoxy)pyrrolidinyl]-2-hydroxybutyl}oxy)-4- methylphenyl] acetamide (diastereomeric mixture),
N-{2-[(3-{4-[(3,4-Dichlorophenyl)oxy]-l -piperidinyl] -2-hydroxy-2- methylpropyl)oxy]-4-fluorophenyl} acetamide hydrochloride, /Y-(2-{(15',2i?,3-S),-3-[(31S)-J-(4-Chloro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy- cyclopentyloxy } -4-fluoro-phenyl)-acetamide (diastereomeric mixture),
N-(5-Chloro-2- {3-[3-(3 ,4-difluoro-phenoxy)-pyrrolidin- 1 -yl]-2-hydroxy-propoxy} - phenyl)-acetamide,
N-(5-Chloro-2-{3-[3-(4-fluoro-phenoxy)-pyrrolidin-l-yl]-2-hydroxy-propoxy}- phenyl)-acetamide, iV-(4-Cyano-2-{3-[4-(3,4-dichloroanilino)-l-piperidinyl]-2- hydroxypropoxy } phenyl)acetamide,
N-(4-Hydroxy-2-{(15,2i?,35)*-3-[(3.S,)-J-(4-chloro-phenoxy)-pyrrolidin-l-yI]-2- hydroxy-cyclopentyloxy } -phenyl)-acetamide (diastereomeric mixture), N-(4-Hydroxy-2-{(l»S,2Λ,3 )-3-[(31S)-J-(4-chloro-phenoxy)-pyrrolidin-l-yl]-2- hydroxy-cyclopentyloxy}-phenyl)-acetamide,
N-(4-Hydroxy-2- {( lR,2S,3R)-3-[(3S)- J-(4-chloro-phenoxy)-pyrrolidin- 1 -yl]-2- hydroxy-cyclopentyloxy}-phenyl)-acetamide,
N-[2-({(15,2i?,35)-3-[(35)-3-(4-Chlorophenoxy)pyrrolidinyl]-2- hydroxy cyclopentyl } oxy)ρhenyl] acetamide,
N-[2-({(\R,2S,3R)-3-[(3S)-3-(4-Cbloτop enoxy)pyπo\id y\]-2- hydroxycyclopentyl } oxy)phenyl] acetamide,
N-[5-Chloro-2-({(15,2i?,35)-3-[(35)-3-(4-chlorophenoxy)pyrrolidinyl]-2- hydroxy cyclopentyl } oxy)phenyl] acetamide, N-{5-Chloro-2-[((15,2i?,3^^3-{[l-(4-chlorobenzyl)-4-piperidinyl]amino}-2- hydroxycyclopentyl)oxy]phenyl} acetamide (racemic mixture), and
N-[2-({(2- )-3-[(3,S)-3-(4-Chloroρhenoxy)pyrrolidinyl]-2-hydroxypropyl}oxy)-4- hydroxyphenyl]acetamide.
8. A process for the preparation of a compound of formula (F) as defined in claim 1 which comprises,
(a) reacting a compound of general formula
R - H (IF) wherein R is as defined in formula (F), with a compound of general formula
wherein Q,
Figure imgf000183_0001
formula (F); or
(b) reacting a compound of general formula
Figure imgf000183_0002
wherein R, R , R ,, RR ,, RR aanndd RR aarree aass ddeefifinneedd iinn f formula (F), with a compound of general formula
L1 - Q - R2 (V)
1 2 wherein L repr reesseennttss aa hhyyddrrooggeenn aaltom or an activating group and Q and R are as defined in formula (F);
and optionally thereafter converting the compound of formula (F) to a further compound of formula (F); and, if desired, forming a pharmaceutically acceptable salt or solvate of the compound of formula (F).
9. A pharmaceutical composition comprising a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
10. A process for the preparation of a pharmaceutical composition as claimed in claim 9 which comprises mixing a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 with a pharmaceutically acceptable adjuvant, diluent or carrier.
11. A compound of formula (F), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 for use in therapy.
12. Use of a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for use in therapy.
13. Use of a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.
14. Use of a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for use in treating rheumatoid arthritis.
15. Use of a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease.
16. Use of a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for use in treating asthma.
17. Use of a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for use in treating multiple sclerosis.
18. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7.
19. A method of treating an airways disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (F), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7.
PCT/SE2001/000403 2000-02-25 2001-02-23 Novel compounds WO2001062728A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
DE60110900T DE60110900T2 (en) 2000-02-25 2001-02-23 NEW CONNECTIONS
HU0300922A HUP0300922A2 (en) 2000-02-25 2001-02-23 Novel compounds, process for their preparation, pharmaceutical compositions containing them and their use
BR0108679-0A BR0108679A (en) 2000-02-25 2001-02-23 New compounds
NZ520718A NZ520718A (en) 2000-02-25 2001-02-23 Hydroxyalkyl compounds
AT01908557T ATE295833T1 (en) 2000-02-25 2001-02-23 NEW CONNECTIONS
CA002400293A CA2400293A1 (en) 2000-02-25 2001-02-23 Novel compounds
US10/204,790 US6943188B2 (en) 2000-02-25 2001-02-23 Hydroxyalkyl compounds
PL01358281A PL358281A1 (en) 2000-02-25 2001-02-23 Novel compounds
AU36299/01A AU783496B2 (en) 2000-02-25 2001-02-23 Novel compounds
EP01908557A EP1263724B1 (en) 2000-02-25 2001-02-23 Novel compounds
IL15120801A IL151208A0 (en) 2000-02-25 2001-02-23 Novel compounds
SK1213-2002A SK12132002A3 (en) 2000-02-25 2001-02-23 Phenyl derivatives, methods for their preparation, pharmaceutical compositions comprising them and their use in therapy
SI200130366T SI1263724T1 (en) 2000-02-25 2001-02-23 Novel compounds
MXPA02008241A MXPA02008241A (en) 2000-02-25 2001-02-23 Novel compounds.
EEP200200470A EE05001B1 (en) 2000-02-25 2001-02-23 Heterocyclic compounds, process for their preparation, pharmaceutical composition containing them and their use in therapy
JP2001561736A JP2003523998A (en) 2000-02-25 2001-02-23 New compound
NO20023934A NO323584B1 (en) 2000-02-25 2002-08-19 New compounds, processes for their preparation and use, pharmaceutical compositions containing said new compounds and said new compounds for medical use.
IS6520A IS6520A (en) 2000-02-25 2002-08-22 New compounds
HK03101130A HK1048990A1 (en) 2000-02-25 2003-02-17 Novel compounds.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE0000620-5 2000-02-25
SE0000620A SE0000620D0 (en) 2000-02-25 2000-02-25 Novel compounds
SE0002234A SE0002234D0 (en) 2000-06-14 2000-06-14 Novel compounds
SE0002234-3 2000-06-14
SE0003979-2 2000-10-31
SE0003979A SE0003979D0 (en) 2000-10-31 2000-10-31 Novel Compounds

Publications (1)

Publication Number Publication Date
WO2001062728A1 true WO2001062728A1 (en) 2001-08-30

Family

ID=27354503

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/SE2001/000405 WO2001062757A1 (en) 2000-02-25 2001-02-23 Novel compounds
PCT/SE2001/000404 WO2001062729A1 (en) 2000-02-25 2001-02-23 Novel compounds
PCT/SE2001/000403 WO2001062728A1 (en) 2000-02-25 2001-02-23 Novel compounds

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/SE2001/000405 WO2001062757A1 (en) 2000-02-25 2001-02-23 Novel compounds
PCT/SE2001/000404 WO2001062729A1 (en) 2000-02-25 2001-02-23 Novel compounds

Country Status (29)

Country Link
US (3) US6943188B2 (en)
EP (3) EP1263724B1 (en)
JP (3) JP2003523999A (en)
KR (3) KR20020076338A (en)
CN (3) CN1229343C (en)
AR (1) AR029806A1 (en)
AT (2) ATE280153T1 (en)
AU (3) AU783475B2 (en)
BR (3) BR0108677A (en)
CA (3) CA2400434A1 (en)
CO (1) CO5300399A1 (en)
CZ (1) CZ20022870A3 (en)
DE (2) DE60106581T2 (en)
DK (2) DK1263724T3 (en)
EE (1) EE05001B1 (en)
ES (2) ES2241796T3 (en)
HK (1) HK1048990A1 (en)
HU (1) HUP0300922A2 (en)
IL (2) IL151208A0 (en)
IS (1) IS6520A (en)
MX (3) MXPA02008244A (en)
NO (3) NO323584B1 (en)
NZ (2) NZ520718A (en)
PL (1) PL358281A1 (en)
PT (2) PT1263725E (en)
RU (1) RU2265011C2 (en)
SI (2) SI1263724T1 (en)
SK (1) SK12132002A3 (en)
WO (3) WO2001062757A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051839A1 (en) * 2001-12-14 2003-06-26 Astrazeneca Ab Novel compounds
WO2003068743A1 (en) 2002-02-18 2003-08-21 Astrazeneca Ab Chemical compounds
WO2004039367A1 (en) * 2002-10-31 2004-05-13 Pfizer Limited Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
WO2005073192A1 (en) * 2004-02-02 2005-08-11 Astrazeneca Ab Novel piperidines as chemokine modulators (ccr)
WO2007015666A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt i
WO2007015667A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt ii
WO2007015668A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt iii
WO2008136754A1 (en) * 2007-05-07 2008-11-13 Astrazeneca Ab Novel benzyl - 2 -oxo-piperazinyl/ 7-oxo/5-oxa- [1,4] diazepanyl/ 2 -oxo- tetrahydropyrimidinyl derivatives
WO2008150231A1 (en) * 2007-06-08 2008-12-11 Astrazeneca Ab New heterocyclic compounds for treatment of respiratory, airway or inflammatory disorders
US7528156B2 (en) 2000-06-20 2009-05-05 Astrazeneca Ab Compounds
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
WO2011012897A1 (en) 2009-07-31 2011-02-03 Astrazeneca Ab New combinations for the treatment of asthma
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
EP2364704A1 (en) 2007-02-08 2011-09-14 AstraZeneca AB Combination of beta-adrenoceptor agonist and corticosteroid
WO2012085583A1 (en) 2010-12-23 2012-06-28 Astrazeneca Ab New compound
WO2012085582A1 (en) 2010-12-23 2012-06-28 Astrazeneca Ab Compound
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
US9063126B2 (en) 2008-09-29 2015-06-23 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US11186564B2 (en) * 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
EP4115885A1 (en) 2021-07-05 2023-01-11 Charité - Universitätsmedizin Berlin A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5300399A1 (en) 2000-02-25 2003-07-31 Astrazeneca Ab HETEROCICLIOCS CONTAINING NITROGEN, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US7005439B2 (en) * 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
AR035230A1 (en) * 2001-03-19 2004-05-05 Astrazeneca Ab BENCIMIDAZOL COMPOUNDS, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION, AND USES OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES
SE0101038D0 (en) * 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
EP1465488A4 (en) * 2001-08-30 2007-04-18 Chemocentryx Inc Arylamines as inhibitors of chemokine binding to us28
WO2003099773A1 (en) * 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
GB0402101D0 (en) * 2004-01-30 2004-03-03 Novartis Ag Organic compounds
JP2008534496A (en) * 2005-03-22 2008-08-28 アストラゼネカ・アクチエボラーグ Novel tetrahydro-1H-pyrido [4,3-b] indole derivatives as CB1 'receptor ligands
BRPI0613925A2 (en) * 2005-08-01 2011-02-15 Astrazeneca Ab new compounds
JP2009544609A (en) * 2006-07-18 2009-12-17 アストラゼネカ・アクチエボラーグ Method for producing substituted 2-acetylamino-alkoxyphenyl
JP5501251B2 (en) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド (1-Azinone) substituted pyridoindoles as MCH antagonists
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
CN104710419B (en) * 2015-03-18 2017-05-24 中国药科大学 Tetrahydropyridine [4,3-b] diindyl compound as well as preparation method and pharmaceutical application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577432A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
WO2000058305A1 (en) * 1999-03-26 2000-10-05 Astrazeneca Ab Novel compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (en) 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Process for the preparation of derivatives of 1- (o-bromophenoxy) -2-hydroxy-3-aminopropane and their acid addition salts
US4029801A (en) * 1970-09-03 1977-06-14 John Wyeth & Brother Limited Pharmaceutical compositions and methods of treating hypertension
JPS5511670B1 (en) 1971-07-13 1980-03-26
US3755584A (en) * 1972-04-03 1973-08-28 Abbott Lab Tranquilizers
FR2190430A1 (en) 1972-06-29 1974-02-01 Ferlux N-aminomethylhydroxamic acids - with antiinflammatory activity pre-pared by Mannich reaction
US3775584A (en) 1972-11-30 1973-11-27 D Moerke Welding gun
US3894030A (en) 1973-01-04 1975-07-08 Janssen Pharmaceutica Nv 1-{8 1-(2-Hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
US3818017A (en) 1973-01-04 1974-06-18 Janssen Pharmaceutica Nv 1-{8 1-(2-hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
US4166119A (en) 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
US4264613A (en) * 1979-08-01 1981-04-28 Science Union Et Cie, Societe Francaise De Recherche Medicale Piperidylbenzimidazolinone compounds
FR2469411A1 (en) * 1979-11-15 1981-05-22 Science Union & Cie NOVEL PIPERIDYLBENZIMIDAZOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0095454A3 (en) 1982-05-13 1985-04-03 Gerot-Pharmazeutika Gesellschaft m.b.H. Nuclens-substituted pyrogallol derivatives
JPS59222484A (en) 1983-06-02 1984-12-14 Kowa Co Tetrahydronaphthylcarboxylic acid phenyl ester derivative
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
DE3723568C2 (en) 1987-07-16 1994-01-27 Siemens Ag Residual current circuit breaker
DE3723648A1 (en) 1987-07-17 1989-01-26 Sandoz Ag Indole derivatives, their preparation and medicaments containing them
ES2027897A6 (en) 1991-01-24 1992-06-16 Espanola Prod Quimicos Diphenylmethylpiperazine derivatives.
IL105716A0 (en) 1992-06-08 1993-09-22 Richter Gedeon Vegyeszet Aminopropanol derivatives,their preparation and pharmaceutical compositions containing them
ZA935697B (en) 1992-08-07 1994-03-10 Sankyo Co Peptides capable of inhibiting the activity of hiv protease their preparation and their therapeutic use
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
DE19703131A1 (en) 1997-01-29 1998-07-30 Bayer Ag Use of quinoxaline in a combination of three with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of AIDS and / or HIV infections
BR9814645A (en) 1997-11-18 2001-07-31 Teijin Ltd Cyclic amine derivatives and their use as medicines
DE19755268A1 (en) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidine derivatives
FR2780057B1 (en) 1998-06-18 2002-09-13 Sanofi Sa PHENOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2000035451A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000053600A1 (en) 1999-03-11 2000-09-14 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivatives
WO2000069820A1 (en) 1999-05-14 2000-11-23 Combichem, Inc. Cyclic amine derivatives and their uses
DE19922316A1 (en) 1999-05-14 2000-11-16 Goedecke Ag N-(Benzofuranyl-alkoxycarbonyl)-tryptophan ester preparation, for use as tachykinin receptor antagonist intermediate, by reacting hydroxyalkyl-benzofuran with disuccinimidyl carbonate, then with tryptophan ester
SE9902987D0 (en) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
FR2802533B1 (en) 1999-12-17 2002-02-15 Sanofi Synthelabo PHENOXYPROPANOLAMINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EP1242083B1 (en) 1999-12-17 2007-03-14 Sanofi-Aventis Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them
CO5300399A1 (en) 2000-02-25 2003-07-31 Astrazeneca Ab HETEROCICLIOCS CONTAINING NITROGEN, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
AR028947A1 (en) * 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
US7005439B2 (en) 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
SE0100903D0 (en) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0101038D0 (en) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577432A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
WO2000058305A1 (en) * 1999-03-26 2000-10-05 Astrazeneca Ab Novel compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JON L. WRIGHT ET AL.: "Discovery of selective dopamine D4 receptor antagonists: 1-aryloxy-3-(4-aryloxypiperidinyl)-2-propanols", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 11, 1997, pages 1377 - 1380, XP002940944 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528156B2 (en) 2000-06-20 2009-05-05 Astrazeneca Ab Compounds
WO2003051839A1 (en) * 2001-12-14 2003-06-26 Astrazeneca Ab Novel compounds
US7709500B2 (en) 2002-02-18 2010-05-04 Astrazeneca Ab Chemical compounds
CN100352807C (en) * 2002-02-18 2007-12-05 阿斯利康(瑞典)有限公司 Chemical compounds
AU2003206554B2 (en) * 2002-02-18 2009-05-07 Astrazeneca Ab Chemical compounds
WO2003068743A1 (en) 2002-02-18 2003-08-21 Astrazeneca Ab Chemical compounds
AU2003269411B2 (en) * 2002-10-31 2009-06-18 Pfizer Inc. Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
JP4555263B2 (en) * 2002-10-31 2010-09-29 ファイザー・インク Proline derivative having affinity for calcium channel α2δ subunit
WO2004039367A1 (en) * 2002-10-31 2004-05-13 Pfizer Limited Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
KR100750782B1 (en) * 2002-10-31 2007-08-20 화이자 인코포레이티드 Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
EA009767B1 (en) * 2002-10-31 2008-04-28 Пфайзер Инк. Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
NL1024677C2 (en) * 2002-10-31 2005-07-04 Pfizer Therapeutic proline derivatives.
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
JP2006328078A (en) * 2002-10-31 2006-12-07 Pfizer Inc PROLINE DERIVATIVE HAVING AFFINITY FOR CALCIUM CHANNEL alpha2delta SUBUNIT
US7956070B2 (en) 2004-02-02 2011-06-07 Astrazeneca Ab Piperidines as chemokine modulators (CCR)
WO2005073192A1 (en) * 2004-02-02 2005-08-11 Astrazeneca Ab Novel piperidines as chemokine modulators (ccr)
WO2007015668A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt iii
WO2007015667A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt ii
US8148405B2 (en) 2005-08-02 2012-04-03 Astrazeneca Ab Salt I
WO2007015666A1 (en) * 2005-08-02 2007-02-08 Astrazeneca Ab New salt i
EP2364704A1 (en) 2007-02-08 2011-09-14 AstraZeneca AB Combination of beta-adrenoceptor agonist and corticosteroid
WO2008136754A1 (en) * 2007-05-07 2008-11-13 Astrazeneca Ab Novel benzyl - 2 -oxo-piperazinyl/ 7-oxo/5-oxa- [1,4] diazepanyl/ 2 -oxo- tetrahydropyrimidinyl derivatives
WO2008150231A1 (en) * 2007-06-08 2008-12-11 Astrazeneca Ab New heterocyclic compounds for treatment of respiratory, airway or inflammatory disorders
US9063126B2 (en) 2008-09-29 2015-06-23 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
WO2011012897A1 (en) 2009-07-31 2011-02-03 Astrazeneca Ab New combinations for the treatment of asthma
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2012085583A1 (en) 2010-12-23 2012-06-28 Astrazeneca Ab New compound
WO2012085582A1 (en) 2010-12-23 2012-06-28 Astrazeneca Ab Compound
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
US11186564B2 (en) * 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
EP4115885A1 (en) 2021-07-05 2023-01-11 Charité - Universitätsmedizin Berlin A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation
WO2023280828A1 (en) 2021-07-05 2023-01-12 Charité - Universitätsmedizin Berlin A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation

Also Published As

Publication number Publication date
DE60106581D1 (en) 2004-11-25
CA2400435A1 (en) 2001-08-30
NZ520719A (en) 2004-06-25
IL151208A0 (en) 2003-04-10
CN1426394A (en) 2003-06-25
CA2400434A1 (en) 2001-08-30
BR0108677A (en) 2002-11-12
PT1263725E (en) 2005-02-28
EP1263725B1 (en) 2004-10-20
MXPA02008241A (en) 2002-11-29
AU3629901A (en) 2001-09-03
NO20023932L (en) 2002-10-24
CN1187326C (en) 2005-02-02
NZ520718A (en) 2004-09-24
DE60106581T2 (en) 2005-09-15
IS6520A (en) 2002-08-22
EE05001B1 (en) 2008-04-15
CN1426393A (en) 2003-06-25
CN1229343C (en) 2005-11-30
WO2001062729A1 (en) 2001-08-30
ATE295833T1 (en) 2005-06-15
ATE280153T1 (en) 2004-11-15
KR20020076338A (en) 2002-10-09
HUP0300922A2 (en) 2003-07-28
EP1263724A1 (en) 2002-12-11
KR100752033B1 (en) 2007-08-28
AR029806A1 (en) 2003-07-16
ES2241796T3 (en) 2005-11-01
NO323584B1 (en) 2006-06-11
US20030158225A1 (en) 2003-08-21
NO20023934L (en) 2002-10-07
BR0108678A (en) 2002-12-03
BR0108679A (en) 2002-11-26
AU783475B2 (en) 2005-10-27
NO20023934D0 (en) 2002-08-19
KR20020075450A (en) 2002-10-04
MXPA02008244A (en) 2002-11-29
HK1048990A1 (en) 2003-04-25
MXPA02008243A (en) 2002-11-29
JP2003523999A (en) 2003-08-12
DK1263725T3 (en) 2005-01-17
DE60110900D1 (en) 2005-06-23
JP2003524011A (en) 2003-08-12
EE200200470A (en) 2003-12-15
NO20023933L (en) 2002-10-24
US6943188B2 (en) 2005-09-13
NO20023933D0 (en) 2002-08-19
US6927222B2 (en) 2005-08-09
NO20023932D0 (en) 2002-08-19
PT1263724E (en) 2005-09-30
EP1263760A1 (en) 2002-12-11
PL358281A1 (en) 2004-08-09
RU2002122100A (en) 2004-01-10
US20030149047A1 (en) 2003-08-07
CO5300399A1 (en) 2003-07-31
DK1263724T3 (en) 2005-08-15
CA2400293A1 (en) 2001-08-30
EP1263724B1 (en) 2005-05-18
AU783496B2 (en) 2005-11-03
CN1426412A (en) 2003-06-25
SK12132002A3 (en) 2003-06-03
US20030144267A1 (en) 2003-07-31
WO2001062757A1 (en) 2001-08-30
DE60110900T2 (en) 2006-04-27
SI1263725T1 (en) 2005-02-28
SI1263724T1 (en) 2005-10-31
JP2003523998A (en) 2003-08-12
US6951874B2 (en) 2005-10-04
AU3630101A (en) 2001-09-03
KR20020079912A (en) 2002-10-19
IL151202A0 (en) 2003-04-10
ES2227140T3 (en) 2005-04-01
CZ20022870A3 (en) 2003-02-12
AU3630001A (en) 2001-09-03
EP1263725A1 (en) 2002-12-11
RU2265011C2 (en) 2005-11-27

Similar Documents

Publication Publication Date Title
EP1263724B1 (en) Novel compounds
JP2003523999A5 (en)
EP1546130A1 (en) Novel piperidine derivatives for use in the treatment of chemokine mediated disease states
KR900005022B1 (en) 1-(aminoalkyl)-alpha,alpha-diaryl pyrrolidine-piperidine-and homo piperidine-acetamides and acetonitriles and preparing process thereof
US4198417A (en) Phenoxyphenylpiperidines
FI106957B (en) Process for the preparation of alpha - [(2-aminoalkoxy) phenyl] omega-aryylalkanes useful as a drug
EP1870396B1 (en) Benzyloxypropylamine derivative
FI106551B (en) Process for preparing α- [(heterocyclylalkoxy)phenyl]-ω-arylalkane compounds or α-[(heterocyclyloxy)phenyl]-ω-arylalkane compounds which can be used as drugs
EP1593679A1 (en) 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands
KR20040030114A (en) Cyclic amine compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 36299/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01064/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 520718

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 151208

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2400293

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002/06665

Country of ref document: ZA

Ref document number: 12132002

Country of ref document: SK

Ref document number: 200206665

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2001 561736

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2002-2870

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008241

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027011127

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001908557

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002 2002122100

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027011127

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018084125

Country of ref document: CN

Ref document number: 10204790

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001908557

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-2870

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 520718

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 520718

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001908557

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 36299/01

Country of ref document: AU